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Abstract 
Introduction. Melanoma extracellular vesicles (EVs) are endowed with pro-tumourigenic 
features and can condition the immune system favouring immune escape. Immune 
checkpoints (IC) are key molecules involved in the regulation of immune responses that 
can be expressed also by tumour cells. The expression of IC in melanoma cells can be 
conditioned by BRAF and MEK inhibitors, a standard treatment for patients affected by 
BRAF-mutated melanoma. Here, I investigated the IC expression in melanoma tumours, in 
melanoma cell lines and EVs, in association with the acquisition of drug resistance, a 
common event during treatment. The interaction of EVs with melanoma and with 
immune cells was investigated in the context of drug resistance, to uncover potentially 
targetable molecules for immunotherapeutic strategies. To this aim, the expression of IC 
was assessed in plasma EVs of melanoma patients during therapy with BRAF and MEK 
inhibitors.  
Methodology. EVs released from melanoma cell lines were isolated by ultracentrifugation 
protocol and characterized for IC expression by qRT-PCR, western blot and latex beads 
flow cytometry. To study the IC modulation induced via EVs in target melanoma and 
immune cells, CD81GFP-tagged EVs derived from drug sensitive and resistant melanoma 
cell variants were used. In vivo IC relevance was assessed in plasma EVs and in tumour 
specimens of melanoma patients. EVs were characterized by Nanoparticle Tracking 
Analysis from the whole plasma. IC expression transcripts were evaluated by qRT-PCR  
isolating RNA from plasma EVs by three different methods: a) exoRNeasy kit; b) ExoQuick 
and c) ultracentrifugation protocol in combination with an RNA extraction kit from 
Mcherey-Nagel. IC expression proteins in plasma EV fractions isolated by differential 
ultracentrifugation were evaluated by western blot analysis.  
Results. In melanoma lesions, IC transcripts CD155, HVEM and GAL9 displayed a 
modulation in association to resistance to treatment. In melanoma cell lines, PDL1, PDL2 
and CD155 showed increased expression, and GAL9 and HVEM a decrease, upon the 
acquisition of resistance in a set of six drug sensitive and resistant cell line pairs. The 
expression of PDL1, PDL2 and GAL9 was modulated by treatment with IFNγ and regulated 
by CCL2 and specific miRNAs. Corresponding EVs reflected the IC expression pattern of 
originating cells carrying several IC. In vitro models showed that CD81GFP-EVs interacted 
with both melanoma and immune cells thereby transfer therapy resistance associated 
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features. The EV uptake in monocytes induced a myeloid-derived suppressor cell (MDSC) 
phenotype accompanied by modulation of IC expression, with PDL1 and HVEM increase. 
EVs isolated from plasma of melanoma patients during therapy displayed significant 
variations of numbers and size, and of studied IC levels, at protein and transcript level, 
which associated to treatment response. 
Conclusions. Melanoma IC expression can be altered by BRAF and MEK inhibitors 
treatment. EVs reflect IC expression of originating cells and may represent a surrogate of 
melanoma resistance status. The effects of IC-carrying EVs on interacting cells suggest 
their involvement in immunomodulation and tumour immune escape, and their 
modulations in plasma may reflect patients’ immune activation in response to therapy. 
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1. Introduction and aims of the thesis 
1.1. Extracellular vesicles  
1.1.1. Nature of EVs 
Extracellular vesicles (EVs) are phospholipid bilayer membrane surrounded structures 
that are released by most types of cells. EVs are present in all body fluids such as plasma, 
serum, lymph, urine, saliva, tears and milk and they are important carriers of biological 
materials. The main function that has been recognized of EVs is to act as mediators of 
intercellular communication in physiological and pathological conditions [1]. Thanks to 
their rich composition, EVs can transfer molecular constituents, including proteins, 
nucleic acids and lipids from the cells of origin into recipient cells [2]. Their stability 
enables EVs to persist and protect their content even under harsh conditions, such as low 
pH, in different body fluids and, once their target has been reached, to act as potent 
signalling vectors. Due to their action and composition, EVs represent potential 
biomarkers and targets involved in pathological processes [3, 4].  
The term “extracellular vesicles” was introduced by the International Society for 
Extracellular Vesicles (ISEV) to uniform the nomenclature of the heterogeneous types of 
vesicles isolated in different research groups. In 2018 a scientific consensus on calling the 
subtypes of vesicles EVs was obtained from the scientific community of researchers 
involved in the field [5]. This was a major step forward, as depending on the research 
group and the isolation method, the vesicles with overlapping characteristics received 
different names, mainly exosomes or microvesicles (MVs).   
1.1.2. Discovery 
The discovery of EVs dates back to 1940, when in plasma samples an “unknown” 
extracellular component which promotes clotting of blood [6] was discovered. More than 
20 years later, these extracellular components were discovered to be small vesicles 
released from platelets and called “platelet dust” [7]. In 1987, EVs sized 40-100 nm 
released from multivesicular bodies (MVB) were isolated from reticulocyte medium and 
called exosomes. It was hypothesized that the role of the vesicles produced during 
reticulocyte maturation in erythrocytes consisted in externalisation of membrane 
proteins (Figure 1.1.2 [8]), and thus for the next decade exosomes were considered a 
mechanism for removing obsolete protein plasma membrane. Subsequently, in 1996 B 
cells and dendritic cells were found to release vesicles carrying essential molecules for the 
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triggering of adaptive immune response [9], firstly assigning to these structures a pivotal 
signalling function. 
      
Figure 1.1.2. Exosomes in maturing sheep reticulocytes. Reticulocytes were labelled with 
monoclonal anti-transferrin receptor antibody and observed at A) 18 h and B) 36 h once attaching 
colloidal gold. The label was detectable in MVBs and at internal exosomes. MVB fuse with the cell 
membrane (arrow) and exosomes are released. Figure taken from [8]. 
1.1.3. EV subtypes and biogenesis  
Different types of vesicles including exosomes, microvesicles (MVs), ectosomes, 
microparticles (MPs), oncosomes and apoptotic bodies are members of the big family of 
EVs (Figure 1.1.3.1 taken from [10]). These have been named and identified according to 
their origin, size, density, composition, functional properties or cell type derivation [11-
14].  
The dimensions that have been defined for each type of EV can be overlapping. In fact 
exosomes are defined as EVs with a size ranging from 50 to 150 nm while MVs measure 
between 100 and 1000 nm [15, 16]. Oncosomes derive, as their name specifies, from 
tumour cells and have first been described in 2008 as membrane-derived MVs that served 
to transfer functionally active EGFRvIII between glioma cells [17]. Oncosomes have a size 
ranging from 1 to 10 μm diameter and derive from bulky cellular protrusions. They could 
be identified in prostate cancer tissue specimens and patients’ plasma [18, 19]. These 
type of EVs were studied primarily in glioma and prostate cancer and results showed that 
these vesicles contribute to reprogramming the microenvironment and promote disease 
progression [20, 21]. 
10 
 
 
Figure 1.1.3.1. Subtypes of extracellular vesicles. During physiological or pathological conditions, 
cells release different type of vesicles of endocytic origin or membrane budding origin. EE: Early 
endosomes, ER: Endoplasmic reticulum, PM: Plasma membrane. Figure taken from [10]. 
MVs and MPs stem from the membrane like oncosomes. MVs deriving from platelets are 
generally called MPs and have been found to be relevant in homeostasis and vascular 
biology and diseases like thrombosis [22]. MPs or platelet-derived MVs play also major 
roles in cancer as they can mediate tumour immune escape and contribute to the 
metastatic processes [23]. Due to their membrane origin, MVs carry a selected surface 
repertoire of the secreting cell, among which Annexin A1 has been recognised as specific 
MV marker in a recent study [24]. This type of vesicle also comprises the ectosomes, 
which were first described as EVs released by neutrophils. Ectosomes were found to be 
produced by activated neutrophils at inflammation sites to focus antimicrobial activity 
onto opsonized surfaces [25].  
Exosomes are the most studied EVs, they originate from MVBs of the releasing cells and 
uptaken by recipient cells [11]. Exosomes differ from the other EV types for their markers, 
which include CD9, CD63 and CD81 tetraspanins, HSC70 and HSC90 heat shock proteins, 
Alix and TSG101 endocytic membrane transport machinery proteins (ESCRT), GTPases 
membrane transporters, and lipid-bound proteins [26, 27]. MVBs contain intraluminal 
vesicles (ILVs) that form by inward budding of late endosomal membranes. The ILVs 
contain proteins and RNAs deriving from the cytosol. MVBs fuse with the plasma 
membrane and release ILVs into the extracellular compartment, these represent the 
exosomes. Alternatively, MVBs may also be subject to lysosomal degradation [10]. These 
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processes are controlled by RAB27A and RAB27B that contribute to the recruitment of 
MVBs to the plasma membrane [28].  
Exosomes can derive from ILVs formed in an ESCRT-dependent or independent way. First, 
ESCRT complexes sort the molecular cargoes after ubiquination into the late endosomes. 
This is followed by the invagination of the endosomal membranes and the formation of 
ILVs inside the MVBs. In addition, proteins are engulfed from the cytosol. ESCRT members 
comprise typical exosomal proteins such as Alix and TSG101 (Anand et al., 2019). In 
contrast, ESCRT-independent sorting of exosomes, involves lipids, tetraspanins and 
RabGTPases. This alternative biogenesis pathway appears to rely on the formation of ILVs 
by conversion of sphyngomyelin to ceramide (Figure 1.1.3.2 [10]). 
 
Figure 1.1.3.2. Schematic representation of biogenesis of exosomes. Biogenesis of exosomes 
involves ESCRT machinery and Alix that are recruited to the endosomal membrane and sort the 
ubiquitinated proteins into intraluminal vesicles (ILVs). In addition, there are ESCRT independent 
mechanisms that include lipids and tetraspanins. MVBs: Multivesicular bodies, ILVs: Intraluminal 
vesicles. Figure taken from [10]. 
A recent study has reclassified EVs based on a thorough characterization of the RNA, DNA, 
and protein constituents. The authors employed high-resolution density 
gradient fractionation and direct immunoaffinity capture to isolate and analyse the 
composition of EVs released by tumour cell lines and isolated from plasma, in order to 
precisely establish the different cargoes of EV subpopulations. They provide evidence 
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that, in contrast to other studies, exosomes are not carriers of dsDNA and DNA-binding 
histones [24]. 
Finally, apoptotic bodies and apoptotic vesicles are generated during apoptosis. These 
EVs display variable dimensions ranging from 100 nm to 5 μm and are characterised by PS 
exposure, thus becoming easily detectable by Annexin V [24]. It is evident that although 
overlapping sizes and characteristics are shared by different EV subpopulations, as 
reported for CD9, CD81 and CD63 expression as well as other markers, major concerted 
effort is being made to find discriminating features to help distinguishing between the EV 
types.  
EVs can carry a cargo of proteins and nucleic acids, a discovery made by most groups 
investigating in the EV field, which is particularly attractive to understand their roles as 
mediators or biomarkers. The general consensus is that sorting into EVs is not occurring 
by chance but that instead the presence of selected molecules follows rules still largely 
unknown. The mechanisms controlling the sorting of selected proteins into EVs depend 
on the ESCRT machinery and post-translational modifications (PTMs). These latter are 
alterations of the proteins that enable their active or inactive state [29]. Among the 
different PTMs ubiquitination, sumoylation, phosphorylation and glycosylation appear as 
the most frequent during packaging of proteins into EVs [10]. The sorting of nucleic acids 
into EVs is described in Section “1.1.10. Tumour EVs as biomarker”. 
1.1.4. Isolation and characterisation of EVs 
The heterogeneity of EV populations and the heterogeneity of single EVs belonging to the 
same EV subtype, but showing differences in composition or surface marker expression 
complicates research in the field ever since the discovery of the EVs. The overlapping 
dimensions and marker expression additionally hampers the isolation of distinct and 
“pure” populations [5]. There are different methods to isolate EVs and each presents 
advantages as well as disadvantages in terms of contaminations, purity and yield. Like 
many other research groups also my hosting laboratory stumbled across same technical 
challenges in 2001. Due to the nanometer size of the vesicles the main isolation method 
was differential ultracentrifugation combined or not with density gradient separation for 
many years [30].  
No definitive consensus has been found yet on the optimal isolation method, which often 
depends also on what kind of vesicle is the subject of the investigation or particular 
characteristics such as expression of particular proteins. The choice of a particular 
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purification method can also depend on what is the target material that will be 
investigated, e.g. proteins or nucleic acids. As shown in Figure 1.1.4 and reviewed by [31], 
the main methods applied to purify EVs are the following: differential ultracentrifgation, 
floatation-related methods, precipitation-based protocols, immunoaffinity isolation, flow 
cytometry, ultrafiltration, field flow fractionation and size-exclusion chromatography 
(SEC). Different studies have been performed to compare the different isolation methods 
on the same starting biological samples, however the choice of a protocol remains a 
challenging question that often influences the results of the investigations.  
 
Figure 1.1.4. EV isolation methods. The different methods currently used to isolate EVs and their 
subpopulations. A) ultracentrifugation B) gradient-based isolation C) ultrafiltration D) size-
exclusion chromatography E) asymmetrical field-flow fractionantion F) precipitation-based G) 
immunoaffinity-based separation. Figure taken from [31]. 
The most widely used ultracentrifugation method refers to indications from 2006: two 
centrifugations at 400×g (to eliminate cells) and 2,000×g (to eliminate debris); then the 
supernatant is subjected to centrifugation at 10,000×g to obtain apoptotic bodies and 
MVs in the pellet. After this, the supernatant is subjected to an ultracentrifugation at 
100,000×g for 1–2 h to obtain an EV pellet that can be further suspended and washed in a 
by ultracentrifugation at 100,000×g for 1–2 h [30]. The combination of ultracentrifugation 
methods with floatation separates vesicles according to the density of EV subtypes, being 
exosome density 1.15-1.19 g/ml, endoplasmic reticulum vesicles density 1.18–1.25 g/ml, 
Golgi vesicles density 1.05–1.12 g/ml [30] and protein at 1.35–1.41 g/ml [32]. 
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Ultrafiltration separates EVs based on molecular weight cut-offs or defined pore sizes of 
semipermeable membranes.  
While the ultracentrifugation is a time-consuming method that can lead to aggregation 
and variable contaminations in the EV pellet, ultrafiltration is a faster method that 
interferes at minimal level with the EVs [33]. This can also be said for field-flow 
fractionation that separates the vesicles in a channel with parabolic longitudinal flow 
combined with an external gradient or “field”. However, this method does not 
discriminate between EV populations or separates proteins [31].  
A promising method seems to the size-exclusion chromatography that is based on the 
different elution profiles characterizing the differently-sized EVs, which run through a 
porous polymer that constitutes the stationary phase (gel filtration matrix or resin) and 
carried through the mobile phase of the SEC column. This technique separates EVs from 
proteins. Indeed, these are slowed down when they enter the polymer pores, thereby 
eluting later than EVs. Instead the bigger EVs travel faster along the column and so elute 
first, right after the column’s void volume, because they are bigger than the polymers’ 
pores [34].  
Precipitation-based protocols, such as ExoQuick, rely on polyethylene glycol (PEG)-based 
volume exclusion precipitation. Here the yield is high, but the pellet contains all soluble 
particles including proteins and EVs. The EV preparations obtained with this method may 
be acceptable for RNA and microRNA studies especially in the translational setting where 
samples of biological fluids are often limited, but are not recommended for functional 
studies, due to contaminants that would influence obtained results.  
Another major isolation method is the immunoaffinity separation that aims at recovering 
only specific EVs based on their surface protein expression. Here, EVs are captured 
through specific antibodies, which can be coupled to beads to be then separated 
magnetically or by centrifugation (Figure 1.1.4). This represents a good method to obtain 
only a certain population of EVs, e.g. EVs expressing the tetraspanins CD63, CD9 and 
CD81, but the lack of a pan-EV marker that still needs to be identified if existing, limits the 
utility of this isolation technique.  
1.1.5. Intercellular crosstalk via extracellular vesicle  
Once released in the extracellular compartment, EVs can interact with the recipient cells 
in several ways. As shown in the Figure 1.1.5, they can dock at the plasma membrane of a 
target cell or they can fuse directly with the plasma membrane; otherwise, they can be 
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endocytosed or uptaken by micropinocytosis and phagocytosis and release their content 
inside of the recipient cells [11, 35]. 
 
 
Figure 1.1.5. Different types of extracellular vesicle uptake. EV can interact with the target 
cells in different ways as illustrated and release its content inside the recipient cell. Figure is an 
original artwork by A. Shahaj. 
The individual types of interaction of EVs is probably dependent on their surface 
composition that determines recognition by the target cells. As with the sorting of 
proteins or nucleic acids, the uptake of EVs by one cell rather than another seems to be 
a controlled and specific process. These aspects are subject to intense investigation and 
the first studies date back to 2000 years, when Denzer and coworkers reported that B 
lymphocyte-derived exosomes that contain major histocompatibility class II (MHC Class 
II) specifically bind to follicular dendritic cells, but not to other cell types [36].  
EVs can interact with target cells also only via membrane-membrane interaction 
without delivering their content, as has been shown for MVs derived from activated 
platelets, which are coated with tissue factor and which can interact with P-selectin 
expressed by neutrophils, macrophages and other platelets [37]. Similarly, EVs 
expressing MHC Class II have been shown to stimulate T cell receptor (TCR) of cognate 
T cells [38]. Apart from the delivery of the content of an EV into the acceptor cell, 
several studies have demonstrated an involvement of EVs in exchange of proteins, RNA 
or toxic components, such as prions [17, 39, 40].  
A definitive consensus on the mechanisms of targeting, interaction and uptake and 
their respective outcomes for the EV accepting cell is far from being reached by the 
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scientific community of the field. One fundamental aspect in need of elucidation is the 
targeting specificity of EVs. A generic uptake of EVs from different cellular origins has 
been shown for HeLa and other cell types cells, such as lung and colon cancer cell lines 
[41]. Even interspecies interaction could be observed between mouse and human. In 
fact, Valadi and colleagues could assess the presence of new mouse proteins in human 
mast cells, indicating that the genetic material present in mouse exosomes was 
functional and was translated after entering a cell [42].  
1.1.6.  Functions of EVs 
Due to their heterogeneity and the limited understanding of their natural targeting and 
interaction mechanisms, the “real” functions of EVs remain to be unravelled. In vitro 
studies are usually performed using isolated EVs that are added to cell cultures to study 
the effects of EVs at different levels. This setting has a major disadvantage in that the 
EV-cell interaction is artificially created. Nonetheless, major advances in the 
understanding of EV functions have been achieved using this experimental setting.  
Importantly, experiments performed in in vivo settings have greatly elucidated the 
natural targeting of EVs [43]. Since the release of vesicles is a conserved mechanism 
across species, a wide variety of biological functions have been described to EVs. The 
first function that has been identified is the elimination of unwanted material, a 
concept that has been recently revisited by Michel Vidal, who advanced the view that 
reticulocytes and other cells use EVs to dispose of components that may prevent their 
differentiation or any other development process [44].  
Other widely investigated functions include the transfer of proteins and nucleic acids 
signalling to the acceptor cells after docking on their membrane via cell surface or to 
endosomal receptors. For example, EVs carrying microRNA miR-21 have been shown to 
function through binding to endosomal TLR8 in human immune cells, thereby triggering 
IL-6 and TNFα release that sustains tumour growth and metastatic potential [45].  
Regarding their physiological functions the identification of the physiological targets of 
EVs will greatly enhance the current understanding of EV turnover and effects and will 
help to develop new experimental models and assays. Examples of physiological 
functions have been described in immune cell intercellular crosstalk. Early research 
showed that during immune response exosomes exposing MHC-peptide complexes 
secreted by B cells could stimulate T cells by activating the T cell receptor [9, 38]. 
Similarly, EVs from antigen presenting cells (APCs) were shown to activate CD4 and CD8 
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T cells due to their expression of MHC Class I and II. These discoveries stimulated great 
interest in the use of EVs as natural stimulators of the immune system in cancer. To this 
end, dendritic cell derived exosomes (DEX) were identified as suitably equipped devices 
for cancer immunotherapy [46]. This gave rise to clinical trials, which advanced cancer 
patients received DEX only or DEX derived from IFNγ-matured dendritic cells [47].  
One major study has elegantly demonstrated the role of EVs and their microRNA 
content in the immunological synapse during intercellular communication of APCs and 
T cells. Mittelbrunn et al demonstrated the existence of an antigen-dependent 
unidirectional transfer of microRNAs by exosomes from the T cell to the APC, thus 
suggesting a targeted and controlled mechanism of intercellular crosstalk can be 
mediated by EVs [48]. Other physiological functions of EVs have been identified in 
angiogenesis and tissue regeneration. EVs can indeed deliver complex information to 
endothelial cells thereby inducing a pro- vs an anti-antigogenic signalling, leading to the 
control of blood vessel formation in tissues [49]. Similarly, EVs have been shown to play 
major roles in cardiac hypoxia and regeneration, as show in newborn mammalian and 
zebrafish hearts, which in contrast to adult mammalian hearts can regenerate 
completely after injury [50].             
1.1.7. Tumour EVs 
Tumour cells release EVs endowed with pro-tumorigenic features and can act at 
multiple levels [51]. Tumour EVs have been shown to boost angiogenesis, activate 
cancer associated fibroblasts, trigger tumour cell epithelial-mesenchymal transition and 
mould the immune environment to a condition of immune escape, thus promoting 
tumour progression and metastasis. These actions may operate between neighbouring 
tumour cells or at distance via EV circulation [52-54].  
Functional studies with tumour EVs helped to define the molecular mechanisms 
involved in their pro-tumorigenic functions such as creating a premetastatic niche, as 
elegantly demonstrated by Peinado and co-workers in 2012 in mice, whose bone 
marrow progenitor cells were educated by administrated melanoma exosomes isolated 
from conditioned medium of highly metastatic melanoma cells. These exosomes 
increased the metastatic behaviour of primary tumours thereby supporting growth and 
metastasis [4]. EVs also contribute to the organotropic metastasis based on their 
integrin expression, namely exosomal integrins α6β4 and α6β1 were associated with 
lung metastasis, while exosomal integrin αvβ5 was linked to liver metastasis [55].  
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Through the release of EVs the tumour cells can influence and shape the whole tumour 
microenvironment. In fact, it has been shown that EVs can interact with fibroblasts, 
endothelial cells, mesenchymal stem cells, myofibroblasts and cells from the immune 
system to generate a favourable microenvironment that fosters tumour growth and 
disease progression. Additionally, tumour EVs contribute to drug resistance by 
sequestering drugs, as shown for immunotherapeutic antibodies like trastuzumab, anti-
CD20 or even anti-PD-L1 avelumab [56]. Tumour EVs have also been shown to actively 
export cytotoxic drugs from the cells thereby preserving the cells from drug action [57]. 
Another mechanism exploited by tumour cells for self-protection is to use intercellular 
EVs transfer to propagate drug resistance by horizontal transfer of molecules that alter 
apoptotic programs and cell cycle control. The several examples include: drug efflux 
pumps thereby contributing to multidrug resistance; survivin, an anti-apoptotic protein 
that promotes cell survival; microRNAs that can be transferred or expulsed via EVs to 
maintain tumour cell homeostasis; transfer of pro-survival cargoes such as platelet-
derived growth factor receptor-beta (PDGFR-β) that has been found as enriched during 
escape of melanoma cells subjected to BRAF inhibitor PLX4720 [56]. Figure 1.1.7 
summarises the main detrimental effect of tumour EVs.  
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Figure 1.1.7. Effects of tumour EVs. General scheme of how EVs secreted by tumour cells can 
influence the cells composing the tumour microenvironment. Through their transport of bioactive 
molecules tumour EVs create a favourable environment in support of tumour growth and 
metastatisation. Figure taken from [56].  
1.1.8.    Immunomodulatory properties of tumour EVs 
1.1.8.1.  Tumour immune escape 
Cancer development creates or originates from a chronic inflammation condition due to 
reactive oxygen and nitrogen species that typically generate mutations. In addition, 
various mechanisms contribute to suppress the immune system thereby creating a 
microenvironment that fosters tumour growth. These pro-tumorigenic pathways shape 
both innate immune cells, such as monocytes, macrophages, neutrophils, dendritic (DC) 
and natural killer cells (NK) and adaptive immunity T and B lymphocytes.  
To avoid immune responses, tumours can impair the capacity of the immune system to 
eliminate them or, by losing target antigen expression, determine a state of non-
recognition by immune cells. Main tumour immune evasion mechanisms can be 
summarized as follows: down regulation of MHC Class I expression, lack of co-stimulatory 
signals necessary for antigen presentation, secretion of immunosuppressive factors by 
cancer to inhibit immune responses, modulation of antigen expression, limiting the ability 
of the immune system to recognise the tumour cell as 'non-self', lack of release of 
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inflammatory warning signals by cancer cells. In my project I focused mainly on the 
mechanisms exploited by melanoma EVs in conditioning immune cells in the context of IC 
expression and targeted therapy resistance development. My hosting laboratory 
contributed to the identification of pathways exploited by melanoma to skew monocytes 
into myeloid-derived suppressor cells (MDSCs), which they first discovered in 2007 [58]. 
1.1.8.2.   Innate immunity and MDSCs 
The innate immunity is crucial in the maintenance of homeostasis and represents the first 
defence mechanism of the organism against pathogens. In the context of tumours, 
members of the innate immunity can detect mutated cells as altered self in response to 
damage-associated molecular pattern (DAMPs), such as tumour-derived DNA, and 
eliminate them (via NK i.e. granzyme B release) or alert and prime the adaptive immune 
system via antigen presenting cells (DC and macrophages producing IFNγ). Nonetheless, 
tumours have developed strategies to skew innate immune cells such as monocytes and 
neutrophils into potent tumour allies called MDSCs. These are pro-tumorigenic cells with 
immunosuppressive properties often recruited to tumour site by chemoattractant 
cytokines.  
MDSCs exert their function in the tumour microenvironment (TME) by inhibiting T and NK 
cells through various mechanisms. Among others, MDSCs can express IC such as, PDL2, 
GAL9, CD155 and the binding to their receptors PD1, TIM3, CD226, TIGIT, CD96 localised 
in the T and NK cell surface, leads to inhibitory signalling and immune suppression [59, 
60]. Thus, MDSCs are associated with increased tumour burden in several cancer types 
[61]. Gabrilovich et al wrote several reviews to explain the MDSC heterogeneity. It is 
known that MDSCs originate from different myeloid progenitors whose maturation is 
interrupted. In physiological conditions these cells would develop into granulocytes, 
dendritic cells or macrophages but in the tumoral condition, bone marrow myelopoiesis 
deviates into MDSC generation.  
Several factors such as tumour cells or microenvironment may be involved in MDSC 
expansion and activation involving IL-6 or TGFB and IFNγ production. This myeloid cell 
dysfunction can also be induced by tumour EVs [62, 63]. The MDSC immunosuppressive 
function depends on their phenotype, as described in 2009 by Gabrilovich & Nagaraj. 
These authors explained that cytokines generally secreted by tumour cells can induce 
MDSCs to produce arginase-1 enzyme, which increases production of reactive oxygen and 
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nitrogen species by L-arginine depletion. These events inhibit T cell proliferation or 
reduce T cell survival [64-66]. 
Concerning the MDSC phenotype, their heterogeneity is a challenging issue. They do not 
express cell-surface markers that are specific for monocytes, macrophages or DCs, instead 
they display a granulocytic and monocytic mixture morphology. Indeed, there are two 
populations of MDSCs in humans: granulocytic or PMN-MDSCs (CD15+CD11b+ PMNs), and 
monocytic M-MDSCs (CD14+HLA-DRneg) detectable in whole blood and purified plasma 
and peripheral blood mononuclear cell (PBMCs) [67]. Both types of MDSCs inhibit T cell 
responses including T-cell proliferation and function with different mechanisms [68]. IC 
molecules are directly involved in these mechanisms and for this reason are part of this 
study. In fact, recent evidence showed that PDL1 is expressed by tumour-induced MDSC 
in an autocrine manner via type I IFN. Thus, MDSCs can continue to suppress T cell activity 
maintaining PDL1 expression even in absence of IFNγ [69]. Moreover, EVs from drug-
resistant cell variants can enhance TGFβ secretion and anti PDL1 expression in drug 
sensitive breast carcinoma cells, thus enhancing resistance to the anti-tumour immune 
response [70]. 
1.1.8.3.   Adaptive immunity and IC expression 
T cell activation requires two different stimuli: one occurs through the MHC antigen 
presentation by APC to the antigen-specific T cell receptor TCR, while the other is 
represented by co-stimulatory or co-inhibitory signals, which tightly regulate T cell 
activity. These signals are conveyed by one of the more than twenty discovered IC 
molecules that belong to immunoglobulin gene superfamily (CD28, CD226, TIM, BTLA, 
CD160, CD155, TIGIT, CD96, LAG3), or part of the tumour necrosis factor (LIGHT) or 
tumour necrosis factor receptor (HVEM) genes [71].  
The negative IC effects compete with co-stimulatory signals to control T cell activity, by 
suppressing activation and impairing T cell survival. Controlling the co-inhibition reduces 
the risk of tumour development from chronic inflammation but, in the case of tumour 
development, T cell inhibition on the contrary, may have a pro-tumorigenic effect. Thus, 
investigating these IC may be important to discover potential drug targets for cancer 
therapy. On the other hand, the identification of a non-invasive way to monitor the 
activation of the immune system in patients undergoing therapy may help to predict their 
response.  
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Given that IC have different effects on T cells depending on the counterpart molecule 
they bind (co-inhibitory or co-stimulatory) it seems important to investigate the entire 
panel of molecules, ligands and receptors, to get a complete overview of the immune 
response scenario. Among T cell subpopulations, regulatory T cells abundantly express 
negative IC. This type of T cells is in fact devoted to the maintenance of tolerance to self-
antigens thereby preventing autoimmune disease. In cancer Treg are major contributors 
to immunosuppression together with MDSC. Treg are CD4+ T cells displaying a CD25 and 
Foxp3 expression that secrete TGFβ and IL-10. Treg prevented co-stimulation of T cells 
through the expression of CTLA-4, an IC targeted by ipilimumab, an immune checkpoint 
inhibitor widely used in cancer therapy [72]. IC expression by T cell subsets is detailed in 
1.2 Section.  
1.1.8.4. Tumour EVs target immune cells 
Tumour cells release a considerable amount of EVs into the TME, which can interfere with 
the immune system through several mechanisms acting on different cell types and mainly 
contributing to create a pro-tumorigenic and immunosuppressive environment [73, 74]. 
Among the different EV subfamilies several studies identified especially tumour exosomes 
as active contributors to tumour escape mechanisms by interfering with the components 
of the innate and adaptive immune response via ligand-receptor interaction or 
modulating gene expression via microRNA [75, 76]. Major effects on the different 
immune cell populations are summarized in Table 1.1.8.4 [54]. 
Monocytes  
In some tumours like glioblastoma, tumour EVs have a predilection for monocytes 
inducing a M2 phenotype and PDL1 upregulation via STAT3 pathway [77]. Moreover, 
tumour EVs are involved in the resistance to chemotherapy via microRNA by targeting 
human monocytes in neuroblastoma through miR-21/TLR8-NF-кB and miR-155/TERF1 
pathways [78].  
Macrophages 
Tumour EVs deriving from breast cancer cells can alter macrophage polarization into M2 
phenotype via gp130/STAT3 causing a decrease of IFNγ gene expression and the increase 
of IL-1β, IL-6, IL-10, CCL2, CXCR4 [79]. In addition, it has been shown that macrophage 
activity is modulated by breast cancer-derived exosomes also via TLR2 and NF-kB pathway 
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[80]. A crucial role in immunomodulation is played by the exosomal microRNA cargo; in 
fact, miR-222 and miR-301a were reported in ovarian and pancreatic cancer, respectively, 
to induce an M2 phenotype in macrophages involving SOCS3/STAT3 pathway or in a HIF-
1a or HIF-2a-dependent manner [81, 82]. Moreover, there is evidence showing that PD1 
immune checkpoint is upregulated in macrophages of patients with advanced-stage 
gastric cancer and that treatment of macrophages with tumour exosomes in vitro could 
be responsible for this phenomenon [82]. Indeed, the expression of negative immune 
checkpoints on immune cells has an immunosuppressive effect on the immune system. 
Dendritic cells  
Recent data from in vivo experiments shows that the treatment of dendritic cells with 
tumour exosomes from hepatocellular carcinoma significantly increases the number of 
PD1+CD8+T cells and also the response to targeted therapy (sorafenib) when combined 
with both exosome treatment and anti-PD1 antibody [83]. This information may be used 
in the clinics to improve the treatment outcome and enhance the relevance of combined 
therapies. Other evidence showed that tumour-derived exosomes interact with dendritic 
cells via microRNA miR-203, which contributes to the dysfunction of dendritic cells by 
controlling TLR4 expression and production of cytokines, such as TNF-α and IL-12 [84]. In 
addition, tumour exosomes promote IL-6 secretion by dendritic cells via TLR2 and TLR4 
signalling through a membrane associated mechanism that relies on HSP72 expressed by 
the exosomes [85]. 
MDSCs 
Tumour EVs possess immunomodulatory properties that can deviate monocyte 
differentiation into MDSCs [53, 62]. EVs from breast, lung and ovarian cancer express 
HSP70 on their membrane and are able to interact and activate MDSCs via TLR2. In 
addition, the number of HSP70 expressing EVs is higher in cancer patients compared with 
healthy donors. Gobbo et al. also showed that their number increased after in vivo and in 
vitro treatment of tumour-bearing mice or melanoma cells with chemotherapeutic agents 
[86]. Furthermore, in renal cell carcinoma, exosomal HSP70 can determine the 
suppressive activity of MDSCs via phosphorylation of STAT3 in a TLR2-MyD88-dependent 
manner, justifying exosomal HSP70 as a significant target in this context [87]. Finally, 
tumour exosomes can mediate an increased proliferation of MDSC in the bone marrow of 
multiple myeloma via STAT3 [88] and a decrease of normal hematopoiesis in AML [89].  
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T cells 
The detrimental effects of tumour EVs affect also T cells in an indirect fashion, i.e. acting 
through innate immunity cells, or in a direct fashion. In fact, cancer EVs may directly 
affect T cells by controlling their recruitment via CCL20 [90] and by increasing the activity 
of regulatory T cells through surface signalling and TGFβ [91, 92]. In addition, exosomes 
were shown to inhibit T cell proliferation and to increase the suppressor phenotype of T 
CD8+, in head and neck cancer and in breast cancer [93, 94]. 
Natural Killer cells 
Exosomes isolated from plasma of AML patients before therapy displayed a high level of 
proteins involved in immune suppression, such as TGFβ1/LAP, CD39/CD73 ectoenzymes, 
PD1/PDL1 or Fas/FasL. In addition, the incubation of these exosomes with NK-92 cells 
reduced the expression of NKG2D, a molecule that positively correlates with NK cell-
mediated cytotoxicity [95]. Moreover, in vitro breast cancer-derived exosomes from mice 
reduced NK cytotoxic activity against tumour cells. 
 
Table 1.1.8.4 Tumour EV target immune cells and suppress the immune system 
Target cell Tumour Effects/ Mechanisms 
Dendritic cell Melanoma 
Pancreatic cancer 
Melanoma 
c↑ immunosuppressive activity via IL-6 and TGFβ 
d↓TLR4 expression and cytokines via miR-203 
↑IL6 via HSP72/ HSP105 in a TLR2/4 manner 
aMDSC Breast/Lung/Ovarian 
Renal cell carcinoma 
Multiple myeloma 
↑ activation via HSP70/TLR association 
↑immunosuppressive activity via p-STAT3 
↑proliferation activation via STAT3 
Macrophage Breast 
Breast 
Ovarian 
Pancreatic cancer 
Gastric cancer 
↑M2 phenotype via STAT3 transfering gp130 
↑pro-inflammatory activity via TLR2/NF-kB 
↑M2 phenotype via miR-222 
↑M2 phenotype via miR-301a 
↑PD-1 and M2 phenotype 
Monocyte Glioblastoma 
Neuroblastoma 
Melanoma 
↑M2 phenotype and PD-L1 
↑chemotherapy resistance by miR-21,miR-155 
↑MDSC phenotype 
Treg Nasopharyngeal 
Head and neck 
Colorectal cancer 
↑cell recruitment via CCL20 
↑TGFβ, IL-10, COX-2, CD39, CD73 
↑T reg induction via TGFβ 
T CD8+ Head and neck 
Breast 
↑suppressor phenotype by loss of CD27/CD28 
↓proliferation 
bNK Acute myeloid leukemia 
Breast 
Lung carcinoma 
↓NKG2D expression and cytolytic activity 
↓cytotoxic activity 
↓activity via TGFβ, miR23a 
        Notes: a  increase;  b decrease. Table adapted from [54] 
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 1.1.9.   EVs as therapeutic devices 
Due to their small dimensions, their presence in body fluids attesting their ability to 
long distance travel and their natural origin, EVs have been envisaged as attractive 
tools for the delivery of therapeutic agents in various diseases. Although still in its 
infancy, growing preclinical and clinical evidence highlights the importance of EVs as 
therapeutic devices, especially in regenerative medicine. These aspects have been 
recently reviewed by Wiklander and other ISEV members (2019) who summarised the 
current understanding of the role of EVs as therapeutic devices thereby accentuating 
the increasing importance of such approaches. Indeed, mesenchymal stem cell (MSC)-
derived EVs derived from diverse sources including human umbilical cord, bone 
marrow and adipose tissue were effective in tissue regeneration under pathological 
conditions such as respiratory hypertension, renal inflammatory and acute injury, 
hepatic injury and fibrosis, bone fractures and arthritis, myocardial infarction and 
neurological injuries [96].  
A similar scenario can be depicted for the employment of EVs in clinical trials, which 
experienced a tremendous development in the last decade. In most clinical trials the 
source of EVs is either dendritic cells or mesenchymal stem cells. EVs are administered 
either unmodified or modified, e.g. loaded with chemotherapeutics, microRNAs or 
peptides, as in the case of DC-derived EVs administered to cancer patients. 
Interestingly, also plant EVs deriving from grapefruits or loaded with curcumin are 
being tested in cancer patients (Figure 1.1.9 [96]).  
My hosting laboratory contributed to research in this setting with TRAIL-bioengineered 
EVs aimed at killing TRAIL-sensitive tumours [97]. Furthermore, great efforts are being 
made to engineer exosomes for systemic siRNA delivery to offer a less toxic and more 
potent alternative to synthetic nanoparticles in systemic delivery applications [98]. 
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Figure 1.1.9. Strategies of EV loading and engineering. Loading of EVs with RNA, proteins, small 
molecule drugs after isolation or during EV biogenesis. Manipulation of the EV-secreting cell to 
obtain EVs expressing therapeutic and targeting proteins, EV-sorting domains, RNA-binding 
proteins and aptamers [96]. 
1.1.10.   Tumour EVs as biomarker 
EVs deriving from cancer cells are considered as a valuable target to identify novel 
biomarkers that could potentially be used in the clinics to predict patient outcomes or 
treatment responses. The main reason for the interest of cancer EVs as non-invasive 
biomarkers is that EVs reflect the biological molecule expression abnormalities of the 
originating cells maintaining the molecules’ stability thanks to their protection by their 
lipid bilayer membrane [99, 100]. Additionally, EVs are part of the liquid biopsy and can 
be detected in almost all body fluids, comprising blood (plasma/serum), urine, saliva, 
tears, cerebrospinal fluid, milk, ascites and others and have been assessed in physiological 
as well as pathological conditions such as cancer.  
The research in this field is rapidly growing, especially in view of exploitation as 
biomarkers, and EVs display a large array of functionally active molecules, including 
tumour antigens, RNAs and microRNAs that could help distinguishing cancer-derived from 
non-cancer-derived EVs. For example, tumour-related large EVs termed oncosomes that 
carry DNA have been detected in blood of prostate cancer patients, and due to their 
dimensions of 1-10 µm they can be detected by immunohistochemistry [19].  
For EVs of melanoma patients, a subset originates from tumour cells, as suggested by the 
expression of melanoma antigens such as gp100, Melan-A/Mart-1 and TYRP2, together 
with VLA-4, HSP70 and HSP90 [4, 53]. Apart from tumour-derived EVs, also EVs originating 
from tumour-altered immune cells abundantly represented in plasma are particularly 
27 
 
appealing as source of biomarkers for monitoring early and advanced melanoma patients. 
These aspects, especially in view of the wide application of immunotherapeutic 
antibodies, which target molecules such as PDL1 and other IC also expressed by EVs, are 
discussed in detail in the IC Section 1.2. 
Tumour EVs appear also particularly interesting due to their content of RNA and 
microRNA. MicroRNAs (miRNAs or miRs) are a family small non-coding regulatory RNAs. 
miRs regulate gene expression by acting at the post-transcription level by binding to 
messenger RNAs (mRNAs), promoting their repression or leading to the mRNA complete 
degradation (Figure 1.1.10). A single miR can target hundreds of mRNAs by interacting 
with the 3’untranslated region (UTR) or with the 5’UTR or with the promoter of the gene. 
This interaction depends on several factors, including the sequence affinity between the 
two RNAs, their concentration and cellular location [101]. miRs are implicated in almost 
all biological processes and are have a role in intercellular cross-talk [102].  
 
 
Figure 1.1.10. Overview of microRNA biogeneis. Once miRNA are transcribed in the nucleus, they 
undergo a maturation process through several cleavages. Mature miRs can directly inhibit mRNA 
translation or leave the cell of origin via EVs. Original artwork by A. Shahaj. 
At the present time, 1917 miRs have been characterized in the human system (miRbase, 
release October 2018). miR genes are dispersed in the genome, generally located in 
introns and rarely in exons, and are usually co-transcribed with the gene in which they 
reside. Some miRs are instead intergenic and have their own promoter regulating 
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transcription. The functional role of miR is connected with the target gene transcripts and 
their biological function. Thus, miR are involved in a variety of cellular processes in 
physiological and disease conditions.  
In tumours, miR expression is dysregulated and miR studies are relevant in different 
cancer research areas, from the discovery of biomarkers, by the definition of their 
expression patterns in tumours and in blood as a liquid biopsy, to the identification of 
potential therapeutic targets therapy. miRs can be shuttled from one cell to another via 
EVs, and several studies showed the transfer of miR loaded in exosomes through 
packaging in MVB [103]. A recent study showed the transfer of miRs via plasma 
membrane-derived EVs, a mechanism regulated by the ARF6-Exportin-5 axis and studies 
on cell-cell communication via EV have defined the transfer of miRs as key actors in the 
context of pro-tumorigenic mechanisms [104, 105]. 
In view of the complexity of analysing body fluids such as blood that contains not only EVs 
but also non-EV particles like lipoproteins and soluble proteins and cells, the ISEV 
community is working towards a consensus to improve standardisation and 
reproducibility of EV research in view of obtaining more clinical relevance of the studies 
[106]. Of particular interest for biomarker research are serum, plasma and urine. In the 
latter exosome microRNA profiling identified different profiles for progression in prostate 
cancer patients, as compared to healthy volunteers [107]. Commercially available EV-
based diagnostic kits first appeared on the US market in 2016: ExoDx Prostate 
(IntelliScore) that detects prostate cancer markers in urine, and ExoDx Lung (ALK) that 
detects lung cancer markers in blood. Both tests were developed by Exosome Diagnostics, 
Inc. (USA) [108].  
In the era of immune and targeted therapies major effort is dedicated to identify EV-
based biomarkers to predict response to therapy. In this context, my hosting laboratory 
and I recently identified a set of microRNAs expressed by plasma EVs we called MDSC-
microRNAs which associate to resistance to immunotherapy of advanced melanoma 
patients [62]. 
1.2. Inhibitory immune checkpoints  
Immune checkpoints (IC) are cell receptors and ligands devoted to the control of immune 
responses, switching on or off the immune system during pathogenic infections. Several 
of the ligands bind to multiple receptors, some delivering costimulatory signals and 
others inhibitory signals, generally displaying distinct expression kinetics. The immune 
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checkpoints involved in switching off the immune system are also called inhibitory IC. 
These negative regulators are involved in modulating the duration and amplitude of the 
response, the maintenance of immune homeostasis and of tolerance to self-antigens, 
protecting the organism from autoimmune diseases [109].  
IC belong to different families of membrane-bound receptors, including  B7 family, the 
immunoglobulin superfamily and TNF family members showing distinct functional profiles 
and signalling pathways (Figure 1.2.1 [110]).  
 
Figure 1.2.1. Immune checkpoints. IC molecules are involved in the complex array of ligand–
receptor interactions between T cells and antigen-presenting cells (APCs) that regulate the T cell 
response to antigen via co-stimulation (+) and co-inhibition (–) signals. The different checkpoint 
superfamilies are shown. Figure taken from [110]  
In cancer patients, negative IC may be expressed not only by immune cells but also by 
tumour cells, determining the suppression of the immune response at the tumour site 
and the promotion of tumour immune escape [111-114]. In addition, tumour cells release 
EVs which may carry inhibitory IC in the circulation thus playing a systemic effect [115, 
116]. However, it is pharmacologically possible to unleash anti-tumour immune responses 
and re-establish immune-mediated tumour control by blocking the negative immune 
checkpoint regulators with specific antibodies [109, 117]. This discovery is based on the 
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pioneering work of James Allison who demonstrated that the T-cell protein CTLA-4 
functions as a brake for T cells and that antagonist antibodies unlock antitumor T cell 
activity and cure tumours in mice [117]. Tasuku Honjo, who shared with Allison the Nobel 
prize for medicine in 2018, discovered another T cell brake, PD1, showing promising 
results as a therapeutic target [118].  
After the initial studies showing the clinical effects of CTLA-4 and PD1 blockade, the 
success and expansion of immunotherapy targeting IC has been dramatic. At the 
moment, six IC inhibitors have been approved for the treatment of different tumour types 
by FDA in the US and by EMA in Europe: Pembrolizumab, Nivolumab and Cemiplimab 
anti-PD1 antibodies, and Durvalumab, Atezolizumab and Avelumab, which are anti-PDL1 
antibodies [119]. Other IC are currently being studied as potential target molecules for 
tumour immunotherapy. In addition, the study of IC expressed in tumours and the 
thorough characterization of IC expression in EVs will possibly identify predictive or 
prognostic biomarkers [120, 121].  
IC expressed by APC or tumour cells bind to different ligands that can be either inhibitor 
or activator molecules expressed by T cells implying a big challenge for their studies 
(Figure 1.2.2 AdipoGen Life Sciences).  
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Figure 1.2.2. Immune checkpoint molecules as receptors and ligands. IC expressed by APC, 
tumour and T cells and the result of their interaction as a positive (green plus arrows) or inhibitor 
stimulus (red minus arrows) is shown. Figure taken from AdipoGen Life Sciences. 
 
For this project, I investigated a set of IC molecules described in the literature as 
expressed by tumour cells including PDL1, PDL2, HVEM, GAL9, VISTA, CD155 to 
investigate their expression in EV released by melanoma cells (Figure 1.2.3). In addition, I 
analysed IC expressed by APC or by T cells, including PD1, BTLA, LIGHT, CD160, TIM3, 
VISTA, CD226, TIGIT, and CD96. In vivo relevance of the studied IC in the context of 
response to targeted therapy was assessed in plasma EVs and in tumour specimens of 
melanoma patients. 
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Figure 1.2.3. Selected IC studied in this project. IC molecules investigated for their inhibitory 
properties (red minus narrows) on T cells. Original artwork by A. Shahaj. 
1.2.1. PDL1/PDL2 – PD1 axis  
Programmed death-ligand 1 (PDL1) and its receptor programmed cell death protein (PD1) 
are the most studied IC because of the therapeutic effects when the axis is targeted in 
malignancies. The physiologic function of this axis is of crucial importance in normal 
tissues during inflammation to prevent autoimmunity and maintain homeostasis by 
inhibiting T cell activation and cytokine production [122]. 
PD1 binds both PDL1 and PDL2 (programme cell death 1 ligand 2). While PD1 is principally 
expressed by activated T cells, its two ligands are expressed by a large number of 
hematopoietic cells and other cell types, including neoplastic cells and stroma in 
tumours.  
PDL1 and PDL2 belong to the B7 ligand Ig gene superfamily, which includes ten members 
regulating immune cells interaction. PDL1, alias B7-H1, is a 209 amino acids protein 
encoded by the CD274 gene, while PDL2, also named B7-DC or CD273, is a 273 amino 
acids protein encoded by the PDCD1LG2 gene. Both human CD274 and PDCD1LG2 genes 
have 7 exons, are located in chromosome 9, and have splice variants, one and three 
respectively [122]. 
PD1 is a 288 amino acids protein encoded by the PDCD1 Ig superfamily gene located in 
chromosome 2; PDCD1 has 5 exons encoding four splice variants. It is a transmembrane 
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protein displaying extracellular, transmembrane and cytoplasmic domains; the 
cytoplasmic domain presents two tyrosin-based activation sites that are absent in the 
PDL1 protein. After the interaction between PDL1 and PD1 takes place, the tyrosine 
motives of PD1 are phosphorylated by Scr kinases, and the two tyrosine phosphatase 
proteins SHP1 and SHP2 are recruited, determining T cell attenuation by targeting T cell 
receptor or CD28 co-stimulatory receptors (Figure 1.2.1.1 Bio-Rad Laboratories). The 
activity of T cell effectors can be impaired in different ways due to PD1-PDL1 interaction, 
i.e. by blocking cell proliferation or cytokine production, and by inducing T cell apoptosis 
[123]. 
 
Figure 1.2.1.1. The PD1 Pathway. Binding of PD-L1 or of PDL-2 to the PD1 receptor leads to 
phosphorylation of SHP-2 and inhibition of signalling through ZAP-70/LCK, determining a 
reduction of T cell activation and effector functions. Red dotted arrows show inhibition, black 
arrows show activation. Figure taken from Bio-Rad Laboratories.  
Although it has been shown that both PDL1 and PDL2 function in T cells overlap, PDL1 and 
PDL2 appear to have also individual downstream pathways which are still under 
investigation [124]. PDL2 binds to PD1 with higher affinity than PDL1 [125]. PDL2 is 
expressed by dendritic and macrophages, as well as mast cells, and its expression is 
induced by Th2 secreted cytokines [123]. 
PDL1 is constitutively expressed in several immune cells, and its expression is up-
regulated in pro-inflammatory conditions [126]. Indeed, once IFNγ is produced by T cells, 
it activates JAK (Janus kinase) that activates STAT (the signal transducer and activator 
transcription) pathways, inducing IRF1 (transcription of interferon regulatory factor 1) 
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activation, which by binding to the promoter of PDL1 activates its transcription (Figure 
1.2.1.2 [109]). 
 
Figure 1.2.1.2. Mechanisms of PDL1 regulation. a) In innate immune resistance PDL1 is 
constitutively expressed by tumour cells independently of inflammatory signals in the tumour 
microenvironment. b) Adaptive immune resistance occurs when PDL1 is induced in response to 
inflammatory signals that are produced by an active antitumour immune response. Activation of 
the AKT and STAT3 pathways has been reported to drive PDL1 expression. IFNγ, interferon-γ; 
MHC, major histocompatibility complex; TCR, T cell receptor. Figure taken from [109]. 
The pathways regulating PDL1 expression are various depending on the type of cells 
(Figure 1.2.1.3 [122]). Especially in tumour cells, its expression can be induced by 
deregulated oncogenic pathways, or by epigenetic mechanisms including miRNAs (Table 
1.2.1.1 [122]). All these mechanisms increase PDL1 expression in tumour cells and 
enhance immune escape by augmenting the inhibition of local T cell function [122], 
protecting tumours from immune system attack, and making tumour cells more resistant 
to apoptosis.  
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Table 1.2.1.1. Regulators of PD-L1 
Type Regulators of PD-L1 Tissue type 
Inflammatory signalling IFNγ, IFNα, IFNβ ↑ different tumours, endothelial cells, monocytes, dendritic cells, macrophages, neutrophils  
 
TLR4, TLR3 ↑ different tumours, endothelial cells, monocytes, dendritic cells, macrophages 
 
IL-1β,IL-4, IL-6, IL-10, IL-12, IL-17, IL-24, IL-27 ↑ different tumours, dendritic cells, monocytes 
 
TNF-α ↑ different tumours, monocytes, dendritic cells 
  TGFβ ↑ dendritic cells, T cells ↓ monocytes 
Oncogenic signalling MYC, JUN ↑ different tumours 
 
HIF1α, HIF2α ↑ different tumours 
 
RELA,STAT3,MUC1-C ↑ different tumours 
 
PTEN loss, CDK5, PI3K-AKT-Mtor ↑ different tumours 
 
RAS, EGFR, ALK, MEK-ERK, MAPK14 ↑ different tumours 
microRNA miR-513, miR-155, miR-34a, miR-142-5p,miR-138-5p ↓ different tumour types  
 
miR-93, miR-106b, miR-217,miR-200, miR-152, , miR-17-5p ↓ different tumour types  
 
miR-15a, miR-193a, miR-16, miR-570, miR-197 ↓ different tumour types  
 
miR-20, miR-21, miR-130b ↑ CRC  
Genetic alteration amplifications, translocations, disruption of 3' UTR region ↑ different tumours 
Post-translational regulation CMTM6, CMTM4 ↑ different tumours, dendritic cells 
 
CDK4, GSK3B ↓ cervical cancer, breast cancer   
B3GNT3, CSN5      ↑ breast cancer 
Adapted from [122]  
  
36 
 
 
 
 
Figure 1.2.1.3. Overview of the regulatory mechanisms of PD-L1 expression. Regulators are color 
coded by class. Green, inflammatory cytokine receptors; orange, signal transduction components; 
blue, microRNAs; red, genetic alterations; brown, PD-L1 protein partners and modifiers. 
Directionality (‘‘up’’ or ‘‘down’’) and references are provided in Table 1.2.1.1. Figure taken from 
[122]   
PDL1 expression may be a prognostic marker for some tumour types. Indeed it has been 
reported that tumours with high level of PDL1 expression are associated with poor 
prognosis, and tumours that were PDL1 negative had a good prognosis [126].  
There are studies reporting PDL1 expression as a predictive biomarker of response to 
immunotherapy in melanoma, NSCLC and bladder cancer [121]. The relationship between 
PDL1 expression in the tumour and the response to immunotherapy was investigated in 
several clinical trials: some studies showed a correlation between PDL1 expression and 
the response rate but in other studies the response was not associated. These 
controversial results may be caused by differences in the analysis in the clinical trials, 
such as a different antibody used for IHC, a different cut-off used for positivity or even 
staining misinterpretation due to its dynamic alteration and tumour heterogeneity [127].  
Since tumour cells may also express PDL2, a recent study investigated the relevance to 
immunotherapy of PDL2 expression in 400 tumour samples of seven different types [128]. 
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Interestingly, results showed a high expression level of PDL2 in breast and gastric 
carcinomas, which was highly correlated with PDL1 expression, while in contrast, only half 
of the HNSCC expressed PDL2, and a low expression level was observed in melanoma and 
RCC. In addition, the study showed that clinical response to treatment with 
Pembrolizumab, an anti-PD1 antibody, correlated with PDL2 expression in HNSCC 
tumours, and that patients positive for both PDL1 and PDL2 at the tumour site responded 
better than patients that expressed only PDL1. These results indicated that PDL2 not only 
may predict clinical response to anti-PD1 immunotherapy, but also that targeting both 
PDL1 and PDL2 might enhance the clinical response.   
Even though a PD1-independent mechanism promoting tumour immunity via PDL1 and 
PDL2 was described [129], the most studied mechanism considers both ligands having 
PD1 as a unique receptor, and the binding leads to anergy in PD1-positive T cells. Indeed, 
knockout mice for PD1 develop lupus-like autoimmune disease, and show altered T cell 
maturation in thymus. In cancer, T cells lose their function becoming exhausted, and the 
high expression level of PD1 maintains this inhibited condition. It is clear that PD1 is 
expressed by all active T cells, although other immune cells including B cells and 
macrophages may express PD1 [122, 123]. Sonja Kleffel et al showed that PD1 is 
expressed in melanoma cells and can promote tumour growth after activation via mTOR 
signalling pathway [130]. Recently, Ogando J et al identified a new downstream element 
of PD1 connecting mitochondrial dysfunction with T cell inhibition, enlightening novel 
possible targeting strategies to restore T cell activity blocked by PD1 axis [131].  
During the last years immunotherapy has been concentrated on PDL1-PD1 axis, and 
several drugs based on blocking antibodies including nivolumab, pembrolizumab, 
atezonizumab, durvalumab and avelumab are approved for treatment of different types 
of tumours, such as melanoma, NSCLC, RCC, HNSCC, urothelial carcinoma, Merkel cell 
carcinoma, Hodgkin’s lymphoma, MSI-H and dMMR CRC, MSI-H and dMMR solid 
tumours, HCC and gastric cancer [122]. 
Although immunotherapy repeatedly showed survival benefit in these tumour types, the 
clinical responses are generally observed in a minority of treated patients and predictive 
markers are still missing. Besides the rate of positivity of PDL1/PDL2 at the tumour level, 
it has been shown that the patient’s tumour burden, the amount of genetic tumour 
mutations, the level of systemic inflammation reflected in lymphocyte-to-monocyte ratio 
38 
 
from full blood count, LDH values and ECOG performance status are all factors associated 
to response to immunotherapy [132]. 
In the recent years the potential of liquid biopsy has been widely investigated for 
biomarker detection. In parallel with PDL1 evaluation by immunohistochemistry on 
tumour tissue sections, several studies considered plasma PDL1 levels in relation to 
clinical outcome [132]. Moreover, since PDL1 is carried by EVs, its expression level has 
been evaluated in EVs isolated from plasma, also because studies showed EV-PDL1 can 
bind to PD1 on T cells and suppress its activity, thus representing a potential systemic 
mechanism impairing immunotherapy. In line with this, EVs from tumour cells genetically 
engineered to lack PDL1 expression in released vesicles showed the induction of systemic 
anti-tumour immunity and memory responses in a mouse model of prostate cancer [133]. 
In melanoma patients, high levels of PDL1 in plasma EVs were found associated with poor 
prognosis in [115]. In HNSCC patients, PDL1 but not PD1 expression by plasma EVs 
correlated with disease stages [134]. The presence of PDL1 transcript in plasma EVs was 
associated with good response in melanoma and NSCLC patients treated with anti-PD1 
antibody [135]. In plasma EVs from glioblastoma patients and in EVs from glioblastoma 
cells, PDL1 expression was shown to correlate with tumour volume and T cell 
suppression, respectively [136]. Data regarding IC studies in EVs are reassumed in Table 
1.2.1.2. Furthers studies are needed to enlighten the complexities of IC modulations 
occurring during anti-PD1 immunotherapy, as tumours may acquire resistance to 
immunotherapy by up-regulating other inhibitory IC. For example during anti-PD1 
treatment, tumour cells increase expression of TIM3 as shown by mouse studies and lung 
cancer patients [137].  
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Table 1.2.1.2. Immune checkpoint expression by cells and EVs. 
IC Ligand Immune cells Tumour cells EVs Biofluid EVs Ref 
PDL1 PD1 
T cells, B cells, DC, Mφ, MDSC, 
Mast Cells 
Melanoma, breast cancer, GC, NSCLC, 
GMB, CRC, PA, PCA 
Melanoma,  
PC, GBM 
Plasma melanoma,  
NSCLC, HNSCC, GBM 
[115, 133-136] 
PDL2 PD1 DC, Mφ, Mast cells 
Melanoma, breast cancer, EC, 
 LC, HNSCC RCC, NSCLC, GC, BC 
NA Plasma HNSCC  [134] 
PD1 PDL1/PDL2 T cells, B cells, NK cells, NKT Melanoma, CRC, RCC, CLL NA 
Plasma and synovial 
fluid RA  
[138]  
HVEM 
CD160/BTLA/
LIGHT 
T cells, B cells, NK, DC, Mo Melanoma, HCC, lung, CRC, GC NA NA  
CD160 HVEM T cells, NK CLL NA NA  
BTLA HVEM T cells, B cells, NK, DC, Mφ  GC, CLL, DLBCL NA NA  
LIGHT HVEM T cells, B cells, NK, DC Melanoma  NA NA  
CD155 
TIGIT/CD96/ 
CD226 
DC, Mφ, neutrophils 
Melanoma, NB, glioma, CCA, OC, LAD, 
ML, CRC, PCA, OSA, HNSCC, MIBC 
Melanoma,  
OC, PC 
NA [139-141] 
TIGIT CD155 Memory T cells, Tregs, NK CRC NA NA  
CD96 CD155 T cells, NK AML, T-ALL NA NA  
CD226 CD155 T cells, B cell, NK, Mo Lymphoma  Platelets Urine PC  [142, 143] 
GAL9 TIM3 T cells, DC, Mφ, Mo  
Melanoma, GC, CRC, HCC, BC, ccRCC, 
LC, PA, ampullary cancer, breast cancer  
NPC 
Serum ACR 
Plasma NSCLC 
[90, 116, 144] 
TIM3 GAL9 T cells, Tregs, NK, NKT, DC, Mo Melanoma, ccRCC, NSCLC NA Plasma NSCLC [144] 
VISTA - 
T cells, NK, DC, Mφ, Mo, 
neutrophils  
Melanoma, OC, endometrial cancer, GC NA NA  
Abbreviations: ACR-acute cellular rejection; AML-acute myeloid leukaemia; BC-bladder cancer; CCA-cholangiocarcinoma; ccRCC-clear cell renal cell carcinoma; CLL-chronic lymphocytic 
leukaemia; CRC-colorectal carcinoma; DC-dendritic cells; DLBCL-diffuse large B-Cell lymphoma; EC-esophageal carcinoma; GBM-glioblastoma; GC-gastric cancer; HCC-hepatocellular 
carcinoma; HNSCC-head and neck squamous cell carcinoma; LAD-lung adenocarcinoma; LC-lung cancer; MDSC-Myeloid-derived suppressor cells; MIBC-muscle invasive bladder cancer; 
ML-myeloid leukaemia; Mφ-macrophage; Mo-monocyte; NB-neuroblastoma; NK-natural killer cells; NKT-natural killer T cells; NPC-nasopharyngeal carcinoma; NSCLC-non small cell lung 
cancer; OC-ovarian cancer; OSA-osteosarcoma; PC-prostate cancer; PCA-pancreatic cancer; RA-rheumatoid arthritis; RCC-renal cell carcinoma; T-ALL - T cell acute lymphoblastic 
leukaemia; NA- Not Assayed 
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1.2.2. GAL9 – TIM3 axis 
TIM3 (T-cell immunoglobulin- and mucin-domain-containing molecule 3) receptor is encoded by 
HAVCR2 (hepatitis A virus cellular receptor) gene, and it exerts immunosuppressive effects by 
inducing apoptosis in Th1 cells when it binds to its ligand GAL9 [145]. TIM3 has been shown to 
bind also other ligands, including Ceacam-1 (carcinoembryonic antigen cell adhesion molecule 1), 
PS (phosphatidylserine), HMGB1 (high-mobility group protein B1), which are less characterized in 
tumour immunity (Figure 1.2.2.1 [146]). 
 
Figure 1.2.2.1. TIM3 ligands and biological functions. TIM3 signalling in T cells and NK cells may 
lead to the development of effector functions, apoptosis, or exhaustion. Likely dependent on the 
cellular context, TIM-3 signalling can enhance cross-presentation of dendritic cells (DC) or inhibit 
innate immune responses of DC and macrophages. Figure adapted from [146]. 
HAVCR2 gene is located in chromosome 5q33.2 in the human genome, has seven exons 
and encodes for 302 amino acid TIM3 receptor, with an N-terminal extracellular domain 
followed by a mucin domain, a transmembrane domain and a cytoplasmatic tail carrying 
tyrosine and SH2-biding residues important for the downstream signalling to the TCR 
[147].  
TIM3 expression is regulated by the transcription factor T-bet and is present in a large 
number of immune cells of the adaptive response [148]: in vitro and in vivo experiments 
showed that constitutive or transiently increased TIM3 expression marks differentiated 
IFNγ producing CD4 Th1 cells, cytotoxic effector CD8 T cells, and highly active CD4FoxP3 
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Treg cells [147]. Nonetheless, TIM3 is expressed also by cells of the innate immunity such 
as dendritic cells, monocytes, macrophages and NK cells (Table 1.2.1.2 [149]).   
As a checkpoint TIM3 plays an important role in immune homeostasis maintenance 
preventing autoimmune disease. Its role in the maintenance of self-tolerance was 
demonstrated in a mouse model of experimental allergic encephalomyelitis (EAE), 
showing that mice treated with anti-TIM3 antibodies showed an atypical hyperacute EAE 
and increased mortality [150]. Moreover, TIM3 knockout mice showed significantly 
reduced CD8 T cell responses, and impaired IFNγ production [151]. In addition, Treg cells 
highly positive for TIM3 were shown to restrain allograft rejection [152] and to promote T 
cell dysfunction in tumour models [153].  
TIM3 expression has been reported also in several human tumours, not only expressed by 
the T cell infiltrate, but also by cancer cells, such as melanoma, ccRCC, lung, cervical 
cancer, and osteosarcoma [148, 154-157]. Its expression level in T cells in patients with B 
cell non Hocking lymphomas, or in tumour-infiltrating Tregs in patients with NSCLC 
correlated with a poor prognosis [158, 159]. TIM3 protein and mRNA levels in tumour 
tissues of renal, prostate, colon, cervical, bladder, urothelial and gastric cancer were 
reported to associate with a poor prognosis [147]. 
TIM3 has been studied as a new target for immunotherapy in preclinical tumour models, 
including melanoma, AML, RCC, HCC, prostate, colon, lung and gastric cancer, with 
promising results [147]. In the clinical setting, the most recent data of treatment with the 
anti-TIM3-antibody LY332 were presented at the Symposium of the Society for 
Immunotherapy of Cancer Clinical Immuno-Oncology during the last ASCO congress (May 
2019) by James J. Harding, medical oncologist at Memorial Sloan Kettering Cancer Center 
and Weill Cornell Medical College. He reported that expansion cohorts had been opened 
for monotherapy in patients with lung cancer, and that preclinical studies clearly 
indicated that blocking TIM3 reinvigorates T cell function and increases the efficacy PDL1 
therapy. In addition, another anti-TIM3 antibody, TSR-022, is currently tested in clinical 
trials for the treatment of solid tumours and lymphomas (NCT03489343) and of liver 
cancer (NCT03680508). Other trials combining anti-TIM3 and anti-PD1 immunotherapy in 
metastatic solid tumours are ongoing (NCT02817633; NCT03099109).     
Among the ligands of TIM3 receptors, Galectin-9 (GAL9) is the best characterized and 
appears of major importance in tumours. GAL9 is a 355 amino acid β-galactoside-binding 
lectin protein, encoded by LGALS9 gene, located in 17q11.2 in the human genome and 
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counting 11 exons. Besides TIM3, GAL9 binds other receptors, i.e. CLEC7A, CD137, and 
CD40 [160-162]. GAL9 is characterized by two conserved carbohydrate recognition 
domains for galactose binding, one in the N-terminal involved in dendritic cell activation, 
and the other in the C-terminal region, responsible for T cell death and TIM3 recognition 
[163].  
GAL9 is widely expressed in various tissues and immune cells, and, probably due to its 
broad distribution, it has numerous and even opposite functions, from promoting 
inflammation through cytokine production in monocytes, to anti-inflammatory activities 
such as inducing T cell apoptosis and supporting Foxp3 positive Treg differentiation [164]. 
In concanavalin A‐induced hepatitis mouse model, GAL9 was up-regulated to promote 
liver T cell homeostasis via Foxp3 Tregs [165]. Moreover, GAL9 appears to regulate NK 
cells as GAL9 knockout mice display increased IFNγ production by NK cells and enhance 
their degranulation [166]. In addition, GAL9 is involved in modulating cell-cell and cell-
matrix interactions in cell aggregation and adhesion processes [163]. 
There are studies focusing on the characterization of TIM3 functions testing GAL9 as an 
agonist ligand for TIM3. In mice chronically infected with Herpes Simplex virus, 
administration of GAL9 reduced TIM3 CD4 T cell number and increased the number of 
Tregs and MDSCs [167]. On the other hand, tumour-bearing mice treated with 
recombinant GAL9 increased the number CD8 T cells positive for TIM3, as well as that of 
dendritic cells [168]. These studies show the positive and negative effect of GAL9 on 
different cells and in different inflammatory contexts. 
The role of GAL9 in tumours remains unclear. GAL9 expression in the cell membrane of 
hepatocellular carcinoma, prostate, cervical, and skin cancer resulted decreased when 
compared with the normal adjacent tissues, in contrast, in oral cancer, pancreatic cancer, 
and hematologic malignancies GAL9 expression was augmented; in gastric cancer, both a 
GAL9 protein increase and a GAL9 transcript decrease were reported [169]. In breast 
cancer, GAL9 expression in primary tumours was observed to be inversely correlated with 
distant metastasis since a low or absent GAL9 expression was detected in metastatic 
patients [170]. 
A meta-analysis that included publications from 2002 to 2017 regarding GAL9 expression 
in tumour tissues showed that a high expression of GAL9 was associated with a good 
prognosis, in particular for cancers of the digestive trait [163]. On the other hand, another 
meta-analysis published in 2017 reported an association between high levels of TIM3 
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expression and poor prognosis in patients with solid tumours [171]. These observations 
showing decrease of GAL9 and increase of TIM3 associated with poor prognosis suggest 
that the anti-tumour effect of GAL9 may be TIM3 independent [172].  
Given its immunosuppressive role promoting tumour immune escape via TIM3 pathway, 
the study of GAL9 targeting can unveil information for cancer immunotherapy. However, 
anti-GAL9 antibodies would possibly lack specificity, and in vivo exposure might be 
problematic because of toxicity. Studies investigating the anti-tumour properties of 
human recombinant GAL9 showed the induction of apoptotic response in haematological, 
gastrointestinal and melanoma cells [169]. Moreover, recombinant GAL9 administration 
in mice suppressed lung metastasis in melanoma [173]. Thus, GAL9 can be an anti-cancer 
agent, although this effect needs to be confirmed and receptors involved identified. It 
appears that the carbohydrate recognition domains are involved in the anti-tumour 
function of GAL9 [169].   
Despite the anti-tumour function of GAL9, other studies support the immunosuppressive 
role of GAL9-TIM3 axis in both adaptive and innate immunity. When GAL9 was evaluated 
in tumour and plasma of melanoma patients, most of the tumours coexpressed GAL9 and 
PDL1, and plasma levels were higher in patients compared with healthy donors. In 
addition, the study showed a correlation between GAL9 levels, Th2 polarisation and poor 
survival. When the immunomodulatory function of GAL9 was tested in vitro treating 
PBMCs from healthy donors, a reduced proliferation, Th1 promoted apoptosis and 
monocyte differentiation to M2 macrophage phenotype was shown, thus proposing GAL9 
as a valuable therapeutic target for metastatic melanoma patients [174]. Moreover, 
Wang et al showed GAL9 up-regulation in CD4 CD25 Foxp3 positive Tregs, and that the 
blockade of this axis neutralised the suppressive activity of these cells in vitro and in 
vivo[175]. Therefore, it appears that GAL9 may promote or inhibit tumour progression 
based on its ligand interaction in immune or tumour cells. Further studies are essential to 
establish GAL9 or anti-GAL9 therapeutic usage.    
TIM3 and GAL9 proteins have been reported as carried by EV released by tumour cells 
and in plasma EVs (Table 1.2.1.2). Firstly, Keryer-Bibes et al reported that nasopharyngeal 
epithelial carcinomas (NPC) cells produced exosomes carrying GAL9 showing intrinsic T 
cell inhibitory activity as a mechanism of immune escape [176]. These findings 
encouraged investigations of NPC exosomes in the blood of tumour patients for the 
assessment of their properties on various types of target cells, and other studies followed 
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showing that GAL9 expression in NPC exosomes supports tumour immune evasion [90, 
116]. A recent study in NSCLC patients showed GAL9 up-regulation in plasma EV and the 
amount of TIM3 and GAL9 correlation with malignant parameters [144]. 
1.2.3. HVEM and its receptors BTLA, CD160 and LIGHT 
HVEM (Tumour necrosis factor receptor herpesvirus entry mediator) is encoded by 
TNFRSF14 gene and acts as inhibitor when it binds to its two receptors in T cells, BTLA 
(immunoglobulin B and T lymphocyte attenuator) and CD160 
(glycosylphosphatidylinositol-anchored ligand). On the other hand, it can also act as an 
activator when binding to the ligand LIGHT, that is encoded by TNFSF14 gene in various 
immune cells. In addition, HVEM is also the receptor to LTα (lymphotoxin α), another 
member of TNF superfamily, and to HSV-1 gD (herpes simplex virus glycoprotein D). 
HVEM and CD160 genes are located in chromosome 1p36.32 and 1q21.1, while BTLA and 
LIGHT in 3q13.2 and 19p13.3, respectively. HVEM is a type 1 transmembrane glycoprotein 
containing in the extracellular part four cystein-rich domain (CRD) with two distinct 
binding regions: a CRD1 region, binding BTLA and CD160 molecules, and CRD2 and CRD3 
sites binding LIGHT, thus giving to HVEM the propriety to switch between both signalling 
(Figure 1.2.3.1 [177]). The short cytoplasmatic domain contains the binding site for TNF 
receptor associated factor (TRAF) family of ubiquitin E3 ligases that initiates activation of 
NF-κB responsible for downstream signalling of HVEM. 
 
Figure 1.2.3.1. HVEM: a coinhibitory ligand binding to CD160 and BTLA and a costimulatory 
ligand binding to LIGHT. Both BTLA and CD160 bind the CDR1 domain of HVEM (left) and inhibit 
CD4+ T cell activation. Binding of LIGHT to CRD2-CDR3 of HVEM does not inhibit the binding of 
BTLA or CD160 (right). For a T cell that expresses CD160, BTLA and LIGHT, the inhibitory signals 
mediated by CD160 and BTLA seem dominant. Figure adapted from [177]. 
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The ability of HVEM to act through different signalling pathways determines a role for this 
axis in both immune stimulation and suppression. HVEM binds the different molecules in 
two distinct sites and plays important roles in inhibition or costimulation of T cells, in 
maintenance of dendritic cell homeostasis, and regulation of autoimmune response 
[178]. The interaction between HVEM and its co-inhibitory receptors BTLA and CD160 is 
more frequent than the interaction with LIGHT possibly depending on ligand-receptor 
affinity, or type of cells expressing these molecules or their differentiation stage. HVEM is 
also expressed by tumour cells, such as melanoma, HCC, lung, CRC and gastric cancer 
[179-184].  
The roles of HVEM axis were investigated in human disease and disease models to 
discover novel therapeutic targets for cancer treatment. However, targeting this axis is 
challenging because of its dual function due to the multiple ligands binding HVEM. 
BTLA is an immune suppressive molecule expressed by B and T cells and by other immune 
cells such as monocytes, dendritic and NK cells. It interacts with HVEM at a 1:1 ratio, and 
forms multimeric structures in the cell membrane that cluster HVEM to start the 
downstream signalling. BTLA has a long cytoplasmic tail of 111 amino acids that contains 
three tyrosine-based inhibition domains. Once BTLA binds with HVEM it recruits protein 
tyrosine phosphatases to limit the stimulatory pathways in the immune cells [178].  
In BTLA-deficient B and T cells an increase of IgM antibodies production and 
hyperproliferation of T cells upon activated with anti-CD3 antibody were observed. In 
addition, BTLA knockout mice increased CD4 T cells in periphery and displayed higher 
autoimmune susceptibility disorders. Moreover, BTLA antagonists suppress alloreactive T 
cell responses in heart allografts [185]. The role of BTLA in tumour immunity is not clear 
yet. BTLA is expressed in exhausted activated anti-tumour CD8 T cells, however TILs 
expressing BTLA were shown to proliferate more and live longer, supporting a positive 
role for them in the tumour microenvironment [185]. 
CD160 is another ligand of HVEM, expressed only by two types of immune cells, NK and T 
cells. It competes with BTLA and LIGHT for binding HVEM, blocking LIGHT-HVEM 
interaction and the induced cytokine production [178]. The exact mechanism of this 
inhibition is unclear because CD160 does not have a transmembrane domain, but only a 
glycosylphosphatidylinositol anchors it to the membrane. 
LIGHT is mainly involved in the maturation of dendritic cells and the expansion of T cells, 
but its expression can be induced also in B and NK cells. LIGHT is a typical membrane 
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ligand with cytoplasmic N-terminal and type II transmembrane domains, and an 
ectodomain that can be selectively cleaved by proteases and become a soluble form 
(sLIGHT). The binding with HVEM leads to NF-kB pathway activation and stimulates T cell 
proliferation, dendritic maturation, B and NK cell activation [178].  
The cellular context of HVEM, BTLA and CD160 expression determines the response of 
this axis. If HVEM and BTLA/CD160 are expressed in the same cell (in cis), BTLA inhibits 
HVEM and turns off NF-kB dependent genes responsible for the survival. This inhibitory 
function of HVEM-BTLA interaction in cis is perhaps a self-tolerance mechanism of naive T 
cells competing with HVEM activation trans complex that is created when the two 
molecules are expressed in two different cells, and their interaction activates pathways 
that enhance cell proliferation [186]. All the studies investigating HVEM expression in 
tumours agree that HVEM expression correlates with a poor prognosis [179-184]. 
1.2.4. CD155 and its receptors TIGIT, CD96 and CD226 
CD155 is a Nectin-like molecule also called Necl-5 that belongs to immunoglobuline 
superfamily and is involved in cell-to-cell adhesion, motility and proliferation. It can serve 
also as Polio Virus receptor, and for this reason it was originally called PVR. The CD155 
gene has 8 exons and is located in chromosome 19q13.31. CD155 is expressed by immune 
cells and is overexpressed by tumour cells, and it was recently studied as a potential 
target for cancer immunotherapy [187]. CD155 has and IgV domain, a C1-like domain and 
a C2 domain in the extracellular region, and shows three conserved motifs with nectins in 
the IgV domain. CD155 has two transmembrane isoforms, and also two soluble isoforms 
secreted in body fluids (sCD155) [188].  
CD155 binds to different inhibitory or activator receptors called PVR-like receptors 
expressed by NK and T cells modulating immune response in cancers (Figure 1.2.4.1 from 
[187]): a) TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory 
motif domain), b) TACTILE (T cell activation increased late expression) also called CD96, 
and c) DNAM-1 (DNAX accessory molecule 1) or CD226 [187]. While TIGIT and CD96 
interact with CD155 to inhibit immune cell activation, CD226 is a co-stimulatory receptor 
expressed on most immune cells [188].  
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Figure 1.2.4.1. CD155 network and its receptors CD226, TIGIT and CD96. A) CD266, CD96 and 
TIGIT on NK and T cells interact with CD155 ligand on tumour cells and mediate activating and 
inhibitory signalling on cytotoxic cells. B) TIGIT expressed on tumour cells may inhibit NK and T 
cells by interaction with CD155. Figure adapted from [187]. 
CD155 was shown expressed in different tumour types, such as melanoma, 
neuroblastoma, glioma, cholangiocarcinoma, lung adenocarcinoma, myeloid leukaemia, 
colorectal, ovarian and pancreatic cancer, osteosarcoma, neck squamous cell carcinoma 
(HNSCC), muscle-invasive bladder cancer (MIBC), and its expression was generally 
correlated with a poor prognosis [188-191]. 
The expression of CD155 is regulated in cells by various stress conditions and stimuli, by 
oxygen and nitrogen reactive species (ROS and RNS), and by the activation of MEK/ERK, 
sonic Hedgehog (SHH) and NF-kB pathways (Figure 1.2.4.2 taken from [192]). Although 
CD155 is a molecule induced when cells are under stress, and consequently it should alert 
the immune system of potential malignancies, its overexpression in human neoplasms 
promotes tumour growth, invasion, and immune escape. Thus, targeting CD155 function 
may enhance antitumor immune responses [188]. In fact, CD155 knockout mice displayed 
reduced tumour growth and enhanced CD8+ T and NK response. In addition, CD155 null 
tumour cells showed a slower tumour growth [193]. 
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Figure 1.2.4.2. Regulation of CD155 expression. a) Chemotherapeutic agents and reactive oxygen 
species (ROS)/reactive nitrogen species (RNS) activate ATM and ATR kinases which upregulate 
CD155 expression. b) RAS via MEK/ERK signalling induces CD155 expression. c) Aberrant 
activation of sonic hedgehog induces CD155 expression. d) Combination of LPS with TLR4 
activates NF‐κB via adaptor protein MYD88 and TRIF, which stimulates CD155 expression. Figure 
taken from [192]. 
No data about CD155 expression in plasma EVs are available at present. Data have been 
reported showing that the levels of sCD155 are higher in the sera of patients with 
different tumour types compared to healthy donors, and decrease after surgery [194]. 
Moreover, in breast cancer, sCD155 serum levels correlated with high risk prognostic 
factors [195]. Tumour EV characterisation studies by proteomic analysis detected CD155 
expression in EVs from melanoma, ovarian and prostate cancer cells [139-141]. 
The TIGIT cytoplasmic tail contains two domains called Ig tail tyrosine-like motif (ITT) and 
immunoreceptor tyrosine-based inhibitory motif (ITIM). Besides CD155, TIGIT also binds 
to CD112 and CD113, two other members of the nectin family [187]. Several studies have 
demonstrated that TIGIT can directly inhibit cytokine secretion and cytotoxicity in NK 
cells, and T cell proliferation by targeting TCR signalling by its ITIM domain present in the 
cytoplasmatic tail, or by direct inhibition of CD226. In addition, TIGIT can indirectly inhibit 
immune cells by induction of cytokine production in dendritic cells via CD155-TIGIT 
interaction [187, 188].  
Recently TIGIT expression was reported in murine and human colorectal tumour cells, 
thus enlightening another mechanism of immune system inhibition mediated by the 
TIGIT-CD155 axis (Figure 1.2.4.1B [187, 196]). Several anti-TIGIT antibodies are now being 
tested in cancer immunotherapy clinical trials, and Phase 1 and 2 clinical trials are 
ongoing testing the combined of block of TIGIT and of PD1/PDL1 axis [187]. 
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CD96 is also a member of Ig superfamily with two cytoplasmic domains, one is the ITIM-
like inhibiting domain, and the other one YxxM activating motif which is present only in 
humans. Thus, its role in human NK and T cells is only partially characterised and still 
unclear. In mouse models CD96 exerts an inhibitory effect on NK cells, and its blockade 
supports anti-tumour responses [187]. In addition, in mouse tumour models, blocking of 
CD96 suppresses primary tumour growth in a CD8+ T cell-dependent manner, and the 
combination of anti-CD96 with anti-PD1 and anti-TIGIT resulted in superior antitumor 
responses. This study showed that CD96 is an immune checkpoint expressed on CD8+ T 
cells and by blocking it, T cell activity is enhanced and tumour suppressed [197].    
CD226 molecule has an extracellular part composed by two Ig-like domains and a 
cytoplasmic domain containing three tyrosine residues. It is expressed in T cells, NK cells 
and monocytes and besides CD155 it can bind also CD112. CD226 down-regulation in NK 
cells was reported in healthy aged donors and in different diseases including cancer. Its 
role in potentiating NK cytotoxicity was shown in several mouse models [187]. 
EVs isolated from urine from prostate cancer patients showed high CD226 expression in 
proteomic analysis [143]. Another study showed that CD226 protein is expressed by 
platelet EVs [142]. 
1.2.5. VISTA immune checkpoint molecule  
VISTA (V-domain Ig suppressor of T cell activation) is another negative IC receptor 
expressed by T cells. VISTA, also called PD1 homolog (PD1H), is a member of B7 family 
with large homology with PDL1 and PDL2 encoded by C10orf54 or VISIR gene. VISTA is a 
type I transmembrane protein encompassing 311 amino acids that presents a single 
extracellular domain, and a 96 amino acid long cytoplasmic tail [198] containing binding 
sites for protein kinase C and docking sites containing proline residues. This conformation 
makes VISTA to act both as a ligand or as a receptor [185]. In fact, little is known about 
ligands or receptors of VISTA. A recent study identified a novel ligand for VISTA called 
VSIG-3 (V-Set and Immunoglobulin domain containing 3), firstly discovered as IGSF11 
member of immunoglobulin superfamily, highly expressed in colorectal cancer, intestinal-
type gastric cancer and hepatocellular carcinoma. As a ligand of VISTA, it inhibits T cell 
proliferation and significantly reduces T cell cytokine and chemokine production, thus 
representing a possible new target for cancer immunotherapy [199] (Figure 1.2.5 [200]). 
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Figure 1.2.5. The ligand-or-receptor paradigm of VISTA in regulating T cell activation. VISTA is 
expressed on both APCs and T cells. VISTA suppresses T cell activation via both T cell-extrinsic and 
intrinsic mechanisms. a) VISTA acts as a ligand when expressed on APCs, and engages a putative 
inhibitory receptor on T cells that suppresses T cell proliferation and cytokine production. b) 
VISTA expressed on T cells may engage a putative inhibitory receptor on T cells via T cell-T cell 
interaction or may act as a self-signalling receptor. Both mechanisms will contribute to T cell 
suppression. The identity of the counter-receptor and detailed signalling downstream of VISTA 
remain to be elucidated. Figure taken from [200]. 
Although VISTA is expressed mainly by myeloid cells, low expression levels were detected 
in T and NK cells, but not in B cells [198, 201]. Moreover, VISTA is over expressed in 
tumour infiltrating immune cells such as MDSC and Tregs, confirming its role in immune 
suppression. Furthermore, VISTA deficient mice showed an enhanced anti-tumour 
immune response, although not sufficient to impair tumour growth. In vitro studies 
showed that soluble VISTA-Ig protein inhibits T cell proliferation, while VISTA blockade 
increases proliferation of T cells, although suppression of T cell proliferation was shown to 
last over time even in the absence of VISTA [185]. In addition, no T cell apoptosis was 
observed after VISTA blockade, as T cells just stopped proliferating or started to 
upregulate Foxp3 expression, and no effect were observed on B cells [198]. Furthermore, 
when overexpressed in sarcoma cells, VISTA has a protective antitumor immunity effect 
[202]. 
VISTA was reported to be expressed at mRNA and protein levels in ovarian cancer cells 
and endometrial cancer cell lines. Its presence in tumour cells was associated with T cell 
infiltration and with a poor prognosis [203]. VISTA expression was also shown in about 
10% gastric cancers and liver metastases [204]. In addition, VISTA was reported expressed 
by human lung carcinomas [205] and by melanoma cells lines [206]. Thus, VISTA could 
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represent another new target for immunotherapy, and its increase during treatment with 
ipilimumab in patients with prostate cancer may support its targeting [207]. Indeed, CA-
170, a small molecule drug targeting VISTA, PDL1 and PDL2 is currently tested in a phase I 
trial in advanced solid tumours and lymphomas (NCT02812875) [208]. 
1.3. Melanoma  
Melanoma is a highly aggressive malignancy arising in the skin, eye or gut mucosa due to 
genetic mutations in melanocytes. Cutaneous melanoma is the most common form of 
melanoma: it occurs in about 1/7,000 in Italy [209] and is the most aggressive type of skin 
cancer. Melanoma is highly curable in its early stages but still life threatening in the 
advanced metastatic stages.  
1.3.1.  From melanocytes to melanoma  
Melanocytes are a key cellular component in the skin and in the eye, but they are also 
located in the inner ear, brain and heart, adipose tissue, lung and gut mucosa. 
Melanocytes have different functions depending on their position: in skin and eye they 
are involved in pigmentation protecting from UV, while in the other tissues they are 
involved in detoxification and anti-inflammatory functions [210]. Melanocytes derive 
from precursor cells called melanoblasts originating from the neural crest during embryo 
development.  
The primary function of melanocytes is the production of melanin, light-absorbing 
pigments derived from the oxidation and polymerization of tyrosine. Human melanocytes 
produce two main types of melanin, brownish-black eumelanin, synthesized from l-
dopachrome, and reddish-yellow pheomelanin, whose synthesis is dependent on the 
availability of sulfhydryl compounds. The type and amount of melanin produced by 
melanocytes is determined genetically and is influenced by a variety of extrinsic and 
intrinsic factors, including exposure to UV light, hormonal changes, inflammation, and age 
[211]. Biosynthesis of melanin takes place in membrane-bound organelles termed 
melanosomes. In the basal layer of skin epidermis melanocytes are surrounded by 
keratinocytes, in a ratio one melanocyte to about 40 keratinocytes, to which they transfer 
the melanosomes [212]. Genetic, biochemical and pharmacological evidence has 
established that signalling from Melanocortin 1 receptor (MC1R) is the main factor 
dictating melanogenesis. Melanogenesis is then regulated by other signalling systems and 
different transcription factors including the tyrosine kinase receptor KIT, its ligand SCF, 
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and microphthalmia-associated transcription factor (MITF). Melanogenic enzymes, a 
number of highly similar metalloproteins, include tyrosinase (TYR), tyrosinase-related 
protein 1 (TYRP1) and tyrosinase-related protein-2 (TYRP2). Melanocytes can be identified 
by the expression of these and other melanocyte-specific markers, the most used being 
MITF, Pmel17/gp100 (premelanosome protein 17), melan-A/MART-1 (melanoma antigen 
recognized by T cells 1), (Figure 1.3.1.1 [213]), (Figure 1.3.1.2 [211]).  
 
Figure 1.3.1.1. The epidermis structure. Melanocytes reside in the basal layer cells and form the 
epidermal melanin unit interacting with keratinocytes by dendritic processes. Melanin 
synthesized in melanocyte is transported by melanosomes to keratinocytes to protect them from 
UV radiation. Figure taken from [213].  
 
Figure 1.3.1.2. Schematic of human skin architecture from light and dark pigmented skin types. 
From top to bottom: SC, stratum corneum; G, stratum granulosum; S, stratum spinosum; B, 
stratum basale; BM, basement membrane; D, dermis. Cell types: K, keratinocyte; M, melanocyte; 
F, fibroblast; shaded oval, melanin granule. Figure taken from [211]. 
Benign proliferation of skin melanocytes results in melanocytic nevi (MN). The most 
common MN are generally referred to as acquired melanocytic nevi, although there are 
different subgroups of MN (congenital nevi, dysplastic or atypical nevi, Spitz nevi, Blue 
nevi). The development of these common benign tumours is a multifactorial process 
under genetic and environmental influences. MN are differentiated from melanoma and 
diagnosed on the basis of their clinical aspects and of histopathology, although the 
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diagnosis may prove quite challenging in intermediate cases, and especially in paediatric 
melanoma. The use of dermoscopy discriminating subsurface skin structures may aid the 
clinical diagnosis [214]. In addition, molecular diagnostic tests have been designed to 
differentiate melanoma from benign nevi by genetic profiling [215], though a consensus 
about the discriminating markers has not been reached yet. Although melanoma 
generally occurs independently from existing MN, high MN counts and atypical nevi are 
risk factors for cutaneous melanoma [216].  
Cutaneous melanoma results from both intrinsic and extrinsic risk factors, the first 
including the individual genetic background conditioning nevi characteristics and familial 
susceptibility, and the second including sun exposure and environmental conditions, 
(Figure 1.3.1.3 [217]). In fact, the incidence of cutaneous melanoma is different in the 
different countries and populations, the highest registered in New Zealand and Australia 
fair skin inhabitants, Northern Europe and North America, while the incidence in the 
Mediterranean area is lower [217, 218]. Furthermore, cutaneous melanoma incidence is 
on the rise in the majority of these countries. 
 
 
Figure 1.3.1.3. Melanocytic neoplasms become more proliferative and polyclonal as they 
evolve. Gene mutations caused by UV radiation accumulate during the transition to invasive 
melanoma. Once melanomas become invasive, copy number alterations become more prevalent. 
PCNA-proliferating cell nuclear antigen. Figure taken from [217].  
1.3.2.  Melanoma classification and clinical stages  
Different types of cutaneous melanoma exist, based on histopathologic definition and 
body localization: superficial spreading melanoma and nodular melanoma are the most 
common and may develop at all body sites, especially in limbs and trunk, while acral 
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melanoma occurs in glabrous skin sites. Lentigo maligna are melanomas occurring in the 
elderly in the face and head [219]. 
Melanoma clinical staging is based on the extent of the primary tumour growth and on 
the occurrence of metastatic spread to regional or distant sites through lymphatic or 
hematogenous routes. Diagnostic histopathological examination of the primary tumour 
considers the vertical thickness (Breslow index) and the presence of microscopic 
ulceration for primary melanoma staging. The current AJCC clinical staging system takes 
into consideration the primary tumour classification and the presence of metastasis in the 
tumour-draining regional lymph nodes and/or at distance, to distinguish four disease 
stages: stages I-II considering the features of primary melanoma growth in the absence of 
metastatic dissemination, and stages III-IV when regional or distant metastases are 
present [220].  
1.3.3.  Molecular characterization of melanoma  
The Cancer Genome Atlas (TCGA) Project of the US National Cancer Institute recently 
characterized a large number of cutaneous melanoma subtypes by a multiplatform 
molecular analysis of DNA, RNA, and protein, and defined four main genomic subtypes: 
mutant BRAF, mutant RAS, mutant NF1, and triple-wild-type [221]. Mutations in the BRAF 
gene are the most common mutations, detectable in about 50% of all cutaneous 
melanoma. The majority of BRAF mutations are point mutations resulting in T1799. A 
transversion and the substitution of valine to glutamic acid (V600E) gives place to a 
constantly active state of the BRAF serine/threonine kinase [222]. Although the BRAF 
mutation is also common in benign MN [223], it represents a major therapeutic target in 
melanoma. Other common mutations include RAS genes mutations, occurring in about 
20% melanoma and benign MN, generally mutually exclusive with BRAF mutation, and 
NF1 mutations (Figure 1.3.3.1 [224]). Common mutations in tumour suppression genes 
CDKN2A, TP53 and PTEN are also observed [225] (Table 1.3.3 [217]). Genetic and 
transcriptomic data implicate activation of MAPK signalling at initiation and subsequent 
amplification of signalling during melanoma progression (Figure 1.3.3.2 [226]). 
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Figure 1.3.3.1. Recurrent mutations in melanoma affecting the MAPK and PI3K/AKT signalling 
pathways. The binding of a ligand to RTKs induces RAS activation and stimulation of the MAPK 
and PI3K/AKT pathways, leading to the transcription of genes involved in cell growth, survival, and 
proliferation. NRAS, BRAF, NF1, and PTEN mutation frequencies are indicated. Figure taken from 
[224]. 
 
Table 1.3.3. Common mutations and their role during melanoma progression  
Table taken from [217]. 
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Figure 1.3.3.2. Somatic alterations in key signalling pathways that drive melanoma appear at 
specific points in the melanoma progression cascade. Each heatmap reflects the frequency that a 
given pathway is activated (red) or inactivated (blue) at a specific point in the melanoma 
progression cascade. Figure taken from [226]. 
Genome sequencing studies determined that melanoma is the human cancer showing the 
highest number of genetic alterations, resulting from UV light mutagenesis and other 
mutational processes [227]. These high number of mutations have been suggestively 
linked to melanoma immune‐responsive state. In fact, melanoma has shown historically a 
high degree of response to immune therapy and to the recently developed immune 
checkpoint inhibitors (ICI). Mutation burden has been associated to response to ICI in 
multiple tumour types: the assumption is that passenger mutations in coding sequences 
generate neoantigens that may be recognized by the adaptive immune system. In 
addition, when the immune infiltrate of melanoma was thoroughly analysed in the TCGA 
dataset, the expression signatures of immune composition showed a clear enrichment in 
most samples [228]. 
Molecular characterization of melanoma by transcriptomic profiling has shown that 
melanoma includes heterogeneous subpopulations of cancer cells with different 
biological features. A proliferative and an invasive state have been identified in melanoma 
cell lines and specimens, the latter including also the category immune, characterized by a 
signature attributable to the presence of tumour-infiltrating lymphocytes [229, 230]. The 
different states can reversibly switch between the corresponding transcriptional 
programs, and this switch is governed in vivo by interactions occurring in the tumour 
microenvironment [231], (Figure 1.3.3.3 [231]). The MITF‐rheostat model, whereby cells 
adopt an invasive phenotype at lower MITF levels and a proliferative phenotype when 
MITF expression is higher, has been proposed to encompass the transcriptional regulation 
underlying the different states [232], (Figure 1.3.3.4 [233]). Different other regulators 
have been associated to the regulation of the invasive cells, which adopt a slow cycling 
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stem cell‐like, nonpigmented state, and the proliferative cells, appearing to be more 
melanocytic and highly pigmented [234]. The cell phenotype switching model is a 
prevalent model not only in tumour progression but also in drug resistance, as MITF-low 
invasive melanoma cells are more resistant than the others to BRAF inhibitors [235]. 
 
Figure 1.3.3.3. Pathways towards metastasis. In the genetic model, the acquisition of novel 
mutations promotes the generation of metastasis. By contrast, in the phenotype‐switching model 
metastasis arise because of microenvironment‐driven changes to the cell’s phenotype. Figure 
taken from [231]. 
 
Figure 1.3.3.4. Low or high levels of MITF contribute to melanoma phenotype. The melanoma 
rheostat model proposes that different levels of MITF regulate distinct phenotypic states: low 
MITF is associated with dedifferentiation, intermediate MITF controls proliferation, and high MITF 
is associated with cell differentiation. The proliferative and slow-cycling phenotype are dependent 
on glycolysis and oxidative phosphorylation, respectively. The dedifferentiated state reduces the 
melanoma cell's dependency on the MAPK pathway, and consequently leads to resistance to 
MAPK pathway inhibition. Figure taken from [233]. 
Moreover, miRNAs negatively regulate gene expression post-transcriptionally and have 
important role in the epigenetic regulation of melanoma progression. Deregulated miRNA 
expression has been linked to tumour progression in melanoma as well as in a variety of 
other cancer types [236]. miRNA dysregulation has been observed during different stages 
of melanoma, and their role in the multiplicity of processes involved in melanoma 
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progression at the primary tumour site and at distant tissues have been highlighted in 
several studies [237].  
1.3.4.  Melanoma treatment: targeted drugs and immunotherapy  
In the last years, the treatment of metastatic melanoma has been revolutionized by the 
advent of two types of therapy, targeted drugs and immunotherapy. Recently, 
randomized trials have confirmed the efficacy of both therapeutic approaches in both the 
adjuvant and neoadjuvant settings [238] (Figure 1.3.4.1 [235]). 
 
 
 
Figure 1.3.4.1. Treatment options for patients with unresectable metastatic melanoma. BRAF-
mutant melanoma patients can receive targeted therapies or immunotherapies as first-line 
treatment. Patients with BRAF wild type tumours usually receive immunotherapies as first-line 
treatment. Patients that do not respond to BRAFi as first-line treatment generally receive 
immunotherapy as second line treatment. Additionally, other local treatment are used (T-VEC). 
Figure taken from [235]. 
Targeted drugs are kinase inhibitors that target BRAF (BRAFi) and MEK (MEKi) 
oncoproteins, currently used in combination to treat BRAF-mutated melanoma. Both 
proteins are involved in the RAF-MEK-MAPK pathway, which is activated by extracellular 
signals bound to their membrane receptor, usually a receptor tyrosine kinase (RTK). 
Targeted therapy with BRAF/MEKi has significantly improved overall survival of patients 
with metastatic melanoma. Although the majority of patients respond to this treatment 
regimen, clinical responses are often followed by the rapid occurrence of disease relapse 
due to emerging tumour drug resistance [239], (Figure 1.3.4.2 [240]).  
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Figure 1.3.4.2. MAPK–PI3K–Akt pathway and BRAFV600 mutation in melanoma. BRAFV600 
mutations in melanoma lead to constitutive activation of the MAPK pathway, which leads to 
uncontrolled cell survival, growth, and proliferation that might be blocked by treatment with 
BRAF inhibitors or MEK inhibitors. Figure adapted from [240].  
Immunotherapy determines the reinforcement of patient immune system response 
against the tumour by blocking key immune inhibitory molecules. Immunotherapy 
regimens consist in the systemic infusion of specific engineered antibodies that bind and 
block negative checkpoint regulators of adaptive immune response [241]. Since 
immunotherapy does not target any tumour mutated protein it represents a mutation 
independent therapy that regulates T cell function via immunological synapses. The first 
immunotherapy drug was Ipilimumab, a molecule inhibiting CTLA4 in cytotoxic T 
lymphocytes developed by James Allison [242]. Few years later other antibodies targeting 
PDL-1 and PD1 have reached clinical practice and are currently used in the therapy of 
different tumour types.  
1.3.5.  Mechanisms of melanoma resistance to targeted therapy 
BRAF/MEKi targeted therapy is currently the first line treatment for metastatic melanoma 
patients carrying BRAF-mutated tumours [240]. BRAF/MEKi treatment shows long-term 
benefit in approximately one third of the patients [243], but the emergence of drug 
resistance in the majority of patients strongly limits its clinical efficacy. 
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Several studies have assessed the genomic correlates of resistance to BRAF inhibitors, 
both induced by tumour changes under the drug selective pressure, i.e. acquired, and the 
pre-existing or intrinsic resistance, observed more rarely in cell lines and in patients with 
very short therapy responses. In general, drug resistance can result from a myriad of 
genetic and epigenetic events and shows a wide intra-patient and intra-tumoral 
heterogeneity of underlying mechanisms. 
A variety of molecular mechanisms have been identified that act by sustaining MAPK 
signalling or parallel signalling networks despite BRAF inhibition, including mutations in 
RAS, MEK, NF1, RAC, RAF genes, or in genes of the PI3K/AKT pathway (AKT, PIK3, PTEN), 
and amplification or alternative splicing of BRAF gene. Other genetic mutations identified 
by next-generation sequencing approaches involved cell cycle control genes such as 
CDKN2A, and TP53 [244].  
However, reactivation of the MAPK signalling derive more frequently from epigenetic 
mechanisms regulating the expression of receptor tyrosine kinase (RTK) genes involved in 
melanoma cell growth. Different signalling pathways downstream RTK have been 
associated with BRAFi resistance that involve other signalling axis besides the MAPK and 
the PI3K/AKT pathways, such as the SRC/STAT and Notch1 pathways, and RTKs such as 
AXL, EGFR, IGF1R, PDGFR, MET, ERBB3, to give some examples [245], (Figure 1.3.5.1 
[246]).  
 
Figure 1.3.5.1. Mechanisms supporting BRAF inhibitor resistance in melanoma. Genetic and 
epigenetic processes regulating receptor tyrosine kinase (RTK) downstream pathways involved in 
melanoma cell growth. Figure adapted from [246]. 
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The acquisition of a resistant state is characterised by a generalised de-differentiation 
leading to activation of several different new signalling pathways able to confer survival 
advantages in the presence of the drugs. Melanoma phenotype switching capacity to de-
differentiated and slowly proliferating invasive cells expressing low MITF and high AXL 
levels has been identified as a mechanism of resistance to targeted therapy in a subset of 
melanoma patients as well as in cell culture systems. Moreover, a metabolic switch 
associates to drug resistance [235]. 
Transcriptomic studies revealed that other mechanisms favouring tumour cell 
proliferation may bestow BRAFi resistance. One example is the increased abundance of 
extracellular matrix (ECM) proteins conferring stiff and more rigid properties to the ECM, 
regulated by fibroblast secreted TGFβ via the HIPPO pathway and TEAD transcriptional 
partner, connected to the de-differentiated and invasive phenotype [230]. Another 
example stems from the observation that tumour cells can adapt to drug-induced stress 
by upregulating autophagy. The mechanisms leading to a BRAFi-mediated induction of 
tumour autophagy include ER stress pathways activation [247]. 
miRNA-mediated resistance mechanisms have been intensively studied, also in 
consideration of their potential manipulation for therapeutic strategies. Several miRNA 
were reported as upregulated in resistant melanoma by regulating nodes in the MAPK, 
PI3K/AKT, STAT3 and MITF pathways [248]. In my hosting lab a set of miRs including miR-
34a, miR-100 and miR-125b were demonstrated to be upregulated in the BRAFi resistant 
variants of melanoma cells in parallel with increased production of CCL2; their inhibition 
restored the in vitro drug sensitivity. These results indicated that these miRs and CCL2 are 
potent prognostic factors and good targets for overcoming drug resistance in metastatic 
[249]. 
Currently, ongoing clinical studies are investigating combinations of targeted therapy with 
IC inhibitors [224]. Several studies reported that BRAF/MEKi-induced alterations strongly 
condition the TME thus influencing anti-tumour immunity [250]. Treatment was shown to 
generate an immune stimulating TME, characterized by increased tumour infiltration of 
immune cells, including cytotoxicity markers but also markers of T cell exhaustion, such as 
TIM3, PD1, and PDL1 [251, 252].  
In vitro studies showed that upon BRAFi/MEKi treatment melanoma cell lines increase 
expression of melanoma antigens MART, TYRP1, TYRP2 and Gp100, and that at 
therapeutic concentrations BRAFi have no effects on lymphocytes viability and functions. 
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While BRAFi displayed a boosting effect on T cells by paradoxical activation of the MAPK 
signalling, in contrast MEKi showed suppressive effects on T cell functions, which were 
not confirmed by in vivo studies. Clinical studies confirmed that treatment does not affect 
blood cell counts, leukocyte subset frequencies or serum cytokine levels [253]. It has been 
hypothesized that the combination of targeted therapy and immunotherapy could 
enhance anti-tumour responses augmenting therapeutic outcome (Figure 1.3.5.2 [254]). 
However progressing tumours show increased expression of inhibitory molecules and 
immunosuppressive cell infiltration, concomitant to decreased T cell numbers. 
 
Figure 1.3.5.2. Immunomodulatory effects of BRAF and MEK inhibitors. Their beneficial influence 
on the antitumor immunity and the tumour microenvironment is mediated by different illustrated 
mechanisms. Figure taken from [254] 
Resistant tumours were characterized by a transcriptional signature determining an 
immunosuppressive TME due to an increase in genes regulating epithelial-mesenchymal 
transition, cell adhesion, extracellular matrix remodelling, angiogenesis and wound-
healing, predictive of resistance to immunotherapy, termed IPRES, for innate anti-PD1 
resistance [255].  
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1.4. Aims of the thesis  
Tumour EVs can shuttle a vast array of functionally active proteins and genetic material to 
other cells at distance or within the tumour microenvironment contributing thereby to 
tumour immune escape. Immune checkpoints control the immune response, and their 
expression level is a key factor for disease outcome of cancer patients. In melanoma, 
negative immune checkpoint molecules (IC), known from the literature to be involved in 
immune system inhibition can be modulated by targeted therapies, such as BRAF/MEK 
inhibitors (BRAF/MEKi). To study the potential role of EVs carrying IC in conditioning 
antitumour response, I investigated the immunomodulating effects of melanoma EVs 
deriving from BRAF/MEKi sensitive or resistant melanoma on tumour and immune target 
cells. To collect evidence about the clinical relevance of EVs carrying IC, I evaluated 
plasma EVs from melanoma patients undergoing targeted therapy for IC protein and 
transcript expression. Given the importance of immunotherapy in melanoma treatment, 
elucidating the role of EVs carrying IC could contribute to improve combined therapy 
planning and to the discovery of new potential immunotherapy targets to improve 
treatment responses as well as to uncover new predictive biomarkers. In particular I 
investigated: 
1) the expression of a set of IC like PDL1, PDL2, HVEM, GAL9, VISTA and CD155, in BRAF-
mutated melanoma cell lines and their released EVs before and after the acquisition of 
resistance to BRAF/MEKi  
2) the effect induced by melanoma EVs on the expression of negative IC in melanoma and 
immune cells, taking advantage of an in vitro model of monocyte skewing MDSC set up by 
the hosting laboratory  
3) the modulation of the expression levels of negative and positive IC in plasma EVs and in 
melanoma specimens, to assess the translational relevance of the obtained results  
  
64 
 
2. Materials and methods  
2.1. Melanoma Patients Samples 
Peripheral blood and surgical specimens were obtained by study protocols approved by 
the Institutional Review Board of Fondazione IRCCS Istituto Nazionale dei Tumori and the 
Independent Ethics Committee (code INT39/11 and INT40/11). All participants, including 
melanoma patients and healthy controls, gave their written informed consent. Healthy 
controls were blood donors of the Immunohematology and Transfusion Medicine Unit of 
the hospital used for in vitro PBMC co-culture experiments in this project. These donors 
were healthy subject selected with no previous and no current tumour disease or any 
other kind of disease. Plasma from stage IIIC-IV melanoma patients at the beginning and 
during targeted therapy with BRAF and MEK inhibitors were studied for circulating EVs. 
Table 2.1.1 represents data regarding melanoma patients involved in plasma EV studies.   
Table 2.1.1. Melanoma patients treated with targeted therapy studied for plasma EVs 
Patient ID Treatment TTP OS sex age 
CAP14-28 D + T >19 >19 F 34 
CP 14-15 D + T >23 >23 F 42 
BR14-22 V + C >19 >19 M 60 
RG 14-07 D + T >25 >25 M 63 
TN14-78 D +T >20 >20 F 67 
BD14-57 D +T 2,7 5,3 M 65 
CA14-34 D + T 7,4 11,2 F 70 
GT 14-20 D + T 5,9 5,9 F 65 
MF14-29 D + T 0,8 4 F 37 
RC14-35 V + C 7,8 10,6 F 49 
SF14-50 D + T 4 8,1 F 48 
D-Dabrafenib (BRAFi), T-Trametinib (MEKi), C-Cobimetinib (MEKi), V-Vemurafenib, TTP-time to 
progression in months, OS overall survival in months. The upper part of the table lists patients 
displaying TTP > 12 months, defined Long responders in these studies. The other patients displaying 
TTP <12 months were defined short responders. F-female, M-male. 
 
Metastatic tumour specimens obtained from stage IIIC-IV melanoma patients were snap 
frozen and processed for RNA extraction and analyses. Table 2.1.2 shows characteristics 
of patients and melanoma tumour metastases.  
Table 2.1.2. Characteristics of melanoma specimens and patients 
Metastases location Mutation Stage Age Sex 
C LN V PT BRAF WT BRAF mut III IV <50 >50 F M 
28 23 6 1 27 31 28 30 17 41 29 29 
C-cutaneous; LN-Lymph node; V-visceral; PT-primary tumour; WT-wild type; BRAF mut- V600E 
and V600K BRAF mutations; F-female; M- male 
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2.2. Cell lines and culture conditions  
Human melanoma cell lines were previously obtained in the hosting laboratory from 
metastatic melanoma surgical specimens [256]. The vemurafenib-resistant cell line 
variants (R) were generated from the parental sensitive ones (S) by repeated exposure to 
the commercially available drug Vemurafenib (PLX4032, Active Biochem) [249, 257]. All 
cell lines were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated 
foetal calf serum (FCS), 20 mM HEPES buffer, 2 mM glutamine, 100 IU/ml penicillin and 
100 µg/ml streptomycin (Lonza). Standard culturing conditions included 21% O2 at 37°C 
and 5% CO2 in 95% humidity. For downstream analyses cells were grown at 80-90% 
monolayer confluence, washed once with 1X PBS and detached using Trypsin EDTA 
(Lonza). Cells were periodically checked by laboratory service for their identity by short 
tandem repeat loci characterization by GenePrint 10 System (Promega), and for the 
absence of mycoplasma contamination (N-GARDE Mycoplasma PCR Euroclone).  
To generate a melanoma cell variant resistant to BRAF/MEKi from sensitive cell line 
LM16S, I treated cells in 150 cm2 flasks with the combination of the BRAF inhibitor 
Dabrafenib (GSK2118436), and the MEK inhibitor Trametinib (GSK1120212), at 10nM. 
Both drugs are commercially available (Selleck). After 7 days of cells incubation in 
medium with the drugs, fresh medium without drugs was added on the few survived cells 
that than were grown to confluence. IC expression by flow cytometry analysis was 
monitored before repeating the section treatment. IC50 values to the drug combination 
were tested after each cycle. 
2.3 Cell transfections  
To set up cell transfection conditions, four different lipid transfection reagents were 
tested at different concentrations. Metafectene (Biontex) and Lipofectamine2000 
(Invitrogen) were tested at 0.5-2 µl, TransIT-X2 (Mirus Bio) at 1.5-6 µl and HiPerFect 
(Qiagen) at 2-6 µl: all were mixed with DNA in 50 µl of final volume of medium FCS free. 
To select the best transfection reagent, the Red Fluorescent Control oligo DNA (BLOCK-iT 
Alexa Fluor, Invitrogen) was used as readout of transfection efficacy by evaluating the 
number of fluorescent cells at 48-72 h. Metafectene resulted the most efficient lipid for 
melanoma cells transfections.  
Plasmid vectors pCMV6-AC-GFP coding for PDL1-GFP and CD81-GFP fusion proteins were 
purchased (OriGene) and replicated by Plasmid DNA Laboratory Facility. Plasmid DNA (2 
µg) and Metafectene (1-2 µl) were used for stable transfection. To determine the 
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concentration required for the selection of transfectants acquiring resistance to Geneticin 
antibiotic (G418 Sulfate, Gibco), a dose-response test was performed. Initially I tested the 
same G418 concentrations (1000, 500, 125, 62.6 µg/µl), and after 21 days of treatment, 
LM16S cells death was clear at doses ≥ 250-500 µg/µl, while for LM16R it was ≥ 125-250 
µg/µl. Based on these results, I set a second dose-response curve test, and identified 450 
µg/ml as the dose for transfectants of LM16S cells, and 150 µg/ml that of LM16R.  
Cell transfection were set by plating 35x104 cells in 6 well plates; after 24 h the medium 
was removed and 2 µg of plasmid DNA mixed with metafectene were added in 800 µl of 
RPMI FCS free medium. After 4 h, complete medium containing G418 was added (1200 
µl). In order to enrich for LM16S-GFP positive cells, the florescence-activated cell sorting 
technique (FACS) by BD FACSAria Fusion flow cytometer was applied in collaboration with 
the Flow Cytometry and Cell Sorting Facility. While FACS was an effective selection 
method for LM16S transfectants, it resulted unsuccessful in the purification of the 
LM16R-CD81-GFP transfectant, because of cell aggregation during sorting. Even though 
two different methods of FACS sorting were used (“Purify” and “Single Cell Sorting”), in 
both cases an heterogeneous population was obtained. To obtain enriched LM16R-CD81-
GFP transfectant cells I cloned the sorted cells by limiting dilution in 96 plates and 
selected cell clones by GFP expression.   
2.4. Isolation of EVs from melanoma cell lines 
For EV isolation from the supernatant of melanoma cell lines, I used a standard 
ultracentrifugation (UC) protocol to enrich small vesicles, such as exosomes [30]. For 
these cultures, I used FCS that was depleted from calf EVs by over-night UC at 113,000 g 
followed by 0.22 µm filtration. Cultures were set in standard conditions seeding 5-10 x 
106 cells in 150 cm2 flasks; after 72 h, conditioned medium was collected, centrifuged at 
300 g for 10 minutes to pellet the cell debris, filtered at 0.22 μm, followed by 4 h UC at 
113,000 g at 4°C by SureSpin 630 Swinging Bucket Rotor to pellet EVs. The pellet was 
washed in 1,5 ml filtered 0.1 μm PBS (Microtube HighG, Thermo Fisher Scientific) for 1 h 
UC at 118,000 g at 4°C. EV pellets were resuspended in PBS and quantified by Bradford 
protein assay (Bio-Rad) or assessed by Nanoparticle Tracking Analysis (NTA) before 
storage in aliquots at -80°C. The proteins yields ranged between 4-7 μg /106 cells. 
2.5. RNA extraction 
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RNA was extracted from cell pellets, melanoma EVs and CD14 cells after homogenizing 
the samples with 1 ml of TRIzol reagent (Ambion) and separating the two phases by 
adding chloroform: the upper clear aqueous layer containing RNA was collected, and RNA 
precipitated with 0.5 ml of 100% isopropanol. For melanoma cells, the time of incubation 
was 10 minutes at room temperature, while EV samples and CD14 cells were lysed 
overnight at 4°C. RNA was precipitated by centrifugation at 12,000 g for 10 minutes at 
4°C; then the pellets were washed with 1 ml of 75% ethanol and dried out before adding 
H2O. RNA was incubated at 55°C for 10 minutes and stored at -80°C. The RNA yield and 
purity were assessed by analysing OD260/OD280 ratio by spectrophotometer (Picodrop Pico 
100). For the RNA extraction from melanoma EVs, 100-500 µg protein were used, and the 
OD260/OD280 ratio resulted often lower than 1.8-2.0.  
For plasma EVs while comparing different protocols, RNA was extracted from samples 
isolated by ExoQuick precipitation (System Biosciences) resuspended in 100 µl of PBS 
without protein quantification by RNA NucleoSpin miRNA (Macherey-Nagel) kit. To 
eliminate any potential residual of non-exosomal RNA, freshly isolated EVs were treated 
with RNaseA (1:1000, Sigma) for 1 h at 37°C prior to RNA extraction. For IC studies on 
plasma EV from patients at different time points of the treatment, to assess IC 
modulation, another commercial kit including EV isolation and total RNA purification was 
used (ExoRNeasy Serum/Plasma kit, Qiagen). The EV isolation consisted in a membrane-
based affinity binding step followed by phenol/guanidine-based lysis (QIAzol Qiagen): the 
aqueous and organic phases were then separated by adding chloroform and by 
centrifugation, the upper aqueous phase was transferred in a silicia-membrane spin 
column and RNA bound to the membrane was eluted in a small volume of water. RNA 
obtained from plasma EVs was reverse transcribed for qPCR without quantification 
because of its low quantity. 
2.6. Quantitative Real Time PCR analysis 
For cDNA synthesis, the High-Capacity cDNA Reverse Transcription kit (Thermo Fisher 
Scientific) was used with 0,1 to 1 µg RNA from melanoma cell lines and EVs. No RNA 
quantification was performed for plasma EV samples due to the low amount recovered 
from these samples. The reaction was carried out in the GeneAmp PCR System 9700 
instrument (Thermo Fisher Scientific) incubating the samples and the RT mix at 25°C for 
10 minutes and 60°C for 120 minutes. The cDNA was assayed by quantitative real-time 
PCR (qRT-PCR), performed in triplicates on an ABI PRISM 7900 Real-Time instrument using 
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a standard setting (50°C for 2 minutes, 95°C for 10 minutes and 40 cycles at 95°C for 15 
seconds and at 60°C for 1 minute). TaqMan gene expression assays (Thermo Fisher 
Scientific) listed in Table 2.6.1 were used at a final concentration 0.2X. The transcript 
expression levels were calculated by normalising data to the expression of ACTB and 
GAPDH genes used as endogenous controls. Relative expression was determined using 2-
∆Ct and expression fold change by 2-∆∆Ct method. Data were analysed with SDS 2.2.2 
software and a cut-off of 35 Ct was used.  
For EVs and cultured monocytes, a pre-amplification step was performed: one third of the 
cDNA was pre-amplified by using a pool of TaqMan assays at 0.2X final concentration 
prepared in 1X TE, mixed with TaqMan Preamp Master Mix (Thermo Fisher Scientific) and 
amplified in the thermocycler (95°C for 10 minutes, 10 cycles of 95°C for 15 seconds, 
followed by 60°C for 4 minutes). After 10 cycles, samples were placed on ice, the 
preamplification products were diluted 1:5 with 1X TE buffer and used for downstream 
analysis by PCR or stored at -20°C. The Ct value 40 was considered as cut-off. Water was 
used as negative control for cross-reaction and unspecific amplifications. To evaluate miR 
expression levels (listed in Table 2.6.2), qPCR analysis was performed according to 
manufacturer’s instructions (Exiqon reagents). Endogenous controls used were U6 snRNA 
and SNORD48 to normalize miRs expression levels. 
Table 2.6.1. Panel of TaqMan gene expression assay 
Gene symbol Description Protein Assay ID  
CD274 Programmed Cell Death 1 Ligand 1 PDL1 Hs01125301_m1 
PDCDLG2 Programmed Cell Death 1 Ligand 2 PDL2 Hs01057777_m1 
PDCD1 Programmed Cell Death 1 PD1 Hs01550088_m1 
PVR Poliovirus Receptor CD155 Hs00197846_m1 
TNFRSF14 TNF Receptor Superfamily Member 14 HVEM Hs00187058_m1 
HAVCR2 Hepatitis A Virus Cellular Receptor 2 TIM3 Hs00958618_m1 
LGALS9 Galectin-9 GAL9 Hs00371321_m1 
C10orf54 V-Domain Ig suppressor of T cell activation VISTA Hs00735289_m1 
CD226 DNAM-1 CD226 Hs00170832_m1 
CD160 Natural Killer Cell Receptor, Ig Superfamily Member CD160 Hs01073987_m1 
TNFSF14 TNF Superfamily Member 14 LIGHT Hs00542477_m1 
CD96 T-Cell Surface Protein Tactile CD96 Hs00976975_m1 
CD3D CD3-Delta CD3 Hs00174158_m1 
CD14 Monocyte Differentiation Antigen CD14 CD14 Hs02621496_s1 
BTLA B And T Lymphocyte Associated BTLA Hs00699198 m1 
TIGIT T Cell Immunoreceptor Ig and ITIM domains TIGIT Hs00545087 m1 
GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase GAPDH Hs99999905_m1 
ACTB Actin Beta Actin Hs99999903_m1 
CD163 Macrophage-Associated Antigen CD163 Hs00174705_m1 
CD68 Macrophage Antigen CD68 CD68 Hs02836816_g1 
CD33 Myeloid Cell Surface Antigen CD33 CD33 Hs01076281_m1 
CD4 T-Cell Surface Glycoprotein CD4 CD4 Hs01058407_m1 
CD8A T-Cell Surface Glycoprotein CD8 Alpha Chain CD8 Hs00233520_m1 
ITGAM Integrin Alpha-M ITGAM Hs00355885_m1 
FOXP3 Forkhead Box P3 FOXP3 Hs01085834_m1 
HLA-DRA MHC Class II Antigen DRA HLA-DRA Hs00219575_m1 
HLA-A MHC Class I Antigen A HLA-A Hs01058806_g1 
PMEL Premelanosome Protein GP100 Hs00173854_m1 
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Table 2.6.2. miRCURY LNA Universal RT microRNA PCR Panel 
microRNA Name Target sequence LNA™ PCR primer set, Product No 
hsa-miR-100-5p AACCCGUAGAUCCGAACUUGUG 205689 
hsa-miR-34a-5p UGGCAGUGUCUUAGCUGGUUGU 204486 
hsa-miR-125b-5p UCCCUGAGACCCUAACUUGUGA 205713 
hsa-miR-100-5p AACCCGUAGAUCCGAACUUGUG 205689 
SNORD48 GATGACCCCAGGTAACTCTGAGTGTGTCGCTG 
ATGCCATCACCGCAGCGCTCTGACC 
203903 
U6 snRNA GTGCTCGCTTCGGCAGCACATATACTAAAATTGGA 
ACGATACAGAGAAGATTAGCATGGCCCCTGCGCAA
GGATGACACGCAAATTCGTGAAGCGTTCCATATTTT 
203907 
All miRNA assays were from Exiqon company 
2.7. Co-culture experiments of melanoma cells 
Sensitive and resistant melanoma cells were seeded in the chambers of 24 well transwell 
plates with 0.4 µm pore size (Corning Costar) at a density 2 x 105/well. After 72 h of 
incubation the insert was removed and cells of the bottom chambers were used for 
downstream analyses. These included western blot and flow cytometry analyses, as well 
as qRT-PCR for evaluation of IC modulation after co-culture incubation.  
2.8. Cell viability assay 
The MTT colorimetric assay was used to determine melanoma cell viability after 
treatment with BRAFi, MEKi, IFNγ, or melanoma EVs. Cells were seeded in 96-cell 
well/plates at a density of 1.5 x 104/well in triplicates left overnight to adhere prior to 
treatment with the drugs. After 72 h, MTT (50 µl of 5 mg/ml, Sigma) was added to each 
well and incubated for 2 h at 37°C; then, the MTT was removed, 100 µl of SDS/DMF were 
added and absorbance at 570 nm was detected by microplate spectrophotometer 
(Tecan). 
2.9. Flow cytometry analysis of melanoma cell lines 
To analyse IC expression on melanoma cells by direct flow cytometry, 2x105 cells were 
suspended in 50 µL of PBS and incubated with specific APC/PE/AlexaFlour647/PerCP-
Cy5.5-conjugated antibodies or respective isotype controls, at 1:25 dilution, in single 
analysis or in combination, for 30 minutes at room temperature in the dark; an unstained 
control sample was included to set sample acquisition. After incubation, the cells were 
washed with 1 ml of PBS, centrifuged at 300 g for 10 minutes, and fixed in 200 μl of 1% 
formalin PBS in cytometry tubes. Tubes were gently vortexed before acquisition with BD 
TYR Tyrosinase TYR Hs00165976_m1 
IL-6 Interleukin-6 IL6 Hs00985639_m1 
TGFB1 Transforming Growth Factor Beta 1 TGFβ1 Hs00998133_m1 
CCL2 C-C Motif Chemokine Ligand 2 CCL2 Hs00234140_m1 
All gene assays were from Thermo Fisher Scientific company. 
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FACSCalibur flow cytometer (BD Biosciences). Data were analysed with FlowJo v8.8.6 
(Becton Dickinson) software, presented as delta geometric mean (ΔgMFI), calculated as 
the experimental gMFI minus the background gMFI of antibody fluorescence) or 
percentage of positivity after setting the marker according to the negative isotype 
control. The used antibodies are listed in Table 2.9. 
2.10. Flow cytometry analysis of melanoma EVs 
Melanoma EVs were analysed by flow cytometry after coupling them to 5 µm diameter 
latex-beads (Invitrogen) to detect them according the standard protocol of Thery et al., 
2006. To this aim, 10 μl of latex-beads were mixed with 10 μg of EVs for 15 minutes at 
room temperature, and then incubated overnight in a final volume of 1 ml PBS at 4°C on a 
test tube rotator. Then, 110 μl of 1 M glycine were added, the mix was incubated for 30 
minutes at room temperature, washed 3 times in PBS 0.5% BSA by centrifugation at 4,000 
rpm in a benchtop microcentrifuge for 5 minutes. Finally, the EV-covered beads were 
divided in different test tubes in 50 μl PBS plus 0.5% BSA for antibody labelling. 5 µl of 
each antibody, including IgG isotype, was added separately to each tube and incubated 
for 30 min at 4 °C. After the incubation the mix was washed twice with PBS 0.5% BSA as 
previously described. Finally the ab-EV-beads were resuspended in 250 µl of PBS 0.5% 
BSA and acquisition in flow cytometry was performed.  
    Table 2.9. Anti-human antibody used for flow cytometry staining 
Antibody Dye Clone Host/Isotype Company Catalogue no. 
anti-CD274 PE MIH1 Mouse IgG1, κ BD Pharmingen 557924 
anti-CD273 APC MIH18 Mouse IgG1, κ eBiosience 17-5888 
anti-HVEM Alexa Fluor647 94801 Mouse IgG1, κ BD Pharmingen 564411 
anti-Galectin-9 PE 9M1-3 Mouse IgG1, κ BD Pharmingen 565892 
anti-VISTA PE 730804 Mouse IgG2b, κ R&D System FAB71261P 
anti-CD155 PerCP/Cy5.5 SKII.4 Mouse IgG1, κ BioLegend 337612 
anti-CD3 PerCP SK7 Mouse  IgG1, κ BD Pharmingen 345766 
anti-CD25 APC M-A251 Mouse  IgG1, κ BD Pharmingen 555434 
anti-CCL2 APC 5D3-F7 Mouse  IgG1, κ eBiosience 17-7099 
anti-CD8 PerCP SK1 Mouse  IgG1, κ BD Pharmingen 345774 
anti-CD4 PE RPA-T4 Mouse  IgG1, κ BD Pharmingen 555347 
anti-HLA-DR PE CY L243 Mouse  IgG2a, κ BD Pharmingen 655874 
anti-CD14 FITC M5E2 Mouse  IgG2a, κ BD Pharmingen 555397 
anti-CD14 APC MφP9 Mouse  IgG2b, κ BD Pharmingen 560180 
anti-CD81 PE 5A6 Mouse  IgG1, κ BioLegend 349506 
anti-CD9 PE HI9a Mouse  IgG1, κ BioLegend 312106 
anti-CD63 PE H5C6 Mouse  IgG1, κ BD Pharmingen 556020 
IgG PE MOPC-21 Mouse  IgG2b, κ BD Pharmingen 556437 
IgG APC MOPC-21 Mouse  IgG1, κ BD Pharmingen 550854 
IgG PerCP/Cy5.5 MOPC-21 Mouse  IgG1, κ BioLegend  400149 
IgG Alexa Fluor647 MOPC-21 Mouse  IgG1, κ BD Pharmingen 557714 
IgG PE MOPC-21 Mouse  IgG1, κ BD Pharmingen 555749 
71 
 
 
Figure 2.10. Extracellular vesicles on beads analysed by flow cytometry analysis. The circled area 
contains the single bead-EV events. The events non included in the area are considered beads 
aggregates, and thus they were not considered for analyses.    
 
2.11. Western blot analysis 
Cell protein lysates were obtained in RIPA buffer (Invitrogen) completed with 1X 
PhosphoSTOP phosphatase inhibitors and 1X complete EDTA-free Protease Inhibitor 
Cocktail (Roche), quantified by Bradford Protein Assay (Bio-Rad), and boiled for 5 minutes 
at 95°C in 1X NuPAGE LDS Sample Buffer (Thermo Fisher Scientific) in the presence of 1,4-
dithiothreitol (DTT), a reagent that maintains SH groups in reduced state. In contrast, EV 
samples were mixed with 1X LDS and 1X DTT and boiled at 95°C for 5 minutes without a 
previous lysing step.  
Samples were loaded on precasted NuPAGE Novex 4-12% Bis-Tris gels in 1X MOPS 
running buffer (Invitrogen), electrophoretically separated and transferred onto 
nitrocellulose filters using a Dry Blotting System (Invitrogen). After 1 h of blocking in 5% of 
BSA, filters were incubated with primary antibodies overnight at 4°C, washed three times 
with 1X TBST (Cell Signaling) and incubated for 1 h with horseradish peroxidase 
conjugated secondary antibody. The used antibodies are listed in Table 2.11. The 
immuno-reactive bands were visualised by chemiluminescence after 5 minutes incubation 
in the dark at room temperature with HRP substrate (ECL Western Blotting Detection 
Reagent, Amersham), substrate removal and filter exposure on the UVITEC 
chemiluminescence imaging system (Uvitec Alliance Q9 Advanced). Image acquisition was 
carried out with standard or manual programs in case of weak chemiluminescence signal. 
The Intensity Volume of the signals was analysed by NineAlliance software, and the ratio 
between the intensity volume of the protein of interest and of the control was calculated. 
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2.12. Confocal microscopy analysis  
Confocal microscopy analysis of melanoma cells co-cultured with EVs was performed by 
incubating 3x104 cells/well with 30 µg of EVs in open wells µ-Slide (Ibidi). After overnight 
culture, medium was removed, cells were washed with 1X PBS to remove the non-
internalized EVs, fixed in 120 µl of 4% paraformaldehyde for 10 minutes, washed twice 
and stained with 5 µg/ml of wheat germ agglutinin (WAG) conjugates (Invitrogen), which 
selectively bind to N-acetylneuraminic acid (sialic acid) residues labelling in red the cell 
membrane. After washing twice with PBS, cells were incubated for 5 minutes with 300 
nM blue-fluorescent DAPI nucleic acid (Invitrogen) diluted in PBS, followed by three 
washes with PBS. Finally, 150 µl of Ibidi Mounting Medium were added to optimize the 
fluorescence signal, and cells were analysed by confocal microscopy. The used Leica SP8 
AFC AOBS WLL HyD microscope has detector sets for super-sensitive imaging with high 
quantum efficiency, low noise and large dynamic range, acting in synergy with the filter-
free spectral detection system and the acousto-optical beam splitter in the gapless light 
detection with maximum photon efficiency, making it suited for imaging of green 
fluorescent nanovesicles. The analysis set was performed by ImageJ software in 
collaboration with Cell Imaging Facility at our institute, and merged images were 
generated from acquisition in green, blue and red channels. 
2.13. Transmission electron microscopy  
TEM was performed in collaboration with Dr A Villa from M.I.A Consortium. To this aim I 
prepared two pellet of isolated EVs (from 200 to 300 µg of protein) from two melanoma 
cell lines LM16S and LM16R by ultracentrifugation protocol. The fresh vesicles were fixed 
in 100 µl of paraformaldehyde 4 % for 20 minutes at room temperature. After the 
incubation, 1.5 ml of PBS were added to wash the EVs following 1h of high speed 
    Table 2.11. Anti-human antibody used for western blot analysis 
Antibody Clone Isotype Dilution Company Catalogue no. 
anti-PDL1 405.9A11 Mouse IgG1 1:1000 Cell Signaling 29122 
anti-CD155 D3G7H Rabbit IgG 1:1000 Cell Signaling 13544 
anti-CD9 TS9 Rabbit IgG 1:500 Invitrogen 10626D 
anti-β-Actin AC-15 Mouse IgG1 1:1000 Sigma A5441 
anti-Alix 3A9 Mouse IgG1,k 1:1000 Biolegend 634502 
anti-tGFP 2H8 Mouse IgG2b 1:2000 Origen TA150041 
anti-GM130 35/GM130 Mouse IgG1,k 1:250 BD G65120 
anti-BIP/GRP78 40/BiP Mouse IgG2a 1:250 BD G73320 
anti-Rab5b 15/Rab5 Mouse IgG1,k 1:500 BD 610725 
anti-STAT3 K-15 Rabbit IgG 1:500 Santa Cruz sc483 
anti-Stat1α p91 C111 Mouse IgG1 1:500 Santa Cruz sc-417 
anti-IRF1 D5E4 Rabbit IgG 1:1000 CellSignaling  8478 
anti-gp100 HMB45 Mouse IgG 1:500 abcam ab787 
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ultracentrifugation at 53,000 rpm with Beckman TLA100.3 Fixed Angle Centrifuge Rotor. 
Finally the washed pellets were resuspended in 10 µl of phosphate buffer 0.12 M. The 
pellet was sent to our collaborators for immunohistochemistry analyses for the detection 
of CD63 marker.     
2.14. Plasma and peripheral blood mononuclear cell (PBMC) collection 
Blood processing was performed within two hours of venipuncture. PBMCs and plasma 
were isolated from whole blood collected in EDTA tubes. To obtain the plasma free of 
platelets, whole blood was centrifuged for 15 minutes at 1,700 g, and plasma was 
collected for a second centrifugation at 1,700 g of 10 minutes before storage at -80°C. The 
blood cell pellet was resuspended in PBS to isolate white blood cells by Ficoll-Paque 
gradient (GE Healthcare Life Sciences). After centrifugation at 800 g for 15 minutes at 
room temperature with brake off, the upper layer containing PBMCs were collected and 
washed once with PBS. Ammonium-Chloride-Potassium Lysing Buffer (ACK) treatment 
was used to lyse red blood cells by adding 5 ml of ACK and incubation at 4°C for 5 
minutes. After washing in PBS cells were counted with Trypan Blue solution prior to 
further experiments or storage at -80°C in freezing solution (RPMI 40% FBS and 10% 
DMSO) in a cool cell (Biocison). For CD14+ cell isolation, CD14 MicroBeads for human 
monocytes were applied to PBMCs according to the manufacturer’s instructions (MACS 
Miltenyi Biotec). Both the CD14+ monocyte and the CD14- cells fraction were collected for 
further experiments. The purity of obtained fractions was assessed by flow cytometry 
(Figure 2.14). 
 
Figure 2.14. Negative and positive CD14 cells isolated by microbeads from PBMCs of an healthy 
donor.  
2.15. Labelling of EVs for immune cell interaction 
To evaluate the interaction of melanoma EVs with immune cells, EV (20 μg) were labelled 
with the membrane lipophilic dye green fluorescent carbocyanine SP-DIOC18(3) (Thermo 
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Fisher Scientific). The SP-DiOC18(3), or 3,3'-Dioctadecyl-5,5'-Di(4-Sulfophenyl) 
Oxacarbocyanine Sodium Salt, is a DiO analogue soluble in water because of a sulfonate 
group that when incorporated into membranes is highly fluorescent. SP-DiOC was diluted 
1:100 in PBS and vortexed for few seconds. EVs were brought to a final volume of 198 µl 
with PBS, 2 µl of the diluted SP-DiOC were added mixing well and incubated for 15 
minutes at room temperature in the dark. The EVs were washed twice in 1 ml of 
exosome-free FBS and thereafter once with 1 ml of PBS for 30 minutes of 
ultracentrifugation at 100,000 g using Beckman Coulter TLA 100.3 ultracentrifuge rotor. 
The stained EVs were suspended in RPMI for co-culture experiments.  
2.16. Interaction of labelled EVs with immune cells 
Sp-DioC-labelled, CD81-GFP+ or PDL1-GFP+ EVs 20 µg were added to 2 x 105 PBMCs to 
assess the uptake by monocytes and T cells. After an overnight incubation PBMCs were 
harvested and labelled with fluorochrome-conjugated antibodies against CD14, CD3 and 
PDL1 to identify monocytes, T cells, EV uptake level and potential modulation of IC such 
as PDL1. After an incubation with the antibodies of 30 minutes at room temperature, 
samples were washed and acquired with a FACSCalibur flow cytometer and analysed with 
FlowJo software (Becton Dickinson). 
2.17. Monocyte-melanoma EV co-cultures 
For monocyte-EV co-cultures CD14+ cells were purified from buffy coats of healthy donors 
by sorting with anti-CD14+ beads (MACS, Miltenyi Biotech) according to manufacturer’s 
instructions. Their purity (>95%) was assessed by flow cytometry using a FACSCalibur flow 
cytometer (Becton Dickinson) after labelling samples with APC-conjugated anti-CD14 
monoclonal antibody (Becton Dickinson). Isolated CD14+ cells (1 x 106 in 1ml) were co-
cultured with purified melanoma EVs (100 μg) in complete medium additioned with 10% 
EV-depleted FCS for 24 h. Then, monocytes were harvested to assess their phenotype by 
flow cytometry. To this aim, cells were labelled with antibodies against CD14 and HLA-DR 
to detect the presence of M-MDSCs in concomitance with IC expression of PDL1, PDL2, 
CD155, GAL9. EV conditioned CD14+ cells were also analysed by qRT-PCR (chapter 2.5. 
and 2.6.). Harvested EV-conditioned CD14+ cells were next co-cultured with autologous 
CD14- fraction containing T cells to measure their immune suppressive potential.  
2.18. Proliferation experiments 
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EV-conditioned monocytes were tested for their suppressive potential on T cell 
proliferation. To test the T cell proliferation by flow cytometry, the CD14- fraction were 
labelled with Carboxyfluorescein succinimidyl ester (CFSE, Thermo Fisher Scientific) 
before co-culturing them with monocytes pre-treated with EVs.  
For CFSE labelling 5 x 106 cells were mixed with 100 µl of a diluted solution of CFSE (1:100 
in complete medium). After mixing cells with the solution, additional 800 µl of medium 
were added to the mix and incubated for 15 minutes at 37 °C. Following the incubation, 
cells were washed twice with 1.5 ml of EV-depleted FCS. To this aim, cells were 
centrifuged at 1600 rpm for 10 minutes, and after counting the labelled cells they were 
resuspended in medium in sterile tubes for co-culture incubation (PBMC 3x105 cells in 300 
µl). For the CD14 negative fraction, 105 cells were seeded into 96 well plates in 100 µl. In 
addition, 1 µl of Dynabeads T-Activator CD3/CD28 were added on cells in a final volume 
of 200ul. After 120 h of incubation, cells were collected and stained for flow cytometry 
analysis with the following antibodies: CD4, CD8, CD25 (Figure 2.18).  
 
Figure 2.18. T cell proliferation by flow cytometry analysis. The histogram on the left is gated on 
CD3 positive cells and shows the proliferation of total T cells. The dot plot (on the right) shows the 
proliferation (CFSE negative cells) in two different subpopulations of CD3, the CD8 positive and 
negative cells.  
2.19. Nanoparticle Tracking Analysis (NTA) of EVs 
NTA was performed with NS300 Nanosight instrument (Malvern Panalytical). For whole 
plasma analysis, samples were thawed at room temperature, vortexed for 20 seconds and 
2 µl of plasma were diluted 1:450 in PBS filtered 0.1 µm and vortexed for further 20 
seconds. Nanosight parameters were set as follows: threshold from 4 to 7, camera level 
value 15 or 16, and screen gain=1. Samples were acquired for 60 seconds for three times. 
Prior to start the automatic analysis by NTA software, I checked the particles per frame 
(P/F) parameter, which should range between 20 to 120 particles per field; new dilutions 
and measurements were performed in case of a higher P/F value.  
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NTA analysis of purified EVs from melanoma cell lines was performed using 2 µl of 
ultracentrifugation isolated EVs diluted in 500µl of filtered PBS and vortexed for 20 
seconds. Both, plasma and isolated EV from cell supernatant are represented in Figure 
2.19. 
 
Figure 2.19. Representative snapshots of EVs by NTA. A) plasma EV of melanoma patients and B) 
EVs isolated from conditioned medium of melanoma cell lines. 
2.20. Isolation of plasma EVs by ultracentrifugation  
500 µl of plasma were diluted 1:8 in PBS previously filtered 0.1 µm and centrifuged at 
16,500 g for 10 minutes to collect the first pellet (fraction 1, F1); supernatant was 
recovered and ultracentrifuged at 118,000 g for 90 minutes to obtain the second fraction 
(F2). A Beckman TLA100.3 Fixed Angle Centrifuge Rotor was used for UC. F1 and F2 pellets 
were resuspended in 100 µl of filtered PBS for downstream analysis and protein was 
quantified by spectrophotometer analysis and by Bradford staining. Both methods 
distinguished the protein yields of the two fractions, as the F1 fraction displayed a low 
protein content ranging between 50 to 300 µg, and the F2 fraction showed a higher 
protein content, in the range of 300 to 1,500 µg. The obtained fractions were 
subsequently used for western blot analysis or functional analysis in co-culture with 
autologus CD14+ monocytes.  
2.21. Isolation of plasma EVs by ExoQuick  
Thawed plasma was centrifuged 3,000 g for 15 minutes to remove cell debris, mixed with 
ExoQuick polymer (System Bioscience), 65 µl for 250 µl of plasma, and incubated at 4°C 
for 30 minutes. Then, the mixture was centrifuged at 1,500 g at room temperature for 30 
minutes, the supernatant removed and the pellet was resuspended in 100 µl of PBS for 
downstream analysis such as qRT-PCR. 
2.22. Statistical analysis 
Data were analysed using GraphPad Prism 5 Software (GraphPad Software Inc.). Results 
are analysed using unpaired or paired Student’s t-test, Mann-Whitney test, Pearson and 
Spearman correlation, as specified. Data were considered significant if p < 0.05.  
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Results 
3. Modulation of IC expression in melanoma 
At the beginning of my studies, I selected a set of IC molecules of potential interest based 
on the available literature data reporting expression in melanoma or in other tumour 
types. The list included PDL1, PDL2, PD1, HVEM, GAL9, CD155 and VISTA.  
3.1. Expression of IC in melanoma tissues and melanoma cell lines 
I first analysed the expression levels of these molecules by qRT-PCR in a series of 
cutaneous, lymph node and visceral metastatic melanoma specimens from stage III and 
stage IV melanoma patients for which other data displayed in Table 2.1.2 were available 
in the hosting laboratory [62]. Results showed that all IC transcripts were expressed, with 
HVEM resulting as the most expressed IC, followed by GAL9 and VISTA. An array of 
immune cell markers including CD14, CD163, CD68, CD33, CD3, CD4, CD8 displayed high 
expression levels in these samples, indicating the occurrence of an immune tumour 
infiltrate, although at lower levels than melanoma markers PMEL, MLANA and TYR (Figure 
3.1.1). 
Figure 3.1.1. Gene expression in tumour specimens. Expression levels of IC and other genes 
related to melanoma and immune infiltrate in metastatic melanoma specimens (n=58). GAPDH 
was used as endogenous control for the relative quantification. IC protein names are written in 
blue. Each gene was tested in triplicate.    
 
Next, I analysed the correlation between the expression of IC and of immune infiltrate-
related genes. IC resulted highly correlated between each other and also correlated with 
the immune cell markers, but were unrelated to the melanoma markers. The 
representation in a correlation matrix of the r values of significant correlations showed 
that the IC also correlated with the expression of cytokines, especially TGFβ and CCL2 
(Figure 3.1.2). 
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Figure 3.1.2. Correlation matrix of the expression levels of IC, myeloid and T cell markers, 
melanoma markers and cytokines genes in melanoma specimens. The indicated r values result 
from univariate Spearman analysis. Each gene was tested in triplicate.    
 
To study if the IC were similarly expressed also in melanoma cell lines, I performed by 
qRT-PCR an initial screening in 31 melanoma cell lines obtained in the hosting laboratory 
from melanoma metastatic specimens [256] (Figure 3.1.3). PDL1, PDL2, HVEM and GAL9 
were expressed at similar levels in melanoma cell lines and specimens, while PD1 and 
TIM3 were not detected in a first set of 14 studied cell lines, thus I decided to not further 
investigate their expression in the 17 remaining cell lines. These data indicate that several 
IC are expressed in melanoma cells and in tumour tissues, where the expression levels are 
highly correlated to markers of immune infiltrate.  
 
Figure 3.1.3. Expression of IC genes in 31 melanoma cell lines. Positive/total tested lines are 
indicated. On top are written the protein names of the ICs. Each gene was tested in triplicate.    
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3.1.1. IC expression by melanoma during acquisition of resistance to BRAF/MEKi 
Few studies investigated the potential modulation of IC expression during the acquisition 
of resistance to BRAF and MEK inhibitors [258-260]. To explore this issue and study the 
molecular mechanisms involved in IC modulation, a BRAF-mutated melanoma cell line 
sensitive to BRAF/MEKi was repeatedly exposed to the drugs and IC expression was 
monitored after each cycle of selection. 
After treatment with the combination of Dabrafenib and Trametinib, cells were cultured 
without the drugs to let them re-grow, and IC expression and drug sensitivity were 
assessed after each treatment cycle. The selection cycles resulted in a reduction of the 
drug effect on cell proliferation, as shown by the results of MTT assays depicted in Figure 
3.1.1.1A. A change in morphology was also observed, with increased cell size and a switch 
from an epithelial-like polygonal shape to a fibroblast-like shape (Figure 3.1.1.1B). IC 
expression assessed by flow cytometry showed that PDL1, PDL2, and CD155 were 
upregulated after the second cycle of treatment, while HVEM and GAL9 displayed a small 
decrease in the percentage of positive cells (Figure 3.1.1.1C). Overall, these data indicate 
that epigenetic modulations occurring upon chronic exposure to BRAF/MEKi include 
pathways regulating the expression of different IC molecules, defining an association 
between increased IC expression and the acquisition of drug resistance in melanoma cells 
as shown by the high level of IC50 value (Figure 3.1.1.1A). 
 Figure 3.1.1.1. Melanoma cell selection with the combination of BRAF/MEKi until the 
acquisition of resistance. A) MTT analysis of cells after chronic exposure to BRAF/MEKi at 1 µM 
depicted an IC50=1,7 of LM16R compared to an IC50=0,6 of the parental LM16S cells. B) Changes 
in cell morphology after drug selection and resistance acquisition. C) Flow cytometry analysis of IC 
expression in LM16S (pre) and LM16R (after drug selection) at 1 and 3 months of treatment. The 
percentage of positivity is calculated as the difference between the positivity of each IC and its 
isotype control. The study started with two different cell lines (LM16S and LM47S) but for 
technical problems it was concluded with only one cell line (LM16). 
 
3.1.2. Expression of IC in melanoma cell lines resistant to BRAF/MEKi 
To obtain an adequate model system to investigate the IC cargo of EVs released by 
melanoma cells and their role in protumoral cell interactions, I characterized a set of 
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resistant BRAF-mutated melanoma cell lines. Taking advantage of a set of six resistant cell 
lines previously obtained in my hosting laboratory I determined their IC expression and 
their potential association with BRAFi resistance. These resistant variants were obtained 
by repeated selection cycles with the BRAF-inhibitor Vemurafenib (PLX4032) until the 
onset of stable resistance [257]. These cell lines displayed cross-resistance to BRAF 
inhibitor Dabrafenib (GSK2118436) and to MEK inhibitor Trametinib (GSK1120212) and 
did not show additional gene mutations compared to their parental cell lines in a set of 
studied genes.  
Before IC studies, I standardized cell culture conditions to obtain samples at similar 
monolayer confluence. The analysis of IC genes in matched resistant (R) and parental 
sensitive (S) cell line pairs depicted in Figure 3.1.2.1 showed different expression patterns. 
PDL1, CD155 HVEM and VISTA transcripts were detectable in all cell lines at different 
levels, while PDL2 and GAL9 showed some negative samples. PDL1 was expressed at 
higher levels in R compared to S in four cell line pairs (LM16, LM11, LM43, LM47), and 
PDL2 transcript was higher in LM16R and LM47R compared to the sensitive counterparts. 
CD155, GAL9 and HVEM transcripts showed higher expression in three resistant cell lines 
compared to the sensitive counterparts, i.e. in LM16, LM43, LM47 for CD155, and in 
LM11, LM17, LM43 for GAL9 and HVEM. VISTA transcripts showed lower expression levels 
in five R cell lines compared to S cells.  
In summary, the expression of PDL1 and PDL2 transcripts were increased in resistant 
compared to sensitive cells, VISTA decreased in resistant cells, while HVEM and GAL9 
were similarly expressed in S and R lines. On the other hand, CD155 increased in 3 to 6 
resistant cell lines, and decreased in the other three.         
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Figure 3.1.2.1. IC gene expression levels in resistant and sensitive melanoma cell line pairs. 
Expression levels of IC genes in R resistant (red bars), S sensitive cell lines (white bars) are 
reported. This experiment was repeated at least twice. Each gene was tested in triplicate and the 
error bars represent the standard deviation of the triplicates.    
 
Western blot analysis confirmed a higher PDL1 expression in R with respect to S cell lines 
in three cell line pairs (LM16, LM43, LM47), while PDL1 was negative in the others. In 
addition, CD155 signal appeared as a double band in most of the samples (Figure 3.1.2.2). 
 
Figure 3.1.2.2. Protein expression level of PDL1 and CD155 in melanoma cells by western blot 
analysis. The bar plot on the right represents relative quantification of PDL1 expression after 
normalising the signal with B-actin. Grey bars- S cell lines; Red bars- R cell lines. This experiment 
was performed at least twice. Results in the figure show representative data.  
Based on these results, three S and R cell line pairs, namely LM16, LM43 and LM47, were 
selected for further studies. Flow cytometry analysis of IC expression showed that 
resistant cell lines LM16R and LM47R co-expressed PDL1 and PDL2, and high levels of 
CD155, while their sensitive counterparts were negative or weakly positive. Furthermore, 
HVEM and GAL9 expression was higher in LM16S and LM47S than in the resistant 
variants. In contrast, LM43 S and R cells showed a similar IC expression pattern, both 
lacked PDL1 and PDL2, while expressing HVEM and CD155. VISTA protein was not 
detectable in any cell lines, despite I could detect its gene transcript. This difference may 
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result from a potential post-transcriptional regulation of the protein expression or from 
the expression of a different VISTA splicing variant transcript (Figure 3.1.2.3).  
 
 
Figure 3.1.2.3. Flow cytometry analysis of IC expression by LM16, LM43 and LM47 cell line pairs. 
The dot plots show the results of double staining. The table reports the [ΔgMFI] as range of ΔgMFI 
from several experiments and the positivity in percentage of the represented data from the 
graphs. This experiment was performed at least twice.   
The results of flow cytometry quantified in terms of the geometric mean of fluorescence 
intensity (ΔgMFI) are reported in Figure 3.1.2.3. In several experiments LM16R 
consistently showed higher levels of PDL1, PDL2 and CD155 as compared to LM16S. 
Fluctuations were observed in LM16S for the expression of PDL1 and CD155 proteins, 
suggesting that their expression is modulated during culture, possibly depending on cell 
density. In contrast, PDL2 was always negative in LM16S. I could assess a similar IC 
expression pattern in LM47 cell lines pair, while the LM43 cell line pair displayed no 
differences between S and R.  
In conclusion, these studies confirmed that different IC are modulated in melanoma cells 
both at gene and protein levels upon the acquisition of resistance to kinase inhibitors. The 
modulation of IC expression may differ in pattern in different cell lines, although some 
changes appear to be shared. 
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3.1.3 Analysis of IC expression in specimens from patients treated with BRAFi  
To determine whether the onset of drug resistance alters the expression of IC in patients’ 
tumours, I interrogated a dataset of gene expression profiles of melanoma samples 
recently analysed in my hosting laboratory that included tumours excised before and 
during treatment of 7 patients (unpublished dataset). The under-treatment samples were 
obtained from metastatic tumours arising de novo or progressing during the treatment 
with BRAFi Vemurafenib, thus showing resistance to therapy.  
By comparing the expression levels in post-treatment vs pre-treatment samples, 
significant differences were evidenced for CD155 gene, showing an increase after 
treatment, and for HVEM and GAL9, showing a decrease (Figure 3.1.3.1). 
 
Figure 3.1.3.1. Expression of CD155, HVEM, GAL9 genes in melanoma tumours progressing 
despite targeted therapy. Pre-treatment and post-treatment melanoma tumours from 7 
melanoma patients. The horizontal line is the median value of the seven patients for each gene, 
and the whiskers are the two lines outside the box that extend to the highest and lowest 
observations. 
These data indicate that the modulation of IC expression associates with the acquisition 
of resistance to BRAF inhibitors in patients’ tumours as previously observed for 
melanoma cell lines. In addition, the specific alterations of IC expression observed in 
resistant cell lines have a correlate in patient tumours, suggesting that drug pressure may 
act on melanoma by common alterations in vitro and in vivo.  
3.2. Expression of IC by EVs released by drug resistant melanoma cells 
Tumour EVs are endowed with pro-tumorigenic features and display immunomodulating 
properties. Tumour EVs may regulate the immune response by transferring their cargo. I 
investigated whether the melanoma EV cargo included IC molecules. 
3.2.1. Melanoma EV characterization 
To evaluate if melanoma EVs carry IC and if they are involved in the modulation of IC 
expression in EV-interacting recipient cell lines, I characterized EV isolated from the 
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conditioned media of the three cell line pairs showing major differences in IC expression 
(LM16, LM43 and LM47) by flow cytometry, western blot and qPCR. Tumour EVs were 
isolated from the conditioned media by ultracentrifugation protocol and characterized for 
their size and concentration by Nanoparticle Tracking Analysis (NTA) and electron 
microscopy, and for EV markers by flow cytometry and western blot. By NTA, the size of 
counted vesicles showed similar peak values of the mean parameter for the sensitive and 
resistant EV variants for LM16 and LM47, while EVs from LM43R cells displayed a higher 
mean and mode compared to EVs obtained from the LM43S cells. The protein yields of 
the isolated EV fractions quantified by Bradford resulted significantly correlated with the 
number of particles per ml detected by NTA, supporting the purity of the vesicle samples 
(Figure 3.2.1.1). 
Figure 3.2.1.1. Characterisation of EVs isolated from melanoma cells by NTA. Histograms show 
NTA of samples isolated from resistant melanoma cell lines and their parental lines. The 
correlation of protein yields of the isolated EV fractions quantified by Bradford with the number 
of particles per ml detected by NTA is shown on the right. 
 
Immunoelectron microscopy analysis performed on LM16S and LM16R EVs showed a 
positivity for the EV marker CD63 (Figure 3.2.1.2A). Indications on the size were also 
given, around 100 nm, but the exact size of the particles was not measured because of 
the shrinking effect during preparatory steps of the samples for TEM [261]. 
Purity was assessed by western blot and flow cytometry. The presence of the exosome 
marker Rab-5B involved in the regulation of vesicular traffic, and of Alix, a regulator of 
exosome biogenesis [262], were confirmed by western blot analysis, as well as the 
absence of the markers GM130 and BIP, a cis-Golgi and an ER marker (Figure 3.2.1.2B). In 
addition, a latex-beads protocol was used for flow cytometry analysis of EVs, which 
allowed to visualize the stained EVs bound to the beads. EVs isolated from LM16S/R cell 
lines resulted positive for CD63, CD81 and CD9 tetraspanin EV marker expression (Figure 
3.2.1.2C).  
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Figure 3.2.1.2. Characterisation of melanoma EVs. A) Immunoelectron microscopy of purified 
LM16S and LM16R EVs labelled with anti-CD63 antibody. B) Western blot showing positivity for 
Rab5 exosomal marker. C) Flow cytometry analysis of CD63, CD81 and CD9 markers on EV coated 
latex-beads. The EV markers are represented by the blue histograms and the isotype control by 
the red histograms. 
3.2.2. Expression of IC by melanoma EVs 
Western blot and flow cytometry analysis on IC showed that EVs expressed the same 
checkpoints their originating cells did, and EVs were negative for IC that the releasing cells 
did not expressed, with some exceptions.  Indeed, LM16 EVs expressed PDL1, CD155 and 
GAL9 as their relative cells, and LM43 EVs were positive for CD155 and lacked PDL1 and 
GAL9 as their cognate cells. On the other hand, EVs from LM47 cell lines expressed low 
levels of all the IC markers although they were detected at high levels in their cells of 
origin (Figure 3.2.2). These results demonstrate that melanoma EVs carry different IC, and 
one of them, GAL9, was observed to be on the EV membrane. 
Figure 3.2.2. IC expression in melanoma EVs. A) Western blot analysis of PDL1 and CD155 
expression in EVs and cognate cells. Alix was used as EV marker and actin as loading control. B) 
Flow cytometry analysis of EV coated latex-beads stained for GAL9 and the EV marker CD81.  
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3.2.3. Analysis of IC gene transcripts carried by EVs  
Since EVs are known carriers of genetic material, I tested whether IC gene transcripts 
were detectable in melanoma EVs. IC transcripts carried by tumour EVs may have 
inhibitory effects on the host immune system once internalised by recipient cells and 
thereby contribute to cancer progression. RNA studies showed that EVs contain IC 
transcripts, consistent with the expression pattern observed in their originating cells. 
Results showed that HVEM and CD155 are carried by both, LM16S and LM16R EVs and 
PDL1, PDL2 were only detected in LM16R EVs. HVEM, VISTA and GAL9 were also detected 
in LM43 EVs. On the other hand LM47 EVs appeared negative for IC transcripts (Figure 
3.2.3). 
 
Figure 3.2.3. Melanoma EVs carry IC transcripts. Quantitative RT-PCR analysis of IC transcripts 
were detected in RNA extracted from EV (lower panels) and cell (upper panels) samples. To 
eliminate potential residuals of non-EV RNA, freshly isolated EVs were treated with RNase 
solution prior to RNA extraction. Two housekeeping genes were tested for result normalisation, 
GAPDH and ACTB; ACTB showing a small Ct variation was used to calculate expression levels. IC 
transcripts were negative in LM47 EVs while ACTB and GAPDH housekeeping genes were instead 
detectable. White bars -sensitive samples and EVs; red bars-resistant samples and EVs. This 
experiment was repeated at least twice. Each gene was tested in triplicate and the error bars 
represent the standard deviation of the triplicates. 
3.3. Mechanisms of IC modulation in melanoma cells 
3.3.1. IFN signalling in the regulation of IC expression 
IFNγ is a major inducer of PDL1, PDL2, and CD155 in tumour cells [263-266]. To evaluate 
the effects of IFNγ treatment on IC expression, flow cytometry analysis of IC was 
performed in four sensitive and resistant melanoma cell line pairs after overnight 
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exposure to IFNγ. Results showed an induction of PDL1, PDL2 and GAL9 expression in 
sensitive cell lines, and upregulated in the resistant lines. The response to IFNγ was also 
ascertained by the upregulation of HLA Class I in sensitive and resistant lines (Figure 
3.3.1.1). 
Figure 3.3.1.1. IC modulation by IFNγ in melanoma cells. The average delta geo mean of the 
intensity value was analysed by paired t test for treated (red histogram) versus untreated samples 
(grey histograms). S, sensitive (n=4); R resistant (n=4). The error bar is the standard deviation of 
the four different values deriving from each cell line.  
Melanoma cells treated with IFNγ were also tested for the activation of the IFN-
associated signalling pathway molecules STAT1/STAT3/IRF1 by western blot analysis. 
Results shown in Figure 3.3.1.2 indicate that IFN-treated LM16S cells displayed an 
upregulation of STAT3, STAT1, IRF1 and PDL1. In contrast, untreated drug resistant LM16R 
cells already displayed detectable levels of all these molecules, which showed 
upregulation after IFNγ treatment.  
 
Figure 3.3.1.2. Western blot analysis on IC and molecules involved in IFN-signalling. A) LM16S 
and LM16R cell lysates were obtained after overnight incubation with (+) or without (-) IFNγ. B) 
Normalized intensity volume of the protein signals (non treated = 1). Blue bars- LM16S cells; pink 
bars- LM16R cells. This experiment was performed at least twice. Results in the figure show 
representative data.  
These results indicate that the expression of IC molecules PDL1, PDL2 and GAL9 were 
induced by IFNγ in melanoma cells. In addition, the expression of IC molecules PDL1 and 
PDL2 in resistant LM16R cells associated to constitutive STAT1/3 signalling, indicating that 
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IC modulation upon acquisition of resistance to BRAF/MEKi in melanoma cells involves 
IFN-signalling.  
IFNγ is a critical cytokine for immune responses and can also act directly on the tumour 
cells with cytostatic and cytotoxic effects. In melanoma, in vitro IFNγ treatment has 
shown growth inhibitory effects mostly associated to the activation of the JAK-STAT 
pathway. I thus tested the effect of IFNγ on proliferation of sensitive and resistant LM16 
cells by MTT. In these experiments I also investigated the potential role of EVs produced 
by resistant cells on the drug response of sensitive cells. Results depicted in Figure 3.3.1.3 
showed that LM16S cells, despite showing responsiveness to IFNγ at molecular level, 
were not growth inhibited by IFNγ treatment. In fact, after 72 h I could measure a 
decrease in cell viability only in the presence of BRAF/MEKi, as expected, but not in the 
presence of IFNγ. In contrast, the growth inhibitory effects of BRAF/MEKi on LM16S were 
reduced by the presence of IFNγ. The addition of EVs did not influence LM16S cell growth 
in any of the tested conditions, regardless if they stemmed from parental sensitive or 
resistant counterpart. The same experiments performed in parallel with LM16R resistant 
cells showed no effect on cell growth of the BRAF/MEKi drug combination, as expected, 
while if IFNγ was added, I could measure a cell growth decrease of about 50% (Figure 
3.3.1.3). Notably, the treatment with IFNγ led to a 30% decrease in cell growth of LM16R 
cells, an effect observed in two independent experiments. Unexpectedly, the addition of 
EVs decreased viability of LM16R cells in all tested conditions.  
 
Figure 3.3.1.3. Cell viability analysis of LM16S and LM16R after BRAF/MEKi treatment in 
combination with IFNγ and LM16S and LM16R EVs. A) 15,000 cells/well of LM16S and B) LM16R 
were cultured in 96-well plates with 1 nM BRAF/MEKi drugs and/or 20 ng/ml IFNγ, in combination 
or not with 15 µg of EVs/well. MTT analysis of cell proliferation was performed after 72h of 
culture. This experiment was repeated at least twice. Each gene was tested in triplicate and the 
error bars represent the standard deviation of the triplicates. 
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These results appear contradictory, since I could measure a response to the cytokine in 
both drug sensitive and resistant cells, but the treatment had no effect on cell 
proliferation of the sensitive and strong effects on the resistant cells. An explanation may 
derive from the observation of dose-response studies for IFNγ, which revealed a 
discrepancy between levels of STAT1 activation and the extent of growth inhibition [267]. 
In my experiments, IFNγ treatment did not have the same effects on LM16S and LM16R 
cells possibly due to the different baseline expression of IFN-related genes. Additionally, 
as proposed by [267], the presence of additional signals emanating from the IFNγ 
receptor may counteract the anti-proliferative function of STAT1 in the case of LM16S 
cells. The anti-proliferative effects mediated by the presence of EVs from sensitive or 
resistant cells in the cultures of LM16 drug resistant melanoma cells, but not in the 
sensitive lines have no explanation.  
3.3.2. IC modulation upon EV interaction with tumour cells  
A main aim of my project was to evaluate the effects of IC proteins and/or transcripts 
carried by melanoma EVs in modulating tumour and immune cells to a tumour promoting 
state. To study this issue, I considered IC modulation in target cells, including melanoma 
cells and immune cells and cell models to assess the potential transfer of IC.  
Experiments were set up by evaluating co-cultures in transwell assays to assess potential 
molecular changes in sensitive cells mediated by the resistant counterpart. Co-cultures of 
LM16S cells in the lower chamber and LM16R cells in the upper chamber, and vice versa, 
were maintained for 4 and 8 days, then cells were harvested and analysed. No difference 
in IC expression was detected, neither at the protein nor at the transcript level. In 
contrast, these experiments showed an increase of STAT3 and a significant increase of 
CCL2 and IL8 gene expression in LM16S cells cultured in the presence of LM16R cells in 
the upper chamber (Figure 3.3.2.1). The expression of these cytokines occurs upon 
acquisition of resistance, as shown in a previous study [249].           
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Figure 3.3.2.1. Western blot and qRT-PCR analysis of cells conditioned in transwell co-cultures. 
Cells were co-cultured for 8 days in 24 wells transwell plates. After incubation, the transwells 
were discarded and the cells in the bottom wells collected for molecular analysis. A) STAT3 
intensity volume quantification. B) qRT-PCR results. ** p<0.01, *** p<0.001 by paired t test. This 
experiment was repeated at least twice. Each gene was tested in triplicate and the error bars 
represent the standard deviation of the triplicates 
To understand if EVs were involved in the modulation of cytokine expression, I performed 
analogous co-culture experiments with EVs isolated from the supernatants of LM16S and 
LM16R cells. qPCR analysis of LM16S cells treated with LM16R-derived EVs revealed an 
upregulation of CCL2 expression, similar to what observed in transwell experiments 
(Figure 3.3.2.2).  
Figure 3.3.2.2. Co-culture of LM16S cells with LM16R EVs. A) qRT-PCR analysis was performed 
after overnight incubation of 2x105 LM16S cells with 200 µg of EVs from LM16R transfected cells. 
LM16R was used as positive control for the tested genes. B) LM16R EVs were used for flow 
cytometry analysis after overnight incubation with latex beads to detect the CCL2 positivity (blue). 
LM16S EVs were used as negative control for CCL2, while CD81 EV marker (pink) is the positive 
control. C) qRT-PCR showed detectable CCL2 transcript in LM16R EVs and cells. The experiment in 
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panel A was repeated at least twice. Each gene was tested in triplicate and the error bars 
represent the standard deviation of the triplicates. 
This effect could be ascribed to the action of the CCL2 protein, of the RNA transcript, or of 
microRNAs carried by LM16R-derived EVs. In fact, EVs isolated from LM16R culture 
supernatant displayed a higher level of miR-34a, miR-100 and miR-125b (Table 3.3.2), 
which are associated to increased production of CCL2 and to resistance to BRAFi, as 
formerly reported by Vergani [249].  
 
 
 
Another microRNA, which has been recently identified by our group as potential mediator 
of resistance is miR-146a ([249] and unpublished results). In her studies, E. Vergani found 
that LM16S cells express miR-146a but are devoid of CCL2 and display low levels of miRs 
100, 34a and 125b. In contrast, LM16R cells express high levels of CCL2 and of miRs 100, 
125b and 34a but express low levels of miR-146a. Thus, to understand the potential role 
of these microRNAs as well as CCL2 in IC modulation, I evaluated IC expression in LM16S 
and LM16R cells after inducing/inhibiting CCL2 or the microRNAs.   
The role of CCL2 was tested in LM16S cells transfected with CCL2 plasmid and in LM16R 
cells transfected with CCL2 inhibitor (short interfering RNA). Results obtained by qPCR 
showed that, compared to control cells, LM16S-CCL2 transfectant cells upregulate PDL1 
at a statistically significant level, while the expression of GAL9, HVEM and CD155 was not 
affected (Figure 3.3.2.3). In contrast, the inhibition of CCL2 in the resistant variant LM16R 
determined a decrease of HVEM expression, while it did not affect the expression of the 
other IC. Furthermore, these experiments showed that the inhibition in LM16R cells of 
resistance-associated microRNAs 100, 34a, 125b determined an upregulation of PDL2 and 
GAL9, while the transfer of miR-146a mimics determined a downregulation of PDL1 and 
GAL9 (Figure 3.3.2.3B). Altogether these findings link CCL2 and miR-146a to the regulation 
of PDL1, while GAL9 appears modulated by all the tested miRNA, and HVEM expression 
appears to be influenced only by CCL2.   
Table 3.3.2  qRTPCR   analysis on  microRNA from melanoma  EV 
EV Avg Ct U6 Avg Ct miR100 Avg Ct miR125b Avg Ct miR34a 
Exp 1 LM16S 28,7 40,0 40,0 40,0 
LM16R 26,1 28,0 27,2 31,9 
Exp 2 LM16S 26,9 40,0 31,9 34,0 
LM16R  28,4 32,4 27,2 30,5 
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Figure 3.3.2.3. IC modulation in melanoma cells by CCL2 and miRs. A) qRT-PCR was performed in 
LM16S cells transfected with CCL2 plasmid and its scrambled control. B) LM16R cells treated by a 
pool of siRNA specific for CCL2 transcript, or with inhibitors for CCL2-associated microRNAs, or 
with miR164a mimic. Grey bars- scrambled controls; violet- transfected samples. This experiment 
was repeated at least twice. Each gene was tested in triplicate and the error bars represent the 
standard deviation of the triplicates 
3.3.3. Melanoma and GFP-tagged EV co-culture studies 
3.3.3.1. Generation of transfectant cells producing GFP-tagged EVs 
To investigate the mechanisms underlying the modulation of IC upon exposure to 
melanoma EVs, and to understand if a direct transfer of IC proteins from the EVs to the 
recipient cells occurs, GFP-tagged EVs were generated. Being that CD81 is a highly 
expressed protein in EVs, a commercial vector encoding CD81-GFP fusion protein was 
used to obtain LM16S and LM16R stable cell variants producing GFP-EVs. GFP-tagged EVs 
isolated from the LM16R-CD81-GFP and LM16S-CD81-GFP transfectants differ for the 
presence of the endogenous PDL1. In addition, to investigate the potential direct transfer 
of PDL1, LM16S cells were also transfected with a vector encoding PDL1-GFP fusion 
protein. This model allowed the tracing of PDL1 protein in the target cells upon EV 
exposure. Transfectants were selected by geneticin resistance, and to enrich transfectant 
cell population with high fusion protein expression, GFP positivity was used for selection 
by FACS. FACS resulted an effective selection method for LM16S-CD81-GFP and LM16S-
PDL1-GFP transfectants, since the fusion proteins CD81-GFP and PDL1-GFP were highly 
expressed as displayed by the double positivity at flow cytometry analysis (Figure 
3.3.3.1AB). However FACS resulted unsuccessful in the purification of the LM16R-CD81-
GFP transfectants, and even if two different methods of FACS sorting were used (“Purify” 
and “Single Cell Sorting”), an heterogeneous population was obtained because of cell 
aggregation formed during the sorting. To obtain enriched LM16R-CD81-GFP transfectant 
cells I eventually cloned the sorted cells by limiting dilution and selected cell clones based 
on GFP expression.  
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Figure 3.3.3.1. Transfectant melanoma cells producing GFP-tagged EVs. A) Flow cytometry 
analysis detection of GFP in melanoma cells transfected with a vector encoding CD81-GFP or 
PDL1-GFP fusion protein after selection by FACS or cell cloning by limiting dilution. Red dot plots 
are the non transfected cells. B) The comparison of non transfected and transfected cells for 
double positivity expression of the fusion proteins. C) Flow cytometry analysis of EVs derived from 
transfected-CD81-GFP cells. D) EVs derived from transfected-PDL1-GFP cells did not show double 
positivity for the fusion protein by flow cytometry analysis; western blot analysis showed a clear 
signal of anti-PDL1 antibody at 76 kDa for the fusion protein PDL1-GFP. LM16R cells and its EVs 
were used as positive control for PDL1, Alix was used as EV marker and actin was used as loading 
control.  
EVs were isolated from the transfectants and characterised. NTA showed no major 
differences between LM16 EVs and their GFP-tagged counterpart (Figure 3.3.3.2). EVs 
obtained from LM16S-CD81-GFP and LM16R-CD81-GFP cells resulted positive for the 
fusion protein CD81-GFP when analysed by western blot and latex-beads flow cytometry 
(Figure 3.3.3.1CD). In contrast, LM16S-PDL1-GFP EVs were negative for PDL1 and GFP 
when analysed by latex-beads flow cytometry, probably due to the low intensity 
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expression level of the PDL1-GFP fusion protein, as determined also by confocal 
microscopy analysis (data not shown here). Nonetheless, by western blot, both EVs and 
cell samples showed detectable fusion protein at 76 kDa (Figure 3.3.3.1 D, right panel).  
3.3.3.2. Analysis of IC expression in melanoma cells upon GFP-EV interaction  
To evaluate if the transfer of PDL1-GFP fusion protein occurred in melanoma cells after 
co-culture experiments with GFP-tagged EVs, treated cells were tested for positivity to an 
anti-GFP antibody by western blot. Results showed that both PDL1-GFP and CD81-GFP 
EVs types were internalised by LM16S cells, as the anti-GFP antibody revealed the bands 
of both the fusion proteins PDL1-GFP and CD81-GFP at 75 kDa and 50 kDa respectively. 
However, a high level of expression of the fusion protein was detectable only for CD81-
GFP EV co-cultures (Figure 3.3.3.2D, central and right panels).  
In addition, I took advantage of the fluorescent vesicles produced by CD81-GFP 
transfectants, which were highly positive for GFP due to CD81 accumulation in EVs, for 
confocal microscopy analysis in collaboration with our Cell Imaging Facility. Experiments 
clearly displayed green GFP signal in LM16S and LM16R cells upon co-culture with LM16S-
CD81-GFP EVs. DAPI and WGA labelling red reagent were used for nucleus and cell 
membrane staining. ImageJ analysis revealed internalized EVs in yellow, as the result of 
merged green CD81-GFP EVs and the red labelled recipient cells (Figure 3.3.3.2B). 
Flow cytometry of these co-cultures showed that LM16S cells displayed a lower uptake of 
CD81-GFP EVs, regardless if they derived from LM16S and LM16R, with 62% and 52% 
positivity, respectively. Instead, LM16R cells showed an uptake of 84% (LM16S) and 86% 
(LM16R) EVs. Of note, LM16R cells displayed a 20 fold higher GFP geometric mean 
fluorescence intensity compared to LM16S cells after EV uptake, confirming the higher 
internalisation ability of the resistant melanoma cells (Figure 3.3.3.2C). EV uptake was 
also detectable by Western blot analysis, where cell lysates from LM16S cells cultured 
with CD81-GFP-tagged EVs showed bands between 38 and 52kD for the CD81-GFP fusion 
detected by an anti-GFP antibody (Figure 3.3.3.2D).  
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Figure 3.3.3.2. Interaction studies of GFP-tagged EVs in melanoma cells. A) NTA results of EVs 
from transfected (second and forth panels) and untransfected control cells (first and third panels) 
analysed by NTA. B) confocal microscopy and C) flow cytometry showing EV internalisation in 
LM16S (upper panel) and in LM16R (lower panel) after co-culture with CD81-GFP EVs produced by  
LM16S or LM16R CD81-GFP transfectants. D) Western blot analysis of transfected cells and their 
EVs (left panels) and LM16S co-cultured samples with GFP-positive EVs (central and right panels). 
GFP-tagged EVs were internalised by LM16S cells, as anti-GFP antibody showed a band between 
38 and 52 kDa corresponding to the molecular weight of CD81-GFP fused protein (central panel), 
and a band between 65 and 76 kDa corresponding to the molecular weight of PDL1-GFP protein 
(right panel). 
In conclusion these experiments demonstrated that EV are internalized in melanoma cells 
and that the uptake appears higher in the resistant LM16R compared to LM16S cells. 
These results also showed that PDL1 protein can be transferred between melanoma cells 
via EVs.  
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4. Role of melanoma EVs in immune cell modulation of IC expression 
The aim of this part of my project was to investigate if IC proteins and/or transcripts 
carried by EVs might have a role in the modulation of IC in immune target cells. 
4.1. Interaction of melanoma EVs with PBMCs 
The target cells of EVs were at first assessed in EV-PBMC co-cultures. To detect any EV-
immune cell interaction, I either labelled EVs from LM16R cells (16R EV) with SP-
DIOC(18)3 (Figure 4.1.1), or I used CD81-GFP and PDL1-GFP EVs purified from the 
transfected LM16S melanoma cell line (EV 16S) (Figure 4.1.2).  
To evaluate the interaction of LM16R melanoma EVs with monocytes and T cells, 20 μg 
isolated EVs were labelled with SP-DIOC(18)3, a membrane lipophilic dye, prior to 
addition to PBMCs isolated from peripheral blood of healthy donors. After an overnight 
incubation, cells were harvested, washed, labelled with antibodies against CD14, CD3 and 
PDL1 and acquired with a FACSCalibur flow cytometer. Results showed that labelled 
LM16R EVs interacted with CD14+ monocytes (Figure 4.1.1A, left panels) but not with T 
cells (Figure 4.1.1A, right panels). About 20% of CD14+ cells gated in PBMCs from two 
different healthy donors acquired green fluorescence (Figure 4.1.1A, left panels). Next, I 
evaluated if the interaction with EVs of monocytes could induce the surface expression of 
PDL1. I could observe that those cells that had acquired the green fluorescence 
(CD14+DIOC+ gate), thus had interacted with EVs, displayed an increase in the percentage 
of PDL1+ monocytes that ranged from 25 to 60% depending on the donor (Figure 4.1.1B, 
left panels). In contrast, from the monocytes that had not interacted with EVs, only a low 
percentage (about 10-15%) displayed an upregulation of PDL1 (Figure 4.1.1B, right 
panels). These experiments showed that in PBMCs the monocytes are the cells 
prevalently interacting with EVs from melanoma cells and that this interaction leads to an 
increased expression of PDL1.    
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Figure 4.1.1 Interaction of LM16R EVs with monocytes and T cells in PBMCs. A) Melanoma EV 
uptake after 18h by PBMC gated CD14 (on the left) and CD3 (on the right), B) PDL1 expression by 
CD14+ monocytes in PBMCs after interaction with melanoma EVs deriving from LM16R. HD - 
healthy donor; green-Isotype control; blue- % of PDL1 positivity 
These interaction experiments were also performed with 16S EV-CD81-GFP or 16S EV-
PDL1-GFP obtained from transfected 16S cells. As shown in Figure 3.3.3.1 PDL1-GFP EVs 
displayed a marked reduction in GFP fluorescence with respect to CD81-GFP EVs. 
Nonetheless, about 20% in CD14 gated monocytes showed an interaction with both types 
of EVs in PBMCs (Figure 4.1.2A). This uptake was accompanied by an upregulation of PDL1 
of 46% for both EVs in monocytes (Figure 4.1.2B).   
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Figure 4.1.2. Interaction of GFP tagged EVs with monocytes in PBMCs. A) GFP-EV uptake by 
CD14+ cells in PBMCs after 18h of co-culture, B) PDL1 expression by CD14+ monocytes in PBMCs 
after interaction with EVs deriving from melanoma cell line LM16S CD81- and PDL1-GFP fused 
protein. Medium-negative control. This experiment was performed at least twice, each time with 
two different HD. Results in the figure show representative data. 
4.2.  IC expression induced by melanoma EVs in PBMCs 
Given the IC modulation in resistant melanoma cells and the IC expression by melanoma 
EVs as showed in the Section 3.2.2 of the results, I aimed to compare the effects of EVs 
isolated from the studied sensitive and resistant melanoma cell line pairs on IC 
modulation in PBMC co-culture experiments. Thus, purified EVs (30 µg) were co-cultured 
with PBMCs isolated from peripheral blood of healthy donors (n=2) for 36 h. Then cells 
were harvested and labelled with fluorochrome-conjugated antibodies against CD14 and 
the IC PDL1, PDL2, GAL9, HVEM and CD155 (Figure 4.2.1 and 4.2.2). Given the potential of 
tumour EVs to induce an M-MDSC phenotype identified as CD14+HLA-DRneg cells, I also 
included the assessment of HLA-DR in combination with CD14 on EV stimulated PBMC 
samples (Figure 4.3.1).  
All tested EVs induced a modulation of IC, measured as geometric mean fluorescence 
intensity (gMFI) on gated CD14+ monocytes. In particular, after 36 h of co-culture only 
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HVEM was upregulated consistently by all EVs, while PDL2, CD155 and GAL9 were 
downregulated, as shown in Figure 4.2.1 for each IC. 
 
Figure 4.2.1. Modulation of IC expression in monocytes after EV-PBMC co-cultures. Average data 
of two HD PBMCs in co-culture with six different melanoma EV. mono- negative control, EV from 
cell lines 16S, 16R, 43S, 43R, 47S, 47R. The error bar is the standard deviation of the two different 
values deriving from each HD.  
I then grouped the effects of EVs from sensitive (S) and resistant (R) to understand if 
modulations induced by the EVs could be associated with their derivation from BRAFi 
sensitive or resistant melanoma cell lines. In contrast to the overnight incubation, the 
incubation at a longer time (36 h) showed that PDL1 expression values did not change in 
monocytes when PBMCs were co-cultured with EV from sensitive melanoma cells. It was 
only downregulated by EVs derived from resistant cell lines, and was accompanied by a 
downregulation of CD14 expression in these monocytes (Figure 4.2.2). In addition, 
statistical analysis with paired t test revealed that the other studied IC, PDL2, CD155 and 
GAL9 were downmodulated when co-cultured with EV from sensitive and resistant 
melanoma cells, but the modulation was accentuated if EVs originated from resistant 
lines. On the other hand, HVEM resulted upregulated in PBMC gated CD14 when these 
data were taken together, and higher modulations were observed if treated with resistant 
EVs (Figure 4.2.2). 
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Figure 4.2.2. Modulation of IC expression in monocytes after EV-PBMC co-cultures grouped 
according to S and R EVs. Average data geometric fluorescent mean of EV deriving from three 
different sensitive and resistant melanoma cell lines. The error bar is the standard deviation of the 
three different values deriving from each EV condition. EVs S: EV from LM16S, LM43S, LM47S; EVs 
R: EV from LM16R, LM43R, LM47R; gMFI: geometric mean fluorescent intensity  
4.3.  Melanoma EVs induce an M-MDSC phenotype in PBMC monocytes 
Since MDSC play a major role in resistance mechanisms to cancer therapies and represent 
a hallmark of poor prognosis for cancer patients, I sought to evaluate the expression of 
HLA-DR on monocytes in PBMC conditioned with EVs from S and R cell lines described in 
Figure 4.2.1 and 4.2.2. I observed a consistent downregulation of HLA-DR mediated by all 
tested EVs, regardless if they derived from sensitive or resistant cell lines (Figure 4.3.1 left 
and middle panels showing all tested EVs and an overlay example). As showed in the right 
panel, both EVs deriving from sensitive as well as those deriving from resistant melanoma 
cell lines induced a statistically significant decrease of surface HLA-DR. However, 
differences in gMFI between untreated monocytes and EVs from resistant lines were 
more significant (p=0.0013) than those between monocytes and EVs from sensitive cells 
(p=0.0173). Thus, I concluded that EVs from BRAFi resistant melanoma cells display a 
higher potential in inducing M-MDSC. 
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Figure 4.3.1. Modulation of HLA-DR expression in monocytes after EV-PBMC co-cultures. 
Average data of EV deriving from three different sensitive and resistant melanoma cell lines in 
two healthy donors. On the left EV are shown separately, on the right the data were grouped in 
EVs S: EV form LM16S, LM43S, LM47S; EVs R: EV from LM16R, LM43R, LM47R. In the middle is a 
representative histogram red- PBMC untreated; green- PBMC+EVs S; blue- PBMC+EVs R; gMFI: 
geometric mean fluorescent intensity. This experiment was repeated at least twice with at least 
two healthy donors each time. The error bar is the standard deviation of the two different HD (on 
the left), or three different values deriving from each EV condition on one of the two HD here 
represented (right).  
 
Considering that all EVs induced a downregulation of HLA-DR, I evaluated IC expression in 
the context of HLA-DR expression (Figure 4.3.2). Results showed that upon HLA-DR 
downregulation, CD14+ cells acquired a marked expression of HVEM (Figure 4.3.2A). 
Statistical analysis of HLA-DR+HVEMlow and HLA-DRnegHVEMhigh monocytes grouped 
according to S and R EVs showed a statistically significant difference with respect to 
untreated monocytes (Figure 4.3.2B).   
HLA-DR
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Figure 4.3.2. HVEM and HLA-DR modulation in EV-PBMC co-cultures. A) Modulation of IC 
expression in gated CD14+ cells after PBMC-EV co-culture. Left panel: untreated samples, central 
panels: samples treated with EVs from BRAF/MEKi sensitive melanoma cells, right panels: samples 
treated with EVs from BRAF/MEKi resistant melanoma cells. B) HVEM modulation in HLA-DR 
positive gated cells (left) and –DR negative cells (right). This experiment was repeated at least 
twice with at least two healthy donors each time. The error bar is the standard deviation of the 
three different values deriving from each EV condition on one of the two HD here represented. 
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Concomitantly, downregulation of HLA-DR was accompanied by negative modulation of 
GAL9 (Figure 4.3.3A). In fact, this IC appeared to be expressed mainly on HLA-DR+ 
monocytes. When I compared the HLA-DR+HVEMlow monocytes for their GAL9 expression 
with the MDSC counterpart with low HLA-DR and high HVEM I observed a loss of GAL9 
gMFI (Figure 4.3.3 A) that was statistically significant for EVs deriving from R cell lines 
(Figure 4.3.3B). This indicates that GAL9 gMFI downregulation in HLA-DRnegHVEMhigh 
monocytes if they were induced by EVs deriving from BRAF resistant melanoma cells. 
 
Figure 4.3.3. GAL9 modulation in EV-PBMC co-cultures. A) Monocytes were gated as follows: red- 
HLA-DR positive and HVEM low expression, green- HLA-DR negative and HVEM high expression. B) 
GAL9 expression as gMFI in the two cell subpopulations of A). This experiment was repeated at 
least twice with at least two healthy donors each time. The error bar is the standard deviation of 
the three different values deriving from each EV condition on one of the two HD here 
represented. 
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4.4.  Interaction and phenotype of CD14+ monocytes induced by melanoma EVs 
To discriminate if the observed effects on monocytes after PBMC co-cultured with 
tumour EVs were due to an indirect effect of the presence of T, B and NK cells as part of 
PBMC population, I performed co-culture experiments with purified monocytes. CD14+ 
cells were isolated from PBMC of healthy donors (n=3) by separation with anti-CD14+ 
magnetic beads, and were co-cultured with EVs obtained from LM16S, LM16R, LM16S-
CD81-GFP and LM16S-PDL1-GFP cells. After an overnight co-incubation, the samples were 
harvested and divided in two parts, one for phenotype analysis and one for functional 
analysis.  
The phenotype assessed by flow cytometry is shown in Figure 4.4.1A as a representative 
example, and included the assessment of interaction evidenced by the acquisition of 
green fluorescence by CD14+ cells in the presence of 16S-CD81-GFP tagged EVs (8%). In 
contrast, no increase of FITC+ cells was detected in the presence of 16S-PDL1-GFP EVs, 
possibly due to their low GFP fluorescence (Figure 4.4.1A, first row). This interaction 
induced an upregulation of PDL1 on cells, which was particularly evident in the presence 
of PDL1-GFP EVs reaching almost 40% positivity. Induction of PDL1 was also detectable 
for 16S and 16R EVs, as well as for CD81-GFP EVs, however to a lesser extent (Figure 
4.4.1A, first and second rows). PDL1 upregulation could be also measured at RNA level in 16S 
and 16R EV-conditioned monocytes (Figure 4.4.1B).  
As detected in the monocyte gate in PBMCs, also purified CD14+ cells downregulated HLA-DR, and 
the HLA-DRneg ranged from 9% for untreated monocytes to 17-22% in the presence of the tested 
EVs (Figure 4.4.1A, third row). Given the purified CD14+ cell population, and the low GFP uptake 
positivity, we stained cells with CD14-FITC risking no interference signal. CD14+ cells expressing 
the highest levels of HLA-DR were also those expressing GAL9 and upon interaction with EVs, I 
could measure a drop of almost 50% of GAL9high cells if 16S and 16R EVs were present (30% in 
untreated, 16-20% in EV-conditioned monocytes (Figure 4.4.1A fourth row of dot plots). In 
contrast, no relevant CD155 modulation was observed in EV-conditioned monocytes (Figure 
4.4.1A, fifth row), although it was evident at RNA level (Figure 4.4.1B). qRT-PCR analysis also 
revealed decreased levels of HVEM although not significant, and a significant decrease for VISTA, 
TIM3, and GAL9, but not for PDL2. Interestingly, a marked upregulation of IL6 and CCL2 hallmarks 
of MDSC was present in monocytes after EV conditioning (Figure 4.4.1B).   
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Figure 4.4.1. Effects of melanoma EVs on purified CD14+ monocytes. A) Flow cytometry analysis 
and B) qRT-PCR for IC modulation in purified monocytes treated with EVs from BRAF/MEKi 
sensitive and resistant melanoma cell lines 16S and 16R. This experiment was repeated at least 
twice, each time with three healthy donors. Each gene is tested in triplicate. Error bar is the 
standard deviation of the triplicate of the represented data.  
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4.5. Functional activity of CD14 monocytes conditioned by melanoma EVs  
To assess the modulatory effects of EVs in functional experiments, monocytes harvested 
after incubation with EVs were washed to eliminate non-internalized vesicles, and co-
cultured at different concentrations with the autologous CD14neg fraction containing 
lymphocytes. CD14neg cells were labelled with CFSE and stimulated with CD3/CD28 beads. 
After 5 days of culture, samples were harvested, stained with CD4, CD8 and CD25 
antibodies and acquired with a FACSCalibur flow cytometer. Results of a representative 
healthy donor are showed in Figure 4.5.1 for EVs deriving from 16S and 16R cell lines, 
while Figure 4.5.1 shows those for EVs with a GFP tag.  
The proliferation is shown in percentage of lymphocytes (left panels), CD4+ (middle 
panels) and CD8+ (right panels). The first row showing grey histograms represents the 
proliferation in the absence of the CD14+ fraction, which is instead present at the 
indicated ratios but in the absence of EVs in the second row. At 1:0.125 and at 1:0.25 
ratios the presence of monocytes had a stimulatory effect on proliferation, while ratios of 
1:0.5 and 1:1 led to its progressive decrease, ranging from 96% with 1:0.25 to about 80% 
with 1:0.5 and to about 33-44% with 1:1 ratio.  
The more affected lymphocytes were the CD8+ T cells. In contrast, the presence of EV-
conditioned monocytes in the cultures interfered with the proliferative activity of T cells 
already at a ratio of 1:0.25, leading to a reduction of 10% in the case of 16S EVs and of 
20% in the case of 16R EVs. This inhibitory effect was potentiated to 20-30% at 1:0.5 ratio 
and reached about 50% of inhibition at a ratio of 1:1 (second and third row of Figure 
4.5.1). At all tested ratios monocytes conditioned with EVs from BRAFi resistant 
melanoma cells 16R displayed a stronger suppressive potential of T cell proliferation and 
CD8+ T cells were more affected.  
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Figure 4.5.1. Effects of EV-conditioned CD14+ cells on T cell proliferation. CFSE-labelled 
CD3/CD28 stimulated CD14neg cells co-cultured for 120 h with different ratios of autologous 
monocytes pre-treated with EVs deriving from LM16S and LM16R cells for 24 h. This experiment 
was performed twice, each time with two different donors. Results in the figure show 
representative data. 
Similar results were obtained with EVs derived from transfected 16S cells for CD81-GFP 
and PDL1-GFP, which are displayed in Figure 4.5.2. If monocytes were preconditioned 
with EVs, they lost their stimulatory activity already at a ratio of 1:0.25. This inhibitory 
effect increased at 1:05 and at 1:1 and affected CD8+ T cells more than CD4+ T cells. Of 
note, suppressive effects were more pronounced if EVs derived from 16S cells transfected 
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with PDL1. The CD14+ responses to added EVs displayed differences in the amplitude of 
uptake, IC/HLA-DR modulation and functional effects which were donor dependent. The 
results obtained with the GFP-tagged EVs indicate their suitability as tool to study 
immune EV interactions.  
 
Figure 4.5.2. Effects of CD14+ cells conditioned with GFP tagged EVs on T cell proliferation. CFSE-
labelled CD3/CD28 stimulated CD14neg cells co-cultured for 120 h with different ratios of 
autologous monocytes pre-treated with EVs deriving from LM16S-CD81-GFP and LM16S-PDL1-GFP 
for 24 h. This experiment was performed twice and each time with two different donors. Results 
in the figure show representative data. 
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4.6.  IC expression in CD14+ cells conditioned with autologous melanoma and plasma 
EVs  
This experiment was aimed at investigating the effects of autologous EVs on purified 
monocytes from advanced melanoma patients. In the case of patient 1 (Pt1) I purified EVs 
from conditioned medium of the autologous melanoma cell line, which had been 
generated from a tumour specimen in my hosting laboratory. Figure 4.6.1A shows the IC 
expression of this cell line: I could not detect PDL1, PDL2 or VISTA on the cells. On the 
other hand they expressed CD155 at 80% and HVEM at 90%, while GAL9 was detectable 
on about 16% of cells. EVs were isolated according to the isolation protocol for cell 
culture-derived vesicles and evaluated by NTA. They displayed a dimension mean of 168.8 
nm and a mode of 120 nm, thus likely resembling EVs of the exosome type (Figure 
4.6.1B).  
To obtain EV conditioned monocytes, these latter were isolated from PBMCs of Pt1 and 
co-cultured with EVs for 24 h. Thereafter cells were harvested and processed for RNA 
extraction and qRT-PCR analysis. As depicted in Figure 4.6.1C, I could observe a 
downregulation of the IC VISTA, GAL9, CD155, HVEM. In contrast, the monocytes from 
this patient upregulated PDL1, PDL2 and CD163 MDSC marker upon encountering their 
autologous melanoma EVs. All observed differences were statistically significant.  
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Figure 4.6.1. Effects of melanoma cell line-derived EVs on autologous monocytes. A) Flow 
cytometry analysis of a cell line derived from a melanoma specimen from a patient (Pt1). 
Expression of PDL1, PDL2, CD155, VISTA, HVEM and Gal9 are tested (right dot plots) with respect 
to their IgG controls). B) NTA of EVs isolated by differential centrifugation of conditioned medium 
of Pt1 melanoma cell line. C) qRT-PCR analysis of purified monocytes from melanoma patient Pt1 
co-cultured with EVs from Pt1 autologous cell line. This analysis was performed in duplicate and 
the error bar is the standard deviation of the obtained data. Expression of IC and CD163 
transcripts. Statistical significance was achieved with paired t-test.       
EVs were also isolated from the autologous plasma and tested with CD14+ cells as 
described above. To isolate EVs from plasma I applied a two-step protocol set up by my 
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C
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hosting laboratory to purify large EVs in F1 at a lower speed centrifugation, and small EV 
fraction F2, isolated by higher speed centrifugation. NTA analysis of unprocessed plasma 
revealed vesicles with a mean size of 109 nm and a mode of 83 nm, indicating that the 
plasma contained EVs of the smaller and potentially exosome type. Of the isolated 
fractions I could measure only F1 by NTA and results showed EVs with bigger mean 
dimensions of 144 nm but the same mode of 83 nm as unprocessed plasma (Figure 
4.6.2A). 
Large and small EVs were the co-cultured with isolated CD14+ cells of Pt1 and as 
described for autologous cell line EVs, harvested and processed for RNA analysis. Results 
depicted in Figure 4.6.2B show that similarly to pure melanoma EVs also plasma EVs 
induce an upregulation of PDL1, PDL2 and CD163. However, in contrast to cell line EVs, 
either F1 or F2 plasma EVs were able to induce an upregulation of VISTA, GAL9, CD155, 
HVEM and PD1. This modulation could be due to the presence of other EVs in plasma, 
especially immune cell-derived EVs, which could be responsible for the observed effects 
(Figure 4.6.2B).  
An analogous experiment with autologous plasma EVs was performed on CD14+ cells 
from another advanced melanoma patient (Pt2) (Figure 4.6.2C). Here I could detect a 
downregulation of VISTA, GAL9, CD155, HVEM and CD163, while only PDL1 and PDL2 
were upregulated upon co-culture with autologous plasma EVs. These modulations were 
similar to those induced by autologous cell line derived EVs, an effect that could depend 
on a potentially higher portion of tumour-derived EVs in plasma. 
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Figure 4.6.2. Effects of plasma-derived EVs on autologous monocytes of melanoma patients. A) 
NTA of unprocessed plasma and F1 isolated EVs of melanoma Pt1. B) qRT-PCR analysis of purified 
monocytes from melanoma patient Pt1 co-cultured with EVs from Pt1 autologous plasma F1 and 
F2 for the expression of IC and CD163 transcripts. C) qRT-PCR analysis of purified monocytes from 
a melanoma patient Pt2 co-cultured with EVs from Pt2 autologous plasma F1 and F2 for the 
expression of IC and CD163 transcripts. These analyses were performed in duplicate and the error 
bar is the standard deviation of the obtained data. Statistical significance was achieved with 
paired t-test.   
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5. Modulation of plasma EV in patients upon BRAF/MEKi treatment 
In this part of my project, I performed exploratory studies on EVs isolated from the 
plasma of melanoma patients treated with targeted therapy. At first I spent major effort 
to set up experimental conditions for these experiments. 
5.1. Analysis of IC transcripts in plasma EV: comparison of different methods 
To explore the potential relevance of IC carried by plasma EVs, three different isolation 
methods were tested for the detection of transcripts. EV were isolated from two plasma 
samples by 1) single step UC, 2) ExoQuick, and in both cases RNA was extraction by the 
Macherey Nagel kit (Isolation of small and large RNA); 3) ExoRNeasy serum/plasma kit, a 
commercial method which isolate EV and extract RNA from plasma samples. Table 5.1. 
reports the average Ct values for the studied genes for the used methodology.  
This analysis displayed different results in the two samples for the two methods ExoQuick 
and ExoRNeasy, although both techniques showed a better performance compared with 
the UC protocol, which was excluded from the possible investigation methods of this 
study.  
 
Next, the set of samples was enriched (n=19), and the experiment was run only with 
ExoQuick and ExoRNeasy methods. In between an independent experiment was 
performed to test different plasma volumes using the two kits: I decided to use 800 µl of 
plasma for ExoRNeasy kit, and 250 µl for ExoQuick, because with more plasma the filter of 
MNagel column was plugged by the polymer and the RNA extraction failed.  
Results indicated that the separation of EV and RNA extraction by ExoRNeasy kit had the 
best performance (Figure 5.1). While ExoRNeasy showed only 4 undetermined values of 
Ct, the undetermined values of ExoQuick were 38. Thus, for further analysis ExoRNeasy 
was selected as the best method for trascript analysis on plasma EV.    
 
 
 
Table 5.1. EV isolation methods and average Ct by qRT-PCR analysis 
Plasma sample EV isolation plasma (µl) PDL1 PD1 PDL2 CD155 CD14 CD3D HLA-A GAPDH CD8
mel pt 1 ExoRNAeasy 0,5 32,0 40 32,8 33,8 29,8 28,9 22,9 22,7 27,2
Single UC 0,5 40 40 40 40 40 36,9 30,9 29,2 32,2
ExoQuick 0,25 31,1 30,9 33,6 27,4 26,4 29,9 20,9 21,8 NP
mel pt 2 ExoRNAeasy 0,5 31,5 31,9 31,6 34,7 27,9 28,3 20,1 19,4 28,7
Single UC 0,5 35,5 40 35,6 40 31,8 32,5 27,6 27,3 31,8
ExoQuick 0,25 40 40 NP NP 33,2 NP 22,3 NP 35,9
Note: mel pt - melanoma patients; UC - ultracentrifugation; NP - not performed
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Figure 5.1. Comparison of methods for detection of IC transcripts in plasma EV samples. qRT-
PCR of 5 genes on 19 EV samples isolated from plasma of melanoma patients by ExoQuick (black 
dots) and by ExoRNeasy (red dots). Undetermined values are plotted as Ct=40. All differences 
were significant. The error bar represent the standard deviation of the 19 samples. 
 
5.1.1. Modulation of IC transcripts carried by plasma EVs   
To evaluate whether the analysis of IC in plasma EVs may contribute to uncover the 
mechanisms governing the response to treatment, I studied plasma EV samples from a set 
of 11 melanoma patients at the baseline and at month 1, 3, and 6 time points during 
treatment. The samples were selected from a retrospective case set of patients with a 
long or a short response to BRAF/MEKi treatment, i.e. less or more than 1 year of time to 
progression (see Table 2.1.1 in material and methods Section 2). RNA was isolated by 
ExoRNeasy kit from 800 µl of plasma, and tested by qRT-PCR for the expression of fifteen 
genes, including negative and positive checkpoints ligands and receptors expressed by 
tumour and immune cells, and immune cell specific markers CD3 and CD14. From a 
technical point of view I observed a high detection rate of the studied genes in plasma EV 
with few undetected values (< 3%).  
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Figure 5.1.1.1. qPCR detection of IC transcripts in plasma EVs. The names of the encoded 
proteins are reported. The expression of ACTB and GAPDH was used for data normalization. The 
different colours represent the different patients. The error bar represents the standard deviation 
for all the patients in that time point. 
Results showed that the levels of most IC significantly increased after one month of 
treatment and then decreased at 3 months of treatment, followed by a non significant 
modification at 6 months: this pattern was observed for HVEM and its receptor CD160, 
for TIGIT (one of receptors of CD155), and for TIM3, and for GAL9 although only 
upregulation at one month was significant. A similar trend was shown for the other 
receptors of HVEM, i.e. BTLA and LIGHT, and for both CD3 and CD14, all showing a 
significant decrease at 3 months (Figure 5.1.1.1).  
In contrast, the markers of the PD1-PDL1/PDL2 axis showed little modulation during 
treatment, except for PDL1 which showed a significant increase at 3 months of treatment 
(Figure 5.1.1.2.). Apart from TIGIT (Figure 5.1.1.1), no significant differences were 
observed for CD155 axis and its receptors CD226 and CD96 (Figure 5.1.1.3). 
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Figure 5.1.1.2. qPCR detection of IC transcripts in plasma EVs. Results of markers of the PD1-
PDL1/PDL2 axis are shown. The error bar represents the standard deviation for all the patients in 
that time point. 
Figure 5.1.1.3. qPCR detection of IC transcripts in plasma EVs. Results of markers of the 
CD155-CD96/CD226 axis are shown. The error bar represents the standard deviation for all the 
patients in that time point. 
To investigate potential differences based on response to treatment, data were analysed 
separately for the long responding (LR with a time to progression from 19 to 25 months) 
and the short responding (SR with a time to progression from 1 to 7 months) patients. For 
LR the pattern and significant differences at the tested time points were generally 
maintained, while this could not be observed for the SR group. In particular, HVEM and its 
three receptors CD160, BTLA, LIGHT, together with CD3 and CD14 showed a similar 
pattern (Figure 5.1.1.4). In contrast, in the SR only a significant upregulation of CD160 at 3 
months from treatment was observed.  
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Figure 5.1.1.4. qPCR detection of IC transcripts in plasma EVs in long and short responding 
patients. The names of the encoded proteins are reported. The expression of ACTB and GAPDH 
was used for data normalization. Red * indicates p<0.05 by t-test analysis between LR and SR at 
the indicated time point. The error bar represents the standard deviation for all the patients in 
that time point. 
Interestingly, when the expression levels were divided into LR and SR for the different 
time points, only LIGHT and PD1 transcripts resulted significantly higher in LR compared 
to SR. (Figure 5.1.1.4 and 5.1.1.5). Additionally, LR patients displayed a significantly higher 
level of PD1 before treatment than did SR. In contrast, I could detect higher PDL1 levels in 
SR compared to LR, which decreased at 3 months. A statistically significant decrease at 3 
months in SR was also observed for CD96, while TIGIT displayed an increased expression 
at 1 month in SR (Figure 5.1.1.5).  
In general, most molecules displayed higher levels in LR compared to SR, with the notable 
exception of PDL1, PDL2 and CD14. In addition, in EV samples from LR most of the studied 
IC showed a modulation during treatment, while this effect was absent in SR. 
Furthermore, CD3 expression was lower in SR compared with LR and that of CD14 was 
higher: although the difference did not reach statistical significance this result suggests a 
different immunomodulation occurring in the two group of patients.  
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Figure 5.1.1.5. qPCR detection of IC transcripts in plasma EVs grouped in long and short 
responder patients. The names of the encoded proteins are reported. The expression of ACTB 
and GAPDH was used for data normalization. Red * indicates p<0.05 by t-test analysis between LR 
and SR at the indicated time point. The error bar represents the standard deviation for all the 
patients in that time point. 
5.2. Characterization of plasma EVs from melanoma patients by NTA  
To assess whether the treatment induced changes in the quantity and size of circulating 
EVs I performed a characterisation of unprocessed plasma by NTA using Nanosight in the 
same set of samples. The concentration ranged between 13 and 97 x 1010 particles/ml. 
Results showed a decrease of concentration between 1 and 3 months of treatment 
(Figure 5.2.1). These data are in agreement with transcript analysis (Figure 5.1.1.1) 
showing that 8/15 genes were down regulated at 3 months post treatment compared to 
1 month, suggesting that the observed expression modulation could be due to a decrease 
of EV concentration.  
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Figure 5.2.1. NTA of plasma samples from melanoma patients: EV numbers. The left graph 
displays the EV concentration in all samples (all mel pt), while the other two report the results for 
LR-long responders and SR-short responders. Data at the different time points are shown. Pre- 
before treatment, M-month post treatment. The error bar represents the standard deviation for 
all the patients in that time point. 
When the results were divided for LR and SR patients, a different pattern appeared. LR 
displayed a higher EV concentration than SR at baseline, and this difference increased at 1 
month, reaching statistical significance (Figure 5.2.1 centre and right panel, Figure 5.2.2). 
During treatment the EV concentration decreased in LR, while in the SR group I measured 
an increasing trend.  
 
 
 
 
 
Figure 5.2.2. EV concentration in plasma of LR and SR melanoma patients. Mean ±SD at the 
different time points are shown. The error bar represents the standard deviation for all the 
patients in that time point. 
I then analysed the results for EV size. Considering all the samples, no differences were 
observed at the time points for mean and mode parameters of EV. However, the data 
showed opposite patterns in the two groups of patients (Figure 5.2.3). In LR samples the 
size increased at 3 months and decreased at 6 months, while in SR patients the EVs were 
smaller at 3 months. Statistically significant differences were observed between LR and SR 
patients at 1 and 3 months for both, mean and mode parameters (Figure 5.2.4). Finally, 
correlation analysis showed that the EV number was inversely related to the EV size 
(Figure 5.2.5).  
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Figure 5.2.3 NTA of plasma samples from melanoma patients: EV size. Mean (upper panel) and 
mode (lower panel) are shown. LR-long responders, SR-short responders. The error bar represents 
the standard deviation for all the patients in that time point. 
 
 
 
 
 
 
 
Figure 5.2.4 EV size in plasma samples from melanoma patients. Mean (left panel) and mode 
(right panel). t-test analysis between LR and SR patients at each time points. The error bar 
represents the standard deviation for all the patients in that time point. 
 
Figure 5.2.5 Correlation analysis of concentration and size of plasma EV obtained by NTA. 
Spearman non parametric correlation analysis was performed to test the association between the 
two parameters.   
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In conclusion, EVs at 1 month from treatment are more concentrated in LR but smaller in 
size, and conversely EVs in SR melanoma patients are less in number but have higher 
mean and mode values. While no difference in number was observed at 3 months, data 
showed that LR EVs have bigger dimensions than SR EVs at 3 months.   
5.3. Analysis of IC protein in plasma EV samples 
A recent publication to which I contributed with experiments involving EVs showed that 
plasma EVs of melanoma patients display increased concentrations and dimensions when 
compared to healthy donors. To investigate the IC presence in bigger or smaller plasma 
EVs (bEV and sEV), I used a centrifugation method to obtain enriched EV pellets for bEV, 
called F1, and sEV, called F2. The two fractions were characterized by TEM and flow 
cytometry analysis as shown in our study [62]. F1 fraction EV size ranged between 200-
500 nm, while the F2 EVs showed a size below 200 nm. Protein detection was performed 
by western blot analysis (Figure 5.3).  
 
Figure 5.3. Western blot analysis of F1 and F2 isolated plasma EV fractions. Expression of PDL1, 
CD155, CD9 and Alix (the latter were used as loading controls), and gp100 melanoma marker. 30 
µg of protein were loaded in each well. Pt-melanoma patient, HD-healthy donor. 
 
To assess IC expression in F1 and F2 plasma EV fractions, western blot analysis was 
performed with samples isolated from plasma 3 metastatic melanoma patients and 1 
healthy subject. PDL1 was only detected in F1, while CD155 and CD9 were expressed at 
higher levels in F1 compared to F2. Both F1 and F2 fractions from the donor were 
negative for PDL1, while CD155 was detected in both fractions. Gp100 was detected only 
in both fractions of 1/3 melanoma plasma samples, indicating the presence of melanoma-
derived EVs. The results also showed that CD9 could represent a good EV marker for F1 
fraction (Figure 5.3). These data demonstrated that F1 plasma EVs are carriers of different 
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proteins including IC, showing different levels between melanoma patients and healthy 
control.  
5.3.1. Analysis of PDL1 levels in plasma EVs of BRAF/MEKi-treated melanoma patients  
I investigated the EV protein expression in plasma EVs from melanoma patients treated 
with BRAF/MEKi, obtained at the beginning of treatment and at 1, 3 and 6 months. I 
chose to study the modulations of the expression levels of PDL1 molecule in plasma EV F1 
fraction containing enriched bEVs isolated from 6 patients responding or not to 
treatment. Western blot was performed by loading the same samples volume in each 
well. Since I detected PDL1 only in the F1 fraction, I considered only the F1 fraction, and 
used LM16R cell lysate as an internal control (Figure 5.3.1.1). 
 
Figure 5.3.1.1. Western blot analysis of PDL1 in plasma EVs from melanoma patients. F1 fraction 
of EVs from plasma of melanoma patients (n=6), at different time points during BRAF/MEKi 
treatment. Pre – before treatment, 1M, 3M and 6M months during treatment. Samples were run 
in three gels, and contained samples from one long-responder patient (LR) and one short-
responder (SR) at different time points. PDL1 and CD9 were tested. The cell lysate from LM16R 
cells was added in each gel as an internal control. (X)- missing sample 
Data showed that the CD9 intensity volumes correlated with the µg of protein loaded in 
the gel, based on protein quantification by spectrophotometer. In addition, the intensity 
volume of PDL1 and CD9 bands were significantly correlated, indirectly indicating that 
PDL1 is carried by the CD9 positive EVs (Figure 5.3.1.2). 
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Figure 5.3.1.2. Correlation analysis of CD9 and PDL1 intensity values. Left: correlation between 
CD9 intensity volume and µg of protein loaded per well. Right: correlation between CD9 and PDL1 
intensity values. Intensity volume of LM16R cell lysate added in each gel was used for intensity 
volume normalisation. AU- ratio intensity volume.  
The results showed a higher intensity volume of PDL1 and CD9 at 3 months of treatment 
in LR compared with other time points and compared with SR. In addition, the intensity 
volumes of both proteins decreased during treatment in SR (Figure 5.3.1.3). 
 
 
 
 
 
Figure 5.3.1.3. Western blot analysis of PDL1 and CD9 in plasma EVs from melanoma patients. 
The F1 fraction of EVs isolated from plasma of melanoma patients (n=6) treatment with 
BRAF/MEKi; before (pre), at 1, 3 and 6 months. PDL1 and CD9 were tested and quantified by 
NineAlliance software (UVITEC Imaging System). The ratio of intensity volume is obtained after 
normalisation with LM16R intensity value control. The error bar represents the standard deviation 
for all the samples at that time point. 
In conclusion these data showed that PDL1 expression levels can be quantified in plasma 
EVs, and that PDL1 levels vary between patients and are modulated by treatment.  
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6. Discussion   
6.1. Melanoma resistance to kinase inhibitors and IC expression. 
The results obtained in the studies addressing IC expression in melanoma indicated that 
IC are modulated upon the achievement of resistance to kinase inhibitors and that the 
transfer of EVs may play a role in melanoma IC expression modulation. 
One major achievement of this part of my studies is the demonstration that molecular 
pathways leading to the acquisition of resistance include the modulation of the 
expression of IC molecules. This evidence is obtained not only for PDL1, for which 
published data were already available, but also for PDL2, CD155, and HVEM and GAL9, 
the last two showing decrease expression. Although the patterns of IC modulation 
showed individual variation in different melanoma cell lines, most changes were 
reproduced in different cell lines. In addition, significant modulations of these IC were 
also detectable in resistant tumour biopsies from treated patients, thus indicating a 
potential clinical correlate to the in vitro findings. IC expression thus adds to the 
complexity of the phenotypic changes occurring in drug resistant melanoma and other IC 
may be considered as new target molecules for therapeutic strategies. 
While for the modulation of PDL1 a large amount of data are available in the recent 
literature [122], due to the importance of this marker in the context of immunotherapy, 
the molecular signalling governing the modulation of the other IC I found modulated in 
resistant melanoma are still poorly characterized. In particular, of the IC increased in 
resistant tumour, CD155 was correlated with a poor prognosis in different tumour types 
including melanoma [188-191] and studies showed that its overexpression in human 
neoplasms promotes tumour growth, invasion, and immune escape [190, 191]. The 
expression of CD155 is regulated by different signalling pathways [192] and that may thus 
include those activated in melanoma resistance. In the set of tumour specimens from 
untreated patients studied here, I found that CD155 expression levels were not correlated 
with PDL1 but rather to HVEM. 
In my studies, a decrease of HVEM and GAL9 expression in association with resistance 
was also reproducibly detected. Moreover, in primary uveal melanoma was observed a 
reduction of HVEM as compared to melanocytes [268]. All the studies investigating HVEM 
expression in tumours agree that HVEM expression correlates with a poor prognosis [179-
184]. Tumour downregulation of GAL9 expression has been previously associated with 
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disease progression in metastatic breast cancer patients [170]. GAL9 protein was shown 
expressed in 57% of melanoma metastases and coexpressed with PDL1 in most of the 
tumours tested [174]. In line with these results, we detected a high correlation of GAL9 
gene expression with genes of the PDL1/PDL2/PD1 axis (Figure 3.1.2 in Results Section).  
In the in vitro cell line models, resistant melanoma displayed constitutively expressed IFN 
signalling molecules, CCL2 upregulation and miRNA modulation [249]. Results indicate 
that the expression of IC molecules PDL1, PDL2 and GAL9 are inducible by IFNγ in 
melanoma cells. In addition, I could also associate PDL1 expression to the constitutive 
expression of CCL2 chemokine and to the expression of miR-146a, for which PDL1 
represents an indirect target via the regulation of NFkB (unpublished results). In addition, 
CCL2 influenced HVEM expression. CCL2 has a known tumour-promoting potential and in 
a previous study of my lab, we showed that CCL2 production by melanoma cells is 
involved in the resistance to BRAF inhibition and that its inhibition may restore drug 
sensitivity [249]. Similarly, miR associated to melanoma cell resistance and to CCL2 
expression appears to regulate GAL9 and PDL2. 
Results of co-culture experiments in transwell assays however showed that although co-
cultured R cells induced expression of CCL2 and IL8 and increased STAT3 in negative S 
cells, this condition did not change IC expression pattern, suggesting that additional 
signalling is needed to impact on IC expression.  
The second major achievement of my studies about association between melanoma 
resistance to kinase inhibitors and IC expression carried by melanoma EVs that may 
condition recipient cell IC expression. EVs released by melanoma cell lines were shown to 
carry IC proteins PDL1, CD155 and GAL9 and to carry IC transcripts reflecting the 
expression of the producing cells. These data represents a novel finding in the context of 
melanoma resistant cells. EV protein studies suffered of some limitations relative to the 
availability of commercial antibodies with limited technical applications: for example anti-
PDL2 and GAL9 antibodies did not work in western blot analysis, and the expression of 
PDL1, PDL2, HVEM and CD155 could not be detected by FACS by staining of EVs-coated 
latex beads, possibly due to a low positivity.  
To study the potential transfer of IC molecules I set up a model system with GFP-tagged 
EV and GFP-PDL1 fusion protein to study the potential transfer of PDL1 between 
melanoma cells, as previously adopted by [269]. Experiments by confocal microscopy 
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demonstrated the occurrence of EV binding and internalization in melanoma cells. 
Moreover, the transfer of PDL1 protein via EV was shown in co-cultured melanoma cells 
thanks to the GFP-tagged EV model. These results represent a proof of principle of the 
potential IC transfer by EV between melanoma cells. 
6.2.  Effects of the interaction of EVs with immune cells 
In the experimental part of the project that investigated the effects of melanoma EV on 
immune blood cells, I showed the EV uptake by monocytes beside the modulation of 
PDL1, CD155, HVEM and GAL9 expression. Indeed, EV-interacting monocytes acquire 
phenotypic and functional properties of MDSC, as already demonstrated from the hosting 
lab. 
Experiments showed that melanoma EVs interacted almost exclusively with the CD14+ 
monocyte fraction in PBMCs of healthy donors, whether obtained from both BRAF/MEKi 
sensitive or resistant cells lines. In fact, I could observe no interaction with CD3 T cells of 
FITC positive EVs. The preferential targeting of monocytes has been demonstrated by 
many studies, thus it represented an expected result [270]. In contrast to recent studies 
reporting EV interaction with T cells majorly by surface-surface receptor-ligand 
interaction [115, 271], my data showed no EV internalisation or interaction with T cells in 
the co-culture experiments. However, an EV-mediated triggering of surface molecules 
expressed by T cells is very likely to occur. EVs that bound to T cells potentially detached 
when I harvested the cell samples for flow cytometry labelling and acquisition. 
Monocyte-EV interaction detected after 18h co-culture was accompanied by an 
upregulation of PDL1 that was particularly evident in those monocytes which internalized 
EVs and were detected either as GFP positive or as DIOC-FITC positive monocytes (Figure 
4.1.1). Similarly, purified CD14+ cells cultured in the presence of GFP-tagged EVs displayed 
an acquisition of green fluorescence and an increase of the percentage of CD14+PDL1+ 
cells. The induction of PDL1 expression in monocytes was previously described in CLL 
patients as mediated by tumour exosome-carried non coding RNA, which targeted TLR7 in 
monocytes [272]. In their work, Haderk et al. also observed a production of 
proinflammatory cytokines CCL2, CCL4 and IL-6 similarly to what we detected upon co-
culture of melanoma EVs in autologous and healthy donors’ monocytes [62]. A recent 
study showed that PDL1 is upregulated by monocytes upon interaction with glioblastoma 
stem cell-derived exosomes. Interestingly, despite these authors observed a preferential 
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interaction with monocytes, they also detected an uptake of these EVs by activated but 
not resting T cells at 6 h of incubation [271]. Additionally, Gabrusiewicz and co-workers 
observed that PDL1 upregulation correlated with STAT3 phosphorylation, a hallmark of 
MDSC [273], occurring by melanoma EVs expressed HSP86 and TLR4 expressed MDSC 
interaction [63].  
In my studies EVs obtained from both BRAF/MEKi sensitive and resistant cell lines induced 
a downregulation of HLA-DR expression by monocytes that was evident in gated CD14+ 
cells in PBMCs as well as after purification. Of note, in the monocyte gate of PBMCs the 
decrease of HLA-DR coincided with an upregulation of HVEM on the HLA-DRneg 
subpopulation. HVEM expression by MDSC may depend on an endogenous regulation by 
the monocytes in response to EV internalisation. In fact HVEM was described as a protein 
that can be expressed by monocytic MDSC [274]. In my experimental setting, the 
increased HVEM expression could also depend on the transfer of HVEM transcripts, which 
I could detect in EVs of the cell line pairs selected for these studies.  
In contrast with data in the literature depicting that patients’ MDSC express increased 
levels of GAL9, my results showed a downregulation of this IC on the HLA-DRnegHVEMhigh 
as compared to the HLA-DRhighHVEMlow monocytes [59]. This discrepancy could rely on 
the different settings, e.g. ex vivo patients’ monocytes vs in vitro experiments. In fact, 
another study investigating the generation of MDSC in an in vitro setting described a 
reduced expression of GAL9 by M-MDSC [274]. Regarding PDL1 and PDL2, my 
experiments showed the induction of membrane expression of these IC on monocytes 
after the short-term incubation of 18 and 24 h, while at 36 h a minor but statistically 
significant reduction was detected. At opposite, PDL1 and PDL2 transcript levels always 
displayed an increase, in healthy donors’ monocytes by both EVs from resistant and 
sensitive melanoma cell lines and in the autologous setting with either melanoma and 
plasma-derived EVs. This coincided with an increase of CD163, a M2 marker of 
macrophages associated with cancer progression through induction of IL-6 expression 
[274]. Interestingly, IL-6 and CCL2 were the main cytokines I found upregulated in 
monocytes cultured with melanoma EVs, as well as when EV-MDSC were induced by 
MDSC-microRNAs carried by EVs [62].  
To test the suppressive ability of MDSC induced by melanoma EVs in monocytes from 
healthy donors’ and to assess potential differences between EVs deriving from sensitive 
vs drug resistant melanoma cell lines, I performed proliferation experiments at different 
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monocytes ratios. In the absence of EVs conditioning, monocytes inhibited T cell 
proliferation if present at high ratios in co-cultures (100% and 50%), while at 25% and at 
12.5% they stimulated proliferation of both CD4 and CD8 T cells. This is in line with 
previous findings showing that in the absence of disease high ratios of monocytes can 
influence T cell activity [275]. The suppressive activity of EVs-conditioned monocytes was 
evident already at 25% monocytes and affected both CD4 and CD8 T cells. At the higher 
ratios of 50% and 100%, the proliferation decreased progressively and at 100% CD8 T cells 
showed no proliferation. These results showed that melanoma EVs induced a 
suppressive phenotype in monocytes, and that no differences could be observed 
between the origin of EVs, from sensitive melanoma cell line LM16S or fromLM16R cell 
line. Additionally, the suppressive activity of monocytes could be also induced by CD81- 
and PDL1-GFP-tagged LM16S EVs, indicating this setting as an in vitro model lacking 
labelling biases suitable for studies investigating EV-mediated effects. 
6.3. Studies on plasma EVs  
In the part of the studies dealing with the characterization of plasma EVs from melanoma 
patients treated with BRAF targeted drugs, I set up methods of analysis to investigate EVs 
and different IC molecules.  
These pilot studies were carried with samples obtained before and during treatment from 
a selected set of patients which showed or not a good response to the therapy. The 
hypothesis was that treatment determined the activation of immune system that could 
be reflected in the modulation of circulating EV. It is known that targeted therapy 
determine a rapid increase of the tumour immune infiltrate [276], possibly due to tumour 
cells death and the enhancement of a systemic inflammatory state of organism [277], but 
also that inhibitory molecules and immunosuppressive cell infiltration increase in 
progressing tumours [251, 252]. Thus, the pattern of IC at different time points during 
treatment might allow an overview of the immune system activation in the studied 
patients.  
Indeed, through qPCR, NTA and western blot experiments I set up conditions for 
successful analysis of IC transcripts and proteins in plasma EV samples. To detect the 
presence and levels of EV transcripts, the technical challenge of RNA extraction by a 
method suitable to qRT-PCR analysis was overcame by selecting a method that worked 
very well in my hands and was reproduced in other samples in the lab. A commercial kit 
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(exoRNeasy [135]) was selected from methods that were less time consuming than UC for 
EV isolation and had a high yield of extracted RNA from a limited quantity of plasma 
sample [278].  
Although the presence of gene transcripts in EV isolated from plasma is already 
documented [279], IC transcripts were not tested before, with the exception of PDL1 in 
EVs from lung and melanoma patients undergoing immunotherapy [135]. Besides PDL1, 
PDL2 and PD1, I tested the following IC transcripts in plasma EV: HVEM axis molecules, 
including HVEM receptors BTLA, CD160, and LIGHT, CD155 and its receptors TIGIT, CD96 
and CD226, most of which were not reported before in EV samples (see Table 1.2.1.2 in 
introduction Section for the other IC EV publications). Results showed variations of the 
expression levels of several IC transcripts during treatment, especially for molecules of 
the HVEM and GAL9 axis. Long and short response patients showed different levels of 
PD1 and LIGHT transcripts in pre-treatment samples, and a general higher expression 
level of most studied molecules was detectable in responding patients compared to 
patients showing a short response to treatment.  
Regarding the NTA analysis, I must underline that the analysis was performed in 
unprocessed plasma samples, in order to avoid the possible selection of particular EV 
populations through isolation and vesicle aggregation or clumping. Results clearly showed 
a different pattern of number and size of plasma EVs between long and short 
responding patients, particularly at 1 month from treatment. The increased EV 
concentration levels observed after the first month of treatment only in long responders 
are suggestive of a different immune condition induced by treatment in this group of 
patients. A low number of plasma exosomes was reported associated to poor prognosis in 
esophageal squamous cell carcinoma [280]. Notably, I found that the mean size of EV was 
inversely associated with the EV concentration values at 1 month from the treatment in 
long versus short responding patients. Thus, suggesting a potential, although unknown, 
different cell origin of the small vesicles in the LR, from the big vesicles on SR (Figure 
5.2.4, right panel).  
To gain insight in the IC carried in EV population with different sizes, protein analysis was 
performed in EV fractions separated by size. Western blot analyses of two fractions of 
plasma EVs separated by UC and characterized for big (F1) or small (F2) vesicle content, 
showed positivity for the melanoma markers gp100 in both fractions, while PDL1 and CD9 
discriminated between two EV fractions and were expressed only in F1.  
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Based on these results and a recent publication on PDL1 protein detection in plasma EV 
[115], I studied a small set of samples from long and short responders for PDL1 expression 
level in F1. It has to be taken into account that after 3 and 6 months, 2 out of 3 short 
responders patients dropped out of the study, thus reducing the samples required to test 
significant differences. However, a different trend between two subgroups of patients 
was observed, as increased PDL1 levels were detected in responders especially at 3 
months of treatment. These data are in agreement with results reported by Chen at al. 
showing an increase of PDL1 between 3 and 12 weeks samples in circulating EV from 
responders to immunotherapy [115]. Similarly, higher levels of PD1 and CD28 positive EVs 
were shown in serum samples from patients achieving clinical response to 
immunotherapy [281].  
In conclusion, my studies suggest that IC expression levels in plasma EVs may reflect the 
anti-tumour immunity state of the patients and may hold predicting information on 
clinical outcome.  
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7. Conclusions and future perspectives   
The downregulation of IC transcripts HVEM and GAL9 and the upregulation of CD155 
detected in treatment resistant tumours of melanoma patients represent relevant 
observations for the interpretation of the results I obtained in this PhD project, though I 
could compare only 7 specimen pairs. The loss or decrease of these IC that can play 
inhibitory as well as stimulatory role in immune regulation has been associated with a 
tumour supportive microenvironment in lymphoma [282]. Similarly, in the immune 
studies, I observed a reduction of several IC transcripts, including HVEM, in monocytes 
conditioned with EVs deriving from melanoma cells, or with autologous EVs from 
patient’s plasma. However, when I evaluated MDSC phenotyped as CD14+HLA-DRneg, an 
increase of HVEM in the HLA-DRneg population was detected. The expression of this IC by 
M-MDSC has been previously shown [274]. 
In melanoma as well as in monocytes I observed the induction of PDL1 expression when 
cells were cultured in the presence of EVs. PDL1 expression increased in resistant 
melanoma cells and was transferred via vesicles in BRAF/MEKi sensitive melanoma cells. 
Naive immune cells and BRAF/MEKi sensitive melanoma cells modulate IC upon 
encounter with EVs, especially if they derive from melanoma cells with acquired 
resistance to the drugs.  
Plasma EVs showed modulation of concentration, size, IC transcripts and molecules, 
occurring during treatment by different patterns in patients with diverse outcomes, 
suggesting that the dynamic levels of IC markers may provide useful information on 
patient outcome and on novel IC targets for new treatment modalities. Given that 
melanoma IC expression is altered in BRAF/MEKi resistant tumours in melanoma patients, 
and that EVs reflect IC expression of originating cells, monitoring of plasma EVs may thus 
potentially provide predicting information on tumour state and immune activation. 
Further studies with a high number of patients are needed to verify the preliminary 
information of plasma EVs obtained in my studies. 
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